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Background: Cardiovascular diseases are responsible for a large proportion of deaths 
globally and disproportionately affects developing countries. Diabetes and hypertension are 
major contributors to the burden of cardiovascular diseases worldwide (WHO, 2017; IDF, 
2017; WHO, 2013).  In Jamaica, the prevalence of diabetes and hypertension was estimated 
at 12% and 22% respectively, and has been attributed to an ageing population, increased 
prevalence of obesity, sedentary living and unhealthy diet (MOHW, 2018; WHO, 2018; WHO 
Global Data Repository). Access and the appropriate use of essential chronic disease 
medicines is an effective public health strategy against the morbidity and mortality 
associated with diabetes and hypertension. The consequences of inappropriate drug 
therapy are poor health outcomes and increased health care costs to individuals and society.  
The National Health Fund (NHF), which was implemented in 2003, provides financial 
assistance for medicines to Jamaicans with one or more of 16 specific chronic diseases, 
including diabetes and hypertension. This benefit is available to all Jamaicans regardless of 
age, sex or socio-economic status. To be eligible, individuals are required to have their 
physician sign an enrollment application confirming their diagnosis (es). Although medicines 
can be accessed with no fee at point of service at public pharmacies, over 80% of the 
pharmacies in Jamaica are privately run and may be a more convenient and accessible 
option for many patients (PAHO, 2012). NHF enrollees have the option of accessing their 
medicines at a subsidized cost through this network of private pharmacies. Affordability of 
medicines was highlighted as a barrier to accessing chronic disease medicines, with 
approximately 25% of Jamaicans reporting not taking medicines due to unaffordability 
(PAHO, 2012).  This study included a literature review, which highlighted multiple barriers 
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to accessing medicines in developing countries.  The extent, to which these barriers affected 
access and use of the NHF, was explored in this study.    
 
Objective: This study set out to answer three research questions related to access and use 
of the NHF in Jamaica among adults with diabetes or hypertension:  1) What are the factors 
predicting enrollment in the National Health Fund? 2) What is the drug utilization patterns 
and the factors associated with adherence to medicines among NHF enrollees with diabetes 
or hypertension?  3) What was the effect of a major health policy (the removal of user fees 
from primary health facilities in 2008) on access and use of the NHF? 
  
Design and methods: The study population was community dwelling adults between the 
ages of 18 and 59 years with diabetes or hypertension.  Data were derived from two 
disparate sources, the Jamaica Health and Lifestyle Survey (2008) and the NHF pharmacy 
claims data. Multiple quantitative methods were used to analyze the data.  Multivariate 
logistic regression models were used to identify predisposing, enabling, need and contextual 
factors associated with enrollment in NHF (n=626), and to identify factors predicting 
adherence among the enrollees (2008, n=20, 264; 2017, n=77, 454). Interrupted Time 
Series (ITS) models were used to examine the impact of the removal of user fees from public 
health facilities on access and use of the NHF (n=49,599; n=74,520). 
  
Results:  Five years following the implementation of the NHF individualized drug benefits, 
only 25% of adults (18-59 years) with diabetes and/or hypertension were enrolled. Low 
enrollment was mainly seen among younger adults. While higher enrollment was observed 
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among those with comorbid hypertension and diabetes. Adherence levels among this 
population of enrollees was also low at just over 50% in 2017, which represents a decline 
from 2008 (p<0.001). Multiple factors were found to be predictive of adherence in both years 
examined. Howvever, out-of-pocket (OOP)/unsubsidized expense had the strongest effect 
on adherence when compared to the other predictors included in the model, with lower 
adherence consistenly observed among individuals with the lowest monthly out-of-pocket 
(OOP)/unsubsidized expense on medicines. Individuals who obtained multiple drug 
therapies; those with comorbid conditions; those who lived in the Southeast Health Region; 
females and those less than 45 years old were also significant predictors of medication 
adherence but with relatively small effects. Using independent sub-group analysis, the study 
found that the removal of user fees from public health facilities in 2008, increased NHF 
enrollment among specific sub-groups (females, urban residents, residents within the 
Southeast health region and adults ages 18 to 39 years and 45 to 54 years). However, the 
policy was not effective at increasing the rate of NHFCard users each month.  
 
Conclusion: The results of this study suggests that adults between the ages of 18 and 59 
years, with diabetes or hypertension had suboptimal access to essential chronic disease 
medicines through the NHF. Additionally, continued access measured by adherence to drug 
therapy was low and showed indications of geographic and socio-economic differences. The 
study also found that different factors are associated with different levels of access, for 
example need and predisposing factors were the primary drivers of NHF enrollment, while 
enabling factors were primary drivers of medication adherence among those already 
enrolled.  These findings highlight the need for interventions in Jamaica to increase access 
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and use of the NHF. Considering the multiple factors predicting access and the limited 
effectiveness of the policy to remove user-fees from public health facilities, interventions 
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CHAPTER 1 - BACKGROUND 
1 Global overview 
 
1.1 Burden of diabetes and hypertension 
 
Chronic non-communicable diseases (NCDs) are a major cause of death and disability in 
the world with an estimated 41 million deaths per year globally.   Developing countries are 
disproportionately affected and account for approximately 80% of NCDs (WHO, 2018). A 
large proportion of deaths from NCDs in developing countries are among people under 70 
years old and are considered preventable (WHO, 2018). Of the estimated 15 million deaths 
annually between the ages of 30 to 69 years, 85% are in developing countries (WHO, 2018).  
The leading causes of NCD deaths are cardiovascular diseases (CVD) such as heart 
disease and stroke (WHO, 2018).  Diabetes mellitus and hypertension are among the most 
important risk factors for CVDs and other NCDs (WHO, 2017). People with diabetes are 2 
to 3 times more likely to suffer from CVDs and 10 times more likely to have end stage renal 
disease (IDF, 2017). Globally, hypertension is reported to be responsible for 45% of deaths 
due to heart disease and 51% of deaths due to stroke (WHO, 2013). The WHO reports that 
in 2005 chronic diseases were responsible for nearly one-half of the disease burden in 
developing countries (Wirtz et al, 2011).  Moreover, the premature loss of life, morbidity and 
disability associated with these diseases are known to have a significant economic impact 
on developing countries.  
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Diabetes is a chronic disease that occurs when the body is unable to produce the insulin 
needed to regulate glucose, leading to elevated blood glucose levels or hyperglycemia (IDF, 
2017).  It is characterized by chronic hyperglycemia (Shah and Afzal, 2013). There are three 
main types of diabetes, type 1 diabetes, type 2 diabetes and gestational diabetes. However, 
90% of all diabetes cases are type 2 diabetes (IDF, 2017).  Global trends in diabetes have 
shown an increase in prevalence over time, with an estimated 8.8% of adults between the 
ages of 20-79 years affected (IDF, 2017). Eight (8) out of 10 adults with diabetes live in 
developing countries (IDF, 2017). If the current trends continue, the International Diabetes 
Federation (IDF) predicts that by 2045, 1 in 10 (628 million) adults will have diabetes 
mellitus. The majority of this increase is predicted to take place in developing countries (IDF, 
2017).  
 
Hypertension is a chronic disease, which is characterized by persistently elevated blood 
pressure. Elevated blood pressure is when the heart systolic blood pressure is equal to or 
greater than 140 mm Hg and a diastolic blood pressure equal to or greater than 90 mm Hg 
(WHO, 2013). Raised systolic and diastolic blood pressure affects the normal functioning of 
vital organs such as the heart, kidneys and brain (WHO, 2013). It is a global public health 
issue because of its high prevalence in many parts of the world, and because it significantly 
increases the risk of heart disease and stroke (WHO, 2013; Sarki et al 2015).  The global 
prevalence of hypertension was estimated at 32.3% in 2015 and is predicted to increase by 
2025 (Sarki et al, 2015). According to Sarki et al (2015), 1 in 3 adults in developing countries 
were diagnosed with hypertension. A projected 75% of the world’s hypertensive population 
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will reside in developing countries in the next decade (Shah and Afzal, 2013; Sarki et al, 
2015).  
 
Diabetes and hypertension are considered metabolic diseases and typically occur together. 
When they co-exist, the risk of CVD increases by 75% (Shah and Afzal, 2013). A 
combination of lifestyle factors and an aging population are being blamed for the increased 
prevalence of these conditions in developing countries.  Life-style risk factors include 
physical inactivity, poor diet and tobacco use.  In public health, these are commonly known 
as ‘modifiable’ risk factors because they are amenable to health promotion and prevention 
interventions. Factors such as, age and genetics are referred to as ‘non-modifiable’ risk 
factors. Together, the modifiable and non-modifiable risk factors are driving the global 
diabetes and hypertension epidemic (WHO, 2005; IDF, 2017).  Both are slow-progressing 
life-long diseases, which can generally be controlled but not cured. Because of this, they 
can have a significant impact on the quality of life of individuals and their family.  In 
developing countries, the onset of diabetes and hypertension tend to occur at a younger 
age, which means people in those countries experience a longer duration of their disease 
or die at a younger age if not managed appropriately (WHO, 2005). Public health 
interventions, which include prevention programmes targeting key lifestyle factors such as 
diet, physical activity and tobacco use are considered the most cost-effective approach to 
manage the burden of diabetes and hypertension. Those strategies are reported to have 
had significant public health impact over time (WHO, 2013; WHO, 2016). However, primary 
prevention strategies which include detecting and managing diabetes and hypertension is 
also critical for preventing CVDs and other life-threatening complications resulting from them 
   
 
 8 
(Hobbs, F, 2004; WHO, 2013; WHO, 2016). It is also important for maintaining quality of life 
for those affected and reducing the economic impact of NCDs in developing countries 
(WHO, 2013). However, detecting and managing these diseases is a known challenge for 
individuals, communities and health systems in developing countries. Largely because of 
their limited financial resources and a general lack of health system infrastructure at the 
community level. To deal with these challenges, countries have been encouraged to 
implement integrated NCD programmes through primary care, as a more affordable and 
sustainable way of managing diabetes and hypertension (WHO, 2013; WHO, 2016). The 
concept of integrated management involves managing diabetes, hypertension and other 
CVD risk factors in primary care, in which early detection and access to essential medicines 
play a key role (WHO, 2016).   
 
1.2 Drug therapy in Chronic Disease Management 
 
NCDs typically require life-long drug therapy, making access to essential medicines in 
primary care facilities a critical component of care (Ewen et al, 2017). In the management 
of diabetes and hypertension, cost-effective drug therapy has shown significant benefits at 
both the individual and societal levels (Wirtz et al, 2011; Grady & Gough, 2014).  For 
individuals with hypertension, medicines can reduce the incidence of stroke and heart attack 
by as much as 40% and 25% respectively (Neal et al, 2000 in Wirtz et al, 2011). Likewise, 
glycemic control with anti-diabetes medicines have been shown to prevent complications 
and is associated with a significant reduction in major cardiovascular events (Younk et al, 
2016; Hayward et al, 2016).  As such, the WHO’s global strategy for the prevention and 
   
 
 9 
control of chronic diseases, considers access to essential medicines a key component for 
strengthening health systems in order to achieve optimal management of these diseases 
(Wirtz et al, 2011; Ewen et al, 2017). According to the WHO, “essential medicines are those 
that satisfy the priority health care needs of the population” and must be selected for each 
country with due regard to disease prevalence and public health relevance. These 
medicines are crucial for survival, preventing significant disability and morbidity and 
preventing inappropriate use of other healthcare services. It is the responsibility of 
governments and policy makers to ensure they are available in adequate quantities and be 
of good quality (Ewen, 2017).  In developing countries where the burden of NCDs is 
increasing, the projected demand for essential medicines to treat them is expected to also 
increase (Wirtz et al, 2011). Sadly, these countries are likely to have the most challenges 
with access to essential medicines to treat NCDs, because of low availability and 
unaffordability (Ewen et al, 2017).  
 
Another key component of effective drug therapy is medication adherence. Medication 
adherence reflects continued access to medicines overtime and is important for effective 
management of chronic diseases. Multiple factors including, drug, patient, provider and the 
health system are said to have an impact on adherence to drug therapy among chronic 
disease patients (WHO, 2003). Adherence improves when medicines are available and 
accessible within the health care system and when patients have a high level of commitment 
to taking them as prescribed by their physicians.  Regardless of the reasons, when patients 
do not take their medicines as prescribed, the behaviour is known as medication non-
adherence. In the US, medication non-adherence cost the healthcare system an estimated 
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290 billion dollars every year (Lemstra et al, 2018). A Canadian study found that 5.4% of all 
hospitalizations were due to medication non-adherence (Iskedjian et al, 2002 in Lemstra et 




2.1 Burden of Diabetes and Hypertension in Jamaica 
 
Jamaica is in the Latin America and Caribbean Region and is classified by the World Bank 
as one of 55 Upper Middle-Income Countries in the world (World Bank Development 
Indicators, 2016).  In 2018, the population was estimated to be 2.8 million (WHO, 2018). 
According to the Jamaica Survey of Living conditions (JSLC), approximately 20% of the 
population live in poverty (PIOJ, 2017). Poverty is more prevalent in the rural areas with 
signs of it increasing over time (PIOJ, 2017).  
 
Over the past several decades, the country has made significant improvements on key 
population health indicators such as life expectancy, infant mortality and control of vaccine 
preventable diseases (Figueroa, JP, 2001; Gordon-Strachan et al, 2010). However, they 
struggle to have an impact on NCDs, which are now the leading cause of death and disability 
in the country. Jamaica has undergone an aging of its population, which saw a doubling of 
seniors (60+ years) from 1970 to 2000 (Bourne and McGrowder, 2009). As a result, the 
main causes of illness and mortality are chronic NCDs (Bourne and McGrowder, 2009). The 
PIOJ (2017) estimated the burden of NCDs in Jamaica to be  25%. In 2016, the age-adjusted 
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mortality rate from NCDs was estimated at 475 per 100,000 population and ranked 9th 
highest among the 28 Caribbean nations (PAHO, 2018). In addition, approximately 15% of 
NCD deaths were premature (PAHO, 2018).  Diabetes and hypertension are major 
contributors to premature NCD deaths making those conditions high on the list of public 
health priorities.  The WHO estimated that in 2014, the prevalence of diabetes in adults (18+ 
years) was 12% in Jamaica, this was an increase from the previous estimate of 10% in 2009 
(WHO, 2018; WHO, 2016). While the prevalence of hypertension remained constant at 
approximately 22% over time, albeit above the global target (WHO, 2018).  These increases 
are occurring concurrently with increasing prevalence of lifestyle risk factors such as obesity, 
tobacco use and physical inactivity (WHO, 2018). Despite national initiatives to promote 
healthy lifestyles over the past several decades.  
 
The rise in diabetes and hypertension is due to an aging population and increased 
prevalence of obesity, sedentary living and unhealthy diet. However, there are marked 
variations in the burden of both diseases between males and females and among socio-
economic groups (Scott & Theodore, 2013). Females of all age groups, adults above 35 
years, persons with lower levels of education and persons in the lowest socio-economic 
category were the most affected by these conditions (Tulloch-Reid et al, 2013). These 
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2.2 An overview of the Jamaican Health Care System 
 
The Jamaican health care system consists of a mixture of public and private health sectors, 
with more than half the population accessing primary healthcare in the private sector 
(Commonwealth Health Online, 2017).  Hospital services (secondary and tertiary care) are 
largely provided by the government who account for 95% of hospital beds (Theodore et al, 
2001). The healthcare financing system can be characterized as segmented, with just over 
60% financed by public funds, followed by 22% out-of-pocket and the other 18% by a 
combination of private health insurance and other private sources (WHO, 2016). Jamaica 
was ranked the lowest when it came to total health expenditure per capita, when compared 
to similar countries in and outside the region (MOHW, 2018).  
 
In 1997, the National Health Service Act gave rise to the decentralization of delivery of public 
health care services in Jamaica. As a result, four geographically based health regions were 
established to deliver primary, secondary and tertiary healthcare services across the 
country. The four health regions are the; Southeast Regional Health Authority; Southern 
Regional Health Authority; Northeast Regional Health Authority and Western Regional 
Health Authority.  Each Regional Health Authority is responsible for operational 
management of public health facilities in their respective geographies (MOHW, 2017). 
 
Since 2008, all patients who use the public health sector pay no user fees for a primary care 
visit, due to a national health policy to remove the user-fees charged at public health 
facilities. User fees were health care costs borne by the patient at the point of care at public 
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health facilities. This policy also included the provision of essential medicines free of charge 
at all public health facilities (PAHO, 2012). The removal of user fees was largely in response 
to concerns that they act as a barrier to healthcare access, with the poor and rural residents 
facing the most challenges (Li et al, 2017).  Although the cost barrier was removed from 
accessing primary care in the public sector, 6 out of 10 individuals were still using the private 
sector for primary care where they are required to pay at each visit (PAHO, 2012).  The 
remainder of the population use the public sector and a small percentage use non-
governmental organization at a reduced cost (PAHO, 2012).   A primary care visit in the 
private sector was estimated to cost an average of J$2,575/US$25.00 (PIOJ, 2015). 
However, these fees do not include diagnostics and medicines, and can vary significantly 
from place to place. Mainly because fees charged within the private sector are not 
government regulated or monitored in any way.   
 
The private health sector dominates primary healthcare services including pharmacy and 
diagnostic services, so patients who regularly use public health facilities are still likely to pay 
out-of-pocket for these services. For individuals with private health insurance, a portion of 
these costs is covered, but less than 20% of the population have private health insurance 
(PIOJ, 2015). Most private health insurance is employer provided, so the poor are less likely 
to have these policies, due to lower employment rates or employment in the informal sector 
(PIOJ, 2015). Rural residents also face greater challenges as there is a higher prevalence 
of poverty, so the physical barriers they often face in accessing healthcare is also 
compounded by financial barriers (PIOJ, 2017).  Private versus public healthcare utilization 
in Jamaica is strongly influenced by socio-economic status (Bourne et al, 2010). It was found 
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that as income increased, individuals were more likely to use private health facilities in 
Jamaica due to their ability to pay and the likelihood of them having health insurance 
(Bourne et al, 2010).   A recent report by the Ministry of Health and Wellness (MOHW, 2019), 
stated that utilization of public sector clinics was declining, due to multiple issues related to 
the financing, organization and delivery of primary healthcare services in the public sector 
(MOHW, 2019).  This has shifted utilization at the primary health clinics to secondary care 
and has resulted in significant burden on public hospitals (MOHW, 2019).  Unaffordability 
and inadequate use of primary care services in the country is likely to place a financial 
burden on Jamaicans.  
 
In Jamaica there are 399 private pharmacies compared to only 83 operational public 
pharmacies (PAHO, 2012). As a result, 80% of medicines are purchased within the private 
sector. Medicines are regulated by the Pharmaceutical and Regulatory Affairs Division, who 
oversee licensing of manufacturers, importers, distributors, wholesalers and exporters of 
medicine. However, the country has very limited control on the retail price of medicines in 
the private sector and there is no medicine monitoring system in place to track these prices 
and their change over time (PAHO, 2012). Generic substitution is permitted by law in public 
and private pharmacies, but there are no incentives to dispense generics (PAHO, 2012).  
Medicine monitoring systems and generic substitution policies are typically implemented 
under a National Pharmaceutical Policy, but Jamaica has not officially adopted one (PAHO, 
2012). The inability of the Jamaican government to monitor the retail price of medicines 
weakens their ability to regulate these prices, thus ensuring their affordability.  
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2.3 Access to chronic disease medicines in Jamaica 
 
An assessment of the pharmaceutical sector found that essential medicines were generally 
available (93%) in both public and private pharmacies (PAHO, 2012).  Availability of 
medicines in the public sector in Jamaica was better when compared to other countries in 
the upper middle-income categories, where medicine availability was critically lower in the 
public sector compared to the private sector (Ewen et al, 2017). Geographical accessibility 
to public and private pharmacies was rated as good, as only a small percentage of people 
had to travel more than an hour to fill their prescription. With respect to the cost of essential 
medicines, they are provided free of cost in the public sector. However, in the private sector 
it was estimated that it would cost 10% of a day’s wage of the lowest paid government 
worker to purchase a 30-day supply of the lowest cost generic medicines for diabetes and 
80% for hypertension (PAHO, 2012).  The cost of originator brands for the same medicines 
was significantly more costly, for example it would take 5.2 days wages of the lowest paid 
government worker to purchase an originator brand of antihypertensive medicine (PAHO, 
2012).  Accessibility to public health facilities was reportedly adequate in most areas across 
the country, but access to medicines was hindered by affordability (PAHO, 2012). Relatively 
low utilization of public pharmacies where medicines are provided free of cost was a big 
contribution to the unaffordability of essential medicines in Jamaica (PAHO, 2012). In a 
household survey, more than one quarter of individuals with a chronic condition reported not 
taking medicines because they could not afford it (PAHO, 2012). This was after the 
implementation of the Jamaica Drug for the Elderly Programme (JADEP) in 1996 and the 
National Health Fund in 2003. These are two government initiatives intended to narrow the 
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gap in access to essential medicines for chronic diseases.  The JADEP provides subsidy for 
medicines to the elderly (60+ years) and the NHF provides subsidy for medicines to all 
Jamaicans diagnosed with selected chronic diseases. Both programs were intended to 
reduce the out-of-pocket costs of essential medicines among patients with chronic diseases. 
 
2.4 Medication Subsidy in Jamaica – The National Health Fund 
 
According to the NHF Act (2003), all Jamaicans could realize health benefits through the 
National Health Fund whose principal objectives are to: 
a)  Provide prescribed health benefits to all residents regardless of age, gender, health 
or economic status; 
b) Provide greater access to medical treatment and preventive care for specified 
diseases and specified medical conditions all residents (NHF Act, 2003); 
c) secure improvement in the productivity of residents by reducing time lost on the job 
that is attributable to personal and family health care problems; 
d) Reduce the island’s disease burden through health promotion and protection 
programmes; and 
e) Provide support to health services and promote and encourage the utilization of 
primary health care to improve the quality of life of the island’s population. 
 
Under the NHF Act (2003), increasing access to essential medicines for NCDs was a key 
objective of the National Health Fund by making “prescribed drugs and other benefits 
available to residents at government-owned and other facilities” (NHF ACT, 2003). This is 
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known as the NHF Individual Benefits. The NHF Individual Benefits programme was 
implemented in 2003. The programme provides financial assistance for medicines to 
Jamaicans with one or more of 16 chronic diseases, including diabetes and hypertension. 
This benefit is available to all Jamaicans regardless of age, sex or socio-economic status. 
To be eligible, individuals are required to have a physician confirmed diagnosis of one of the 
16 chronic diseases covered.  Although medicines can be accessed free through the NHF 
at public pharmacies, the majority of the pharmacies in Jamaica are privately run, where 
NHF enrollees can access their medicines at a subsidized cost.  
 
To enroll, patients must complete an application form with their names, address, sex and 
their date of birth and have it signed by their physician confirming their diagnosis (es). The 
patient is also required to actively go to an NHF enrollment office to submit their application 
for an NHF beneficiary card (NHFCard) in order to access the subsidy.  Almost all 
pharmacies within the private sector participate in the NHFCard programme. In 2017, the 
NHF subsidized chronic disease medications for over 240,000 Jamaicans, over one-third of 
whom received subsidies for hypertension and diabetes medicines (NHF, 2018). Majority of 
NHF beneficiaries are females (62%) over 45 years (84%) (NHF, 2018). The average 
number of illnesses covered per patient was 3 and the average subsidy paid was 44% of 
the drug retail price (NHF, 2018).  
 
Subsidy rates varied by chronic disease and was higher for anti-diabetic (56%) compared 
to anti-hypertensive (42%) (NHF, 2016). Antihypertensive was among the medicines with 
the lowest subsidy rates (NHF, 2016). There was a 10% decrease in the overall subsidy rate 
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since 2012, which was attributed to an increase in the retail price of prescription drugs (NHF, 
2016, 2018).   This is largely because the price of medicines in Jamaica is strongly 
influenced by the devaluation of the Jamaican dollar (NHF, 2018).   Therefore, overtime we 
are seeing a decreasing impact of the NHF Individuals Benefits on the out-of-pocket cost of 
chronic disease medicines to patients in Jamaica. The amount of subsidy received is not 
dependent on income and is the same for all individuals. Low-income families are therefore 
required to pay the same out-of-pocket when they use the subsidy. Those with private health 
insurance will have lower out-of-pocket expenditures. 
 
2.5 Study Rationale  
 
Access to essential medicines and adherence to these medicines are important for 
effectively managing life-long chronic diseases such as diabetes and hypertension in 
primary care. The Jamaican government has over the years endeavored to make healthcare 
more accessible. The removal of user fees from public health clinics in 2008, was 
implemented to increase access to primary care services for those who could not afford to 
pay. The Jamaica Drug for the Elderly Programme (JADEP, 1996) and the National Health 
Fund (NHF, 2003) were implemented to narrow the gap in access to essential medicines for 
chronic diseases and ensure quality treatment with medicines.  Despite the implementation 
of these policies and programmes, disparities in healthcare utilization and health status in 
Jamaica was still a problem (Scott & Theodore, 2013).  These disparities may be influencing 
access to the medicine subsidy through the NHF.  Also, the high rate of utilization of the 
private sector for primary care services and medicine purchases may have a 
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disproportionate negative impact on low-income families. This is largely because the 
government has little control over the fees charged and price of medicines sold in the private 
sector. This may result in catastrophic health expenditures on chronic disease management 
for those families.  It is well known that families exposed to catastrophic health expenditures 
have poorer outcomes. It also puts unnecessary burden on the already strained healthcare 
system.  
 
In 2008, five years following implementation of the NHF, approximately 40,000 adults with 
diabetes and 270,000 adults with hypertension reported not taking prescription medicines 
for their condition (Wilks et al, 2008).   The NHF Individual Benefit was designed specifically 
to reduce the gap between need and access to medicines. However, this data suggests that 
there was still a significant gap between the need for prescription medicines to treat these 
common chronic diseases and access to these medicines.  It was previously highlighted that 
socio-economic and socio-cultural factors influence utilization of health services in Jamaica 
(Bourne et al, 2010). However, there is no empirical evidence of the effect that these factors 
have on access to the NHF. Considering the public health impact of diabetes and 
hypertension in Jamaica, and the importance of essential medicines in reducing the burden 
of those diseases, ensuring equitable access to the NHF medicine subsidy is important for 
Jamaicans, particularly the poor.  To my knowledge, no research has been conducted to 
investigate the factors driving utilization of this important public health initiative.  Medication 
adherence is key to the effective management of chronic diseases. Now that medications 
are made more affordable through the NHF, no studies have investigated the levels of 
adherence and the factors associated with medication adherence among the patients 
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enrolled in the programme. Additionally, although previous studies have examined levels of 
adherence to chronic disease medicines, no studies have used actual pharmacy utilization 
data to examine adherence to diabetes and hypertensive medications on a large cohort of 
the Jamaican population. The removal of user fees from public health facilities in 2008 was 
an important policy decision towards making primary care and by extension essential NCDs 
medicines more accessible. The impact of that policy on use of NHF among diabetics and 
hypertensives has not been investigated. The impetus for this research is to address some 
of these unanswered questions related to accessing the NHF. 
 
3 Research aim 
 
This research aims to use real world national data sources to understand access and 
utilization of the NHF Individual Benefits programme among adults with diabetes and 
hypertension.  
 
3.1 Specific Research questions 
 
The research will specifically address three questions related to accessing the NHF 
Individual Benefits programme among adults with diabetes and hypertension: 
 
a) Is there differential access to this medication subsidy programme? Can those 
differences be attributed to patient needs or other non-need factors? 
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b) What are the utilization patterns and the factors predicting adherence among NHF 
enrollees with diabetes or hypertension? 
c) What was the effect of the removal of user fees from public health facilities on use of 
the NHF subsidy? 
 
The government has over the years made large investments in this medicine subsidy 
programme. It is important for policy makers to understand how the programme is being 
used and if the individuals most in need are benefiting. 
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CHAPTER 2 - LITERATURE REVIEW 
1 Chapter introduction 
 
This chapter comprises three sections. The first section discusses the definition of access 
within the context of healthcare and its relevance to research on access to medicines. This 
definition will be used as a framework to analyze the literature on access to medicines and 
to make recommendations about interventions to improve access to the NHF.  The second 
section examines the literature on the factors associated with access to medicines in 
developing countries and will be used to guide the selection of study variables for this thesis. 
The third and final section is a systematic review, which focuses on describing the 
experience of developing countries with policies aimed at influencing access and use of 
chronic disease medicines. The systematic review is intended to highlight how developing 
countries have used policies or programmes like the NHF and the scope of these policies in 
addressing the broad range of issues related to access to medicines.   The review is also 
intended to highlight some of the gaps in research related to these policies in developing 
countries. 
 
2 Definition of access 
 
According to Penchansky & Thomas (1981), access in healthcare is defined as “the degree 
of fit between clients and the system”, in other words, the extent to which the needs of 
patients are addressed by the healthcare system.  They argued that access is a general 
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concept consisting of five distinct but related dimensions, accommodation, accessibility, 
availability, affordability and appropriateness.  This multi-dimensional concept of access was 
later supported by Peters et al (2008), Bigdeli et al (2013) and Suarman et al (2016). 
According to the Penchansky & Thomas (1981), the five dimensions of access can be 
characterized as: 
 
1. Availability – which can be characterized by the volume and types of services that 
exist within the healthcare system relative to the patients’ need. With regards to 
access to medicines, this would be associated with health system factors, such as 
adequate drug supplies in pharmacies and the availability of essential medicines to 
meet the needs of the population. 
 
2. Accessibility - This dimension of access has to do with the physical and 
geographical location of patients versus healthcare sites and takes into account 
distance, travel time and their associated costs. This dimension is associated with 
health system factors, such as location and distribution of primary care facilities, 
diagnostic facilities and pharmacies. This enables patients to be appropriately 
diagnosed, receive ongoing disease monitoring and fill prescriptions for chronic 
disease medicines.  
 
3. Accommodations - These are the administrative services or operational 
components such as hours of operation, waiting time and whether they are 
appropriate for the patients being served.  These are also associated with health 
   
 
 24 
system factors that enable timely access to chronic disease management services. 
Government policies may have very little control over these factors in countries where 
the private sector is a major player within the healthcare system. 
 
4. Affordability - This is the patient’s perception of the cost of healthcare services 
versus its value, this takes into account insurance coverage, patients’ income and 
the price of healthcare services. This is a combination of health system and patient 
factors.   Financial barriers exist when patients are unable to receive needed 
healthcare services and medicines due to unaffordability, either because they are 
poor or the cost of healthcare accounts for a large proportion of their household 
expenditure.  This is especially true in countries where primary care services and 
medicines are determined by the private sector without government oversight, as 
these services are for profit rather than needs driven.  
 
5. Acceptability is concerned the relationships of the patients with the healthcare 
system and takes into account patients’ characteristics such as education level, 
socio-cultural and religious beliefs. The informal healthcare system such as 
traditional healers and alternative medicine practitioners also plays a key role if they 
exist. Treatment factors, such as medicine side effects and provider factors are also 
associated with this domain. It characterizes the patients’ perception of the need for 
services or the quality of healthcare services.  
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Access to health services is optimized when all the five dimensions are accounted for. 
Penchansky & Thomas (1981) demonstrated that multiple factors were influencing the 
different dimensions of access. These factors were a combination of health system and 
population characteristics such as, physician’s office wait-times, travel time, length of 
relationship with physician, sex, persons with high health concerns and use of private 
physicians.  Later, Saurman et al (2016) proposed a sixth dimension of access - awareness 
- which emphasized the importance of communication and information.  Awareness has to 
do with service provider awareness as well as patient awareness.  Based on these 
dimensions, access to health services can be summarized as consisting of multiple 
dimensions that can be linked to a broad range of inter-related health system and patient 
factors.  
 
By considering all the dimensions of access, the literature review in section two is intended 
to identify the factors associated with access and adherence to chronic disease medicines 
in developing countries. 
 
3 Literature review on access and adherence to medicines in 
developing countries 
 
A review of the literature was conducted to identify factors associated with access and 
adherence to chronic disease medicines in developing countries.  Ninety-three (93) studies 
were identified between 2010 and 2019 using the search terms in Appendix 2.1. 
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A review of the titles and abstracts identified 24 relevant studies. One (1) was a systematic 
review including fifteen (15) studies from developing countries across Africa, Asia, Europe, 
the Middle East, Latin America and the Caribbean (Christiani et al, 2016). Another 
systematic review included fourteen (14) studies from Iran on adherence (Sarayani et al, 
2013).  Ten (10) were studies involving multiple countries across Africa, Asia, Latin America, 
the Caribbean and the Middle East (Ewen et al, 2019; Barbar et al, 2019; Macquart de 
Terline et al, 2019; Chow et al, 2018; Attaei et al, 2017; Ewen et al 2017; Emmerick et al, 
2015; Srivastava et al, 2015; Vialle-Vallentin et al, 2015; Wagner et al, 2011).  Others were 
single country studies from Kenya (Rockers et al, 2019; Shannon et al, 2019; Rockers et al, 
2018), Kyrgyzstan (Murphy et al, 2016), Indonesia (Rahmawati et al, 2018), India (Elias et 
al, 2017), Iran (Sarayani et al, 2014), Ghana (Marfo et al, 2017), Guatemala (Flood et al, 
2017); Mozambique (Gama et al, 2013), Tanzania (Jande et al, 2017) and Pakistan (Shams 
et al, 2016).  
 
Definitions and measurement of access and adherence varied between studies. Only three 
studies included a theoretical framework in their analysis, Vialle-Valentin et al (2015) and 
Elias et al (2017) used the Medicine Access framework developed by Bigdeli et al (2013) 
and Srivastava et al, 2015 used the Demand for Health Economic framework. A wide 
variation of patient, health system and contextual factors were examined in these studies. 
A summary of the access to medicine outcomes measured, and the factors examined can 
be found in Table 1 below. 
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Factors examined and direction of 
effects 







Use of at least one 
antihypertensive 
Number of blood pressure lowering 
drug classes at community pharmacies 
(+), cost of medicines at community 
pharmacies (+), rurality (+), countries 
economic development (+), number of 
therapies (+) 
Use of combination 
therapy 
Blood pressure control 






countries economic development (+), 
generics (+), cost (-) 
Medicine stock at legally 
permitted dispensing 
sites 







Availability of medicine 
on the day the pharmacy 
is visited Countries economic development (+) 
Cost of medicine 






Access to anti-diabetes 
medicines 
Rural (X/-), race/ethnicity (-), 
occupation (X), Female gender (+/X/-), 
education (+/X), socio-economic 
status/income (+), age (+/-), health 
insurance coverage (+), physical 
disability (-) 
Elias et al, 2017 India 
Diabetes and 
Hypertension 
Access to medicines 
Health system components defined by 
Bigdeli et al (2013) Access to Medicine 
Framework (+) 








obtaining all medicines 
sought for the chronic 
conditions reported. 
Age 65+ years (+/X),age of household 
head (+),rural(X),gender (X),ethnicity 
(X),health insurance coverage 
(X),education (+/X),literacy (X), physical 
disability (X),health status (X),status in 
the household (X), seeking care in the 
formal health system (+) , proximity to 
public and private health facilities 
(X),medicine insurance (x),household 
economic level (+/X), seeking care in 
the private sector (+/X), obtaining 
medicine in the private sector (+/X), 
receiving free medicine (+/X) 










Countries economic development (+); 
Private sector (+); generic medicines 
(+) 
Medicine stock at legally 
permitted dispensing 
sites 





Medicine prices (generics 
vs originator brands) 
Countries economic development (+); 
Income (+); Biosimilars (+) 





Medicine stock at legally 
permitted dispensing 
sites. 





Access to low-cost 
generics 
Providers' positive perception (+) 






Female Gender (+), age (X), 
overweight/obesity, smoking (X), BMI 
(X), use of traditional medicine (X), 
rural (X), education (X), aware of 
hypertensive status (+) 
Jande et al, 
2017 
Tanzania Hypertension Adherence 
Patient's positive perception about 
medication (+) 
Macquart de 






age (X), male gender (X), patient 
wealth index (+), countries income 
level (+), rural (X), duration of disease 
(X), CVD Risk Factors (X), use of 
traditional medicine (+), drug class (X), 
polypharmacy (X), Complications (X) 
Marfo et al, 
2017 
Ghana Hypertension 
Blood pressure control 
and adherence  
Pharmaceutical care model 
(Community level Intervention) (+) 
Murphy et al, 
2016 
 Kyrgyzstan Hypertension Adherence 
Age (X), Male gender (X), rural (X), 
marital status (+), insurance coverage 





How and where people in 
rural villages obtain their 
medicines 
age (X), Female gender (X), education 
(+), employment status (X), proximity 
to clinic (+), health insurance coverage 
(+), physical activity (+), duration of 
chronic diseases (+), knowledge of 
disease (X) 






Medicine available in the 
home (location and cost).  
Wealth (+), proximity to health 
facilities (+), Out-of-pocket cost (-) 






Availability and price of 
portfolio medicines at 
health facilities 
Low-cost medicines (X) 
Availability of medicines 
at patient households 
*Sarayani et al, 
2013 
Iran Diabetes Adherence 
Age (-), gender (X), education level 
(+/X), duration of pharmacotherapy 
(+/X), beliefs about medicine (+/X/-), 
knowledge of the disease (+), 
perception of disease severity (+), 
regular visits to physician (+), insurance 
coverage (+/X), polypharmacy (X) 
Sarayani et al, 
2014 
Iran Diabetes 
Prevalence of diabetes 
medicine utilization 
Time (+), drug class (+) 
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Shams et al, 
2016 
Pakistan Diabetes Adherence 
Age (X), Gender (X), polypharmacy (-), 
alternative therapy (-), duration of 
disease (X), education/Illiteracy (+), 
poverty (-), dietary adherence (+), drug 
type (X), glycemic control (+) 
Shannon et al, 
2019 
Kenya Diabetes Access 
Stable and affordable insulin supply at 
dispensing sites (X) 






Patient utilization as a 
measure of access 
Age (x), Gender (+), marital status (-), 
health status (+), insurance coverage 
(+), rural (-), education (+), 
employment (+), household 
expenditure (+) 
Vialle-Valentin 








Regularly taking medicine 
for a diagnosed chronic 
disease and data 
collectors 
Age (-/X), gender (X), education level 
(+/X), poverty (+/X/-), distance to 
health facilities (+/X), household size 
(+/X), Living in the capital (+/X), Free 
medicines (+/X), Insurance (+/X), 
positive attitude towards medicine 
(+/X), awareness of generic medicines 
(+/X), positive opinions about medicine 
availability (+/X/-), history of 
borrowing money to pay for medicines 
(-) 
Found a medicine 
indicated for that disease 
in their homes 









Household respondent in 
need of treatment and 
medicines received care 
Health Insurance (+), High public sector 
functioning (+) 
Household respondent 
with at least 1 chronic 
illness was treated or 
reported taking medicines 
for his/her condition in 
the past 2 weeks 
Household respondent 
that usually requires 
treatment with medicines 
received all or most of the 
medicines needed 
 Note: Covariate has a positive effect on one or more access to chronic disease measures (+); Covariate has a negative effect on one or 
more access to chronic disease medicines (-); Covariate was not significant on the access to chronic disease medicines (X) 
 
The common theme from the identified studies over the last decade, was that affordability 
and availability of essential chronic disease medicines was still a barrier to access and 
adherence in developing countries ( Ewen et al, 2019; Babar et al, 2019; Shannon et al, 
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2019; Rockers et al, 2018; Chow et al, 2018; Rahmawati et al, 2018; Attaei et al, 2017; Ewen 
et al, 2017; Flood et al 2017; Christiani et al, 2016; Murphy et al, 2016; Emmerick et al, 
2015; Sarayani et al, 2014; Wagner et al, 2011). Availability was often measured by 
determining medicine stock or inventory in community pharmacies or at the household level 
(Rockers et al, 2019; Babar et al, 2019; Attaei et al, 2017; Chow et al, 2018). Affordability 
was measured by people’s capacity to pay for medicines, or by the price of drugs at medicine 
dispensing sites (Rockers et al, 2019; Barbar et al, 2019; Chow et al, 2018, Ewen et al, 
2017).  Factors other than affordability and availability of medicines were also found to be 
significant in determining access to chronic disease medicines. For example, poor 
accommodations within primary care health clinics were considered a barrier, including gaps 
in the organization of care for diabetes and hypertension at primary health centres and 
availability of quality trained healthcare professionals (Shannon et al, 2019; Elias et al, 2016; 
Christiani et al, 2016). Underdiagnosis and poor disease management within the health 
sector were identified as barriers to accessing chronic disease medicines (Sarayani et al, 
2014). Geographic accessibility also affected access to chronic disease medicines. For 
example, patients who lived in communities near a health centre and people living in urban 
areas had better access, while patients living in remote locations had poorer access 
(Emmerick et al, 2015; Srivastava et al, 2015; Christiani et al, 2016; Rahmawati et al, 2018). 
A range of patient characteristics such as age, sex, education, socio-economic status, 
insurance coverage, patient belief, marital status, knowledge of condition, seeking care or 
purchasing medicines in the private sector, treatment acceptability and use of alternative 
treatments were found to significantly influence access to chronic disease medicines in 
developing countries (Emmerick et al, 2015; Vialle-Vallentin et al, 2015; Shams et al, 2016; 
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Gama et al, 2013; Wagner et al, 2011; Jande et al, 2017; Macquart de Terline et al, 2019). 
Provider awareness and perceptions about medicine quality and safety were also found to 
have a significant impact on access in these settings (Marfo et al, 2017; Flood et al, 2017).  
Factors associated with the disease condition and drug therapy were also significant 
predictors of access and adherence, such as polypharmacy and the presence of comorbid 
disease conditions (Macquart de Terline et al, 2019; Gama et al, 2013; Shams et al, 2016). 
 
Five studies specifically examined the factors associated with adherence to chronic disease 
medicines.  Multiple factors were found to be associated with adherence, including poverty, 
socio-economic status, illiteracy, use of traditional medicines, poor knowledge of condition 
and medicines, patient beliefs about the medicine efficacy, dietary adherence, poly-
pharmacy, duration of pharmacotherapy, perception of disease severity, regular visits to 
physician and medication side-effects (Macquart de Terline et al, 2019; Marfo et al, 2017; 
Jande et al, 2015; Shams et al, 2016; Sarayani et al, 2013).   
 
The literature review on the factors associated with access and adherence to chronic 
disease medicines in developing countries supports Penchansky and Thomas’ (1985) 
multidimensional concept of access.  It also  highlighted the problems faced by lower income 
countries and households in developing countries, concerning equitable access and 
adherence to chronic disease medicines (Babar et al, 2019; Ewen et al, 2019; Macquart de 
Terline et al, 2019; Chow et al, 2018; Attaei et al, 2017; Elias et al, 2017; Christiani et al, 
2016; Murphy et al, 2016; Emmerick et al, 2015; Wagner et al, 2011). The next section 
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examines developing countries' use of government policies to improve access and 
adherence to medicines in developing countries. 
 
4 A Systematic review of developing countries experience with 




WHO (2011) recommends that developing countries have policies as a basic intervention to 
promote access and quality use of essential medicines.  As demonstrated earlier, there are 
many challenges to achieving the goal of equitable access to chronic disease medicines. A 
major challenge to achieving these goals is limited supply of low-cost essential medicines. 
This results in patients paying out-of-pocket or receiving poor quality treatment, particularly 
in the public sector. Vulnerable populations, such as the elderly and low-income families are 
more susceptible to the financial risks associated with the high cost of medicines. Patients 
with chronic diseases also face greater financial burdens, due to the complexity and 
longevity of these diseases (Viswanathan et al, 2012; Sum et al, 2018). However, while 
patient’s risk profiles tend to be a big consideration in pharmaceutical policy designs, the 
country’s economic status also plays a strong role (Maniadakis et al, 2017).  
 
A search of systematic reviews databases in December 2018 (PDQ Evidence and Health 
Evidence) on the effects of pharmaceutical policies identified eighteen (18) systematic 
reviews completed in the last five years. The countries included in these reviews were 
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primarily developed countries in Europe and North America. The reviews highlighted that 
when policies do not offer sufficient financial protection from high out-of-pocket costs, 
patients are more likely to experience negative outcomes (Lee et al, 2013; Sinnott et al, 
2013; Angela et al, 2014; Happe et al, 2014; Mann et al, 2014; Jia et al, 2014; Tang et al, 
2014; Barnieh et al, 2014; Lee et al, 2015; Njie et al, 2015; Rashidian et al, 2015; Luiza et 
al, 2015; Kesselheim et al, 2015; Ogbechie & Hsu, 2015; Aziz et al, 2016; Kolasa & 
Kowalczyk, 2017; Park et al, 2017; Sum et al, 2018; Babar et al, 2018).  Vulnerable 
populations, such as the elderly and low-income groups were at a greater risk of negative 
outcomes because of their limited financial resources (Jia et al, 2014; Sum et al, 2018).  For 
patients with chronic diseases, when policies did not include sufficient pharmaceutical 
assistance or subsidy, access and adherence to essential medicines were negatively 
impacted and often lead to inappropriate use of health services (Mann et al, 2014; Tang et 
al, 2014; Njie et al, 2015; Luiza et al, 2015; Sum et al, 2018).   On the other hand, some 
researchers argue that lowering or removing out-of-pocket expenses may cause 
overconsumption of unnecessary health services or irrational use of medicines (Jia et al, 
2014; Luiza et al, 2015; Kolasa & Kowalczyk et al, 2017). There was also a general 
consensus from recent reviews that there was a lack of consistency in the findings pertaining 
to the effects of pharmaceutical policies on drug use outcomes, and that more research is 
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4.2 Why do this review? 
 
Ratanawijitrasin et al (2001) who conducted a systematic review almost twenty years ago 
concluded that there was a lack of reliable data in developing countries to answer questions 
about the effects of pharmaceutical policies on access to medicines. The authors also 
highlighted that most studies in developing countries used weak study designs.   In the 
reviews examined more recently, except for Sum et al (2018), which included one study in 
India, systematic reviews on the effects of pharmaceutical policies, were based on high-
income countries. This is consistent with a previous study, which concluded that there was 
a gap in evidence related to pharmaceutical policies in developing countries (Gray & 
Suleman, 2015). A number of limitations were highlighted in recent reviews, such as 
heterogeneity of populations studied, policy designs, study designs and outcomes 
measured outcomes (Lee et al, 2013; Sinnott et al, 2013; Angela et al, 2014; Happe et al, 
2014; Mann et al, 2014; Jia et al, 2014; Tang et al, 2014; Barnieh et al, 2014; Lee et al, 
2015; Njie et al, 2015; Rashidian et al, 2015; Luiza et al, 2015; Kesselheim et al, 2015; 
Ogbechie & Hsu, 2015; Aziz et al, 2016; Kolasa & Kowalczyk, 2017; Park et al, 2017; Sum 
et al, 2018; Babar et al, 2018). As a result, very few reviews included meta-analysis or 
pooled analysis of results. Those limitations plus the lack of inclusion of studies from 
developing countries, means that the existing evidence on this topic has limited 
transferability to policy makers in developing countries.  
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This review is intended to summarize existing research on the effects of pharmaceutical 
policies on drug utilization outcomes. By focusing on developing countries, it is adding to 
much needed evidence within this context. 
 
4.3 Review objective 
 
This review aims to examine the effects of government pharmaceutical policies on access 




The study selection criteria were based on the Population Intervention Comparator Outcome 
(PICO) framework. For this review, there were no set criteria for comparators. 
Participants/population 
Consumers of prescription medicines and healthcare providers who prescribe or dispense 
prescription medicines in developing countries. Only studies on community dwelling 
populations were included.  
 
Developing countries were identified using the 2018 World Economic Situation and 
Prospects (WESP) report, produced jointly by the United Nations Department of Economic 
and Social Affairs (UN/DESA), the United Nations Conference on Trade and Economic 
(UNCTAD) and the five United Nations Regional Commissions (Economic Commission for 
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Africa (ECA), Economic Commission for Europe (ECE), Economic Commission for Latin 
America and the Caribbean (ECLAC), Economic and Social Commission for Asia and the 
Pacific (ESCAP) and Economic and Social Commission for Western Asia (ESCWA).  
 
WESP classifies all countries into their basic economic condition. Based on that 
classification system, three broad groups were defined; developed economies; economies 
in transition and developing economies (WESP, 2018). Only studies pertaining to countries 
in the ‘developing economies’ group were included in the review. 
Intervention 
Government pharmaceutical policies aimed at influencing consumer or healthcare provider 
behaviour related to access and use of prescription medicines. For the purpose of this 
review, policies are defined as laws, regulations, policies and programs implemented at the 
national or regional level or in the public sector.  This definition is consistent with previous 
reviews (Rashidian et al, 2015; Ratanawijitrasin et al, 2001). 
Outcomes 
• Medicine access and use 
o Access (availability, affordability) 
o Prescribing/dispensing patterns 
o Consumption patterns e.g. adherence or compliance 
 
Although five dimensions of access was described earlier, the literature review in section 
two identified availability and affordability as the main concern in developing countries when 
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it comes to accessing chronic disease medicines. As such, the systematic review focused 
specifically on these two access dimensions along with other outcome which represent key 
steps in the medicine consumption life cycle in which government pharmaceutical policies 
can influence change. They are also key priorities for improving the quality of drug therapy. 
Types of study to be included 
Quantitative study designs, including randomized control trials (RCTs), repeated measures 
studies (RM), non-randomized control trials (NRCTs), cohort studies, interrupted time series 
designs (ITS), controlled before-and-after studies (CBA), cross-section designs and other 
quantitative designs found in the literature.  
Search strategy 
PRISMA Guidelines for conducting systematic reviews were followed. Major online health 
related, and multidisciplinary databases were searched to identify peer-reviewed articles 
published in English.  The databases searched were Medline, Web of Science, CINAHL and 
EMBASE were searched.   Finally, the reference lists of included studies and reviews from 
the online bibliographic search were reviewed to identify additional studies. Search terms 
were based on the PICO framework and were refined by a trained librarian at Lancaster 
University.  The search strategy was executed between November 1, 2018 and December 
31, 2018 (Appendix 2.2) 
Data extraction and management 
All titles included in the search criteria were screened for inclusion/exclusion. Abstracts were 
then screened, followed by a full text review of articles for final inclusion.  The information 
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extracted from each included study can be found in Appendix 2.3. Other pertinent 
information, such as the study limitations, that might affect the interpretation of the study 
were also noted. Data extraction was completed between January 1 to 30, 2019. 
Methodological quality assessment 
As this review is intended to evaluate evidence regarding public policies related to 
pharmaceutical access and use, the Effective Public Health Practice Project (EPHPP) tool 
was used to assess the methodological quality of included studies.  This tool was designed 
to assess all types of quantitative studies and evidence related to public health programs 
and policy. The EPHPP tool outlines six components for assessing the methodological 
quality of quantitative studies (Appendix 2.4). 
 
Each component was assessed and rated individually as either ‘strong’, ‘moderate’ or 
‘weak’, then a global rating was given based on the combined assessment outcomes of the 
individual components. For the global rating, studies were also placed into one of three 
methodological quality categories, ‘strong’, ‘moderate’ or ‘weak’. Studies with two or more 
‘weak’ component ratings were assessed as having ‘weak’ methodological quality, studies 
with one ‘weak’ component rating were placed in the ‘moderate’ category and studies with 
no ‘weak’ component rating were placed in the ‘strong’ methodological quality category. 
Studies were not excluded from the review on the basis of their methodological quality.  
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Strategy for data synthesis 
The findings from all included studies are presented in a descriptive summary table.  
Information includes country, authors, policy name/time period, and policy goal and policy 
intention.  
 
A narrative approach was used to synthesize the findings of all included studies. This 
approach was chosen for two reasons. Firstly, because of the observed heterogeneity in 
population, study design, and policy designs. Secondly, because the objective of the review 
was to develop an understanding of the experience of developing countries with respect to 
their National Pharmaceutical policies. The narrative summary was organized and 
presented by the primary outcomes evaluated. 
4.5 Results 
 
The search yielded 2,714 citations. Upon screening of titles and review of abstracts, 2,656 
records were excluded. The full text of the remaining 56 articles were retrieved and 
assessed for eligibility. Twenty-six (26) articles were eligible from the search. The reference 
list of all eligible studies was reviewed for additional articles not found in the search, which 
yielded eight (8) additional articles. A total of thirty-six (34) studies were included in the 
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Figure 1: Prisma Chart Outlining Process for Study Inclusion 
 
 
Description of included studies 
A total of thirty-four (34 studies) related to policies in ten developing countries were included 
in this review. Over half (52%) were related to policies in the East Asian region (China and 
Taiwan); One-fifth (21%) to policies in the Latin American Region (Brazil and Mexico); 9% 
of included studies were related to countries on the African Continent and one (3%) each 
from three countries across Asia and the Middle East (Turkey, Nepal, Thailand).  A 
description of policies examined by included countries is provided in table 2 below. 




Table 2: Description of policies and policy intervention evaluated in included studies 
Country Authors Policy/time period Policy intention Policy 
component 
evaluated 
China He at al, 2018; 
Xi et al, 2018; 
Guo et al, 
2017; Ding et 
al, 2017; Yi et 
al, 2015; Zhou 
et al, 2015; Yao 
et al, 2015; 
Chen et al, 
2014; Song et 
al 2014a; Song 
et al 2014b; 
Zhang et al, 
















































China Huang et al, 
2018; Zhang et 
al, 2017; Sun et 
al, 2009 
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Brazil Mengue et al, 
2016; Monteiro 
et al, 2016; 
Bertoldi et al, 
2012; Bertoldi 
et al, 2011; 
Paniz et al 
2010; Bertoldi 
et al, 2009  
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Taiwan Liu et al, 2003 The National Health 
Insurance Scheme 







Reduce burden of 
pharmaceutical 
expenditure on 





Taiwan Chu et al, 2011; 
Chu et al, 2008 
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Reimbursement 
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over the counter 
(OTC) status 
Nepal  Holloway et 
2001a; 
Holloway et al 
2001b 
Bamako Initiative – 
Fee per item at 















Thirteen studies evaluated the National Essential Medicine Policy (NEMP), which was 
introduced in China in 2009 (Huang et al, 2018; He at al, 2018; Xi et al, 2018; Guo et al, 
2017; Ding et al, 2017; Yi et al, 2015; Zhou et al, 2015; Yao et al, 2015; Chen et al, 2014; 
Song et al 2014a; Song et al 2014b; Zhang et al, 2014; Yang et al 2013). The NEMP 
contained three key components, the National Essential Medicines List (NEML), Zero Mark-
up Drug Policy and Centralized Procurement Policy. The NEMP was implemented as part 
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of China’s healthcare reform and was intended to increase access to essential medicines 
and curb irrational prescribing in primary health centres.  Two additional studies evaluated 
China’s three government health insurance schemes, the Urban Employee Basic Medical 
Insurance established in 1998; National Cooperative Medical Scheme established in 2003; 
Urban Resident Basic Medical Insurance Scheme established in 2008 (Zhang et al, 2017; 
Sun et al, 2009). These policies were introduced in China at various points over time to 
increase equitable access to primary health care services, including access to medicines.  
 
Six studies evaluated Brazil’s National Medicine Policy under the Unified Health System 
(SUS) (Mengue et al, 2016; Monteiro et al, 2016; Bertoldi et al, 2012; Bertoldi et al, 2011; 
Paniz et al 2010; Bertoldi et al, 2009). Key policy components evaluated were, free access 
to medicines in the public sector and access to low-cost medicines in the private sector 
under the ‘Popular Pharmacy Program”.  Aruaja et al (2014) evaluated the “Health Has No 
Price Program”, which was introduced in 2011 to allow for free access to selected anti-
hypertensive medicines in the private sector. 
 
Two studies investigated Mexico’s Seguro Popular (SP) policy, which was introduced in 
2003 to improve access and availability of healthcare services, particularly the portion of the 
population without access to employer provided health insurance (Moye-Holtze et al 2018; 
Rivera-Hernandez et al 2016).  
 
Three studies evaluated Taiwan’s National Health Insurance Scheme (NHI). One study 
evaluated the Out-Patient Prescription Drug Cost-Sharing Program, which was introduced 
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in 1999 (Liu et al, 2003) to address irrational physician prescribing. The other two studies 
evaluated the Reimbursement Rate Reduction Policy which followed in 2000 (Chu et al, 
2008; Chu et al, 2011) with a goal of reducing pharmaceutical expenditure.  
 
National Drug Policies tied to the Bamako Initiative was evaluated in four studies from three 
separate countries, Nigeria (Uzochukwu et al, 2002), Mali (Maiga et al, 2003) and Nepal 
(Holloway et al, 2001a; Holloway et al 2001b). The Bamako Initiative was formulated in 
1987, as a cost-recovery mechanism where low-cost generics are sold at a profit and user-
fees are charged to the patient. This was to ensure financing for the continued supply of 
essential medicines in public health centres and improve access and quality of care in the 
public health sector. 
 
One study evaluated South Africa’s National Drug Policy which was introduced in 1996. In 
2003, the policy was updated to include mandatory generic substitution (Gray et al, 2016). 
It allowed for pharmacists had to offer a generic substitute, but patients could choose to 
accept or refuse the offer. Additionally, prescribers could write ‘no substitution’ on the 
prescription and pharmacists were disallowed from offering the generic substitute.  The 
intent of this policy was to achieve generic prescribing in the public and private sectors in 
an effort to lower the burden of drug expenditure on the healthcare system. 
 
One study evaluated Thailand’s Universal Health Scheme (UCS), which was introduced in 
2001 to ensure universal access to healthcare, including essential medicines. The policy 
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includes a payment capitation for outpatient services and essential medicines for each 
enrolled member (Garabedian et al, 2012).  
 
Turkey’s National Drug Policy (2006) was evaluated in one study. The main component of 
this policy is the removal of reimbursable prescription medicines to non-reimbursable over 
the counter status. This policy initiative was prompted by the government’s ever-increasing 
expenditure on prescription medicines (Gur Ali et al, 2011).  
 
A summary of the outcomes examined, and study designs of included studies is included in 
table 3 below. 
 
Table 3: Outcomes examined in relation to National Pharmaceutical Policies 




Maiga et al, 2003; Uzochukwu et 
al, 2002, Holloway et al, 2001a; 
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medicines; no cost/low-
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He at al, 2018; Xi et al, 2018; Guo 
et al, 2017; Ding et al, 2017; Yi et 
al, 2015; Zhou et al, 2015; Yao et 
al, 2015; Chen et al, 2014a; Song 
et al 2014a; Song et al 2014b; 
Zhang et al, 2014; Yang et al 
2013; Huang et al, 2018; Zhang 
et al, 2017; Sun et al, 2009; 
Mengue et al, 2016; Monteiro et 
al, 2016; Bertoldi et al, 2012; 
Bertoldi et al, 2011; Paniz et al 
2010; Bertoldi et al, 2009; Arauja 
et el. 2014; Moye-Holtze et al 









reduction; payment caps) 
Prescribing 
behaviour 
Garabedian et al, 2012; Chu et al, 
2011; Liu et al, 2003;  




Generic substitution Prescribing 
behaviour 
Gray et al (2016) ITS 
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Gur Ali et al, 2011 CBA 
 
Methodological quality of included studies 
Of the thirty-four included studies, thirty (31) were assessed as having ‘weak’ 
methodological quality, two (2) had ‘moderate’ and one (1) had ‘strong’ methodological 
quality.  With respect to study designs, sixteen studies had various cohort analytic designs 
i.e. Cohort (multiple groups) or Cohort (pre-post) and were rated as having a ‘moderate’ 
study design (Holloway et al, 2001a; Holloway et al, 2001b, Uzochukwu et al, 2002; Liu et 
al, 2003; Chu et al, 2008; Sun et al, 2009; Gur Ali, 2011;  Chu et al, 2011; Yang et al, 2013; 
Song et al, 2014a; Song et al, 2014b; Chen et al, 2014; Zhang et al, 2014; Yao et al, 2015; 
Zhou et al, 2015; Ding et al, 2017; Moye-Holz et al, 2018). Three (3) used an interrupted 
time series (ITS) design and were also rated as having a ‘moderate’ study design 
(Garabedian et al, 2012; Gray et al, 2016; He et al, 2018). All other studies used various 
cross-sectional study designs and were rated as having a ‘weak’ study design (Maiga et al, 
2003; Bertoldi et al, 2009; Paniz et al, 2010; Bertoldi et al, 2011; Bertoldi et al, 2012; Araujo 
et al, 2014; Yi et al, 2015; Mengue et al, 2016, Monteiro et al, 2016; Rivera-Hernandez, 
2016; Guo et al, 2017; Zhang et al, 2017; Huang et al, 2018; Xi et al, 2018). Confounding, 
data collection methods and blinding of investigators were rated as ‘weak’ in a large 
proportion of included studies (Appendix 2.5).  
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4.6 Narrative synthesis 
Access (Availability and Affordability) – Essential Medicine 
According to the WHO (2011), “essential medicines are those that satisfy the priority health 
care needs of the population” and must be selected for each country with due regard to 
disease prevalence and public health relevance.  Access to essential medicines is a basic 
measure of the quality of a healthcare system. Availability and affordability of medicines are 
basic requirements to ensure equitable access. However, poor availability and affordability 
of medicines continue to challenge governments in developing countries. Governments use 
various mechanisms, such as cost-recovery and financial incentives, to ensure the 
availability and affordability of essential medicines. 
 
Cost recovery mechanisms were used to ensure a steady supply of medicines in the public 
health sector.  This involved the sale of low-cost generics in order to finance the purchase 
of essential medicines in primary health centres. The Bamako Initiative (BI) Model, which 
was adopted in a number of developing countries in Africa and Asia, was evaluated in 
Nigeria, Mali and Nepal (Holloway et al, 2001a; Holloway et al, 2001b; Uzochukwu et al, 
2002; Maiga et al, 2003).  They reported that cost-recovery mechanisms, based on the sale 
of drugs, had the intended effect of greatly increasing the availability and affordability of 
essential medicines (Uzochukwu et al, 2002; Maiga et al, 2003). The initiative also showed 
a positive impact on the availability of low-cost generics in the private sector in Mali, due to 
an increase in the demand for these drugs created in the public-sector (Maiga et al, 2003). 
However, there was a concern that while the BI Model was effective at improving access, it 
may have had an unintended consequence of over prescribing or irrational prescribing.   
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Financial incentives to ensure access to essential medicines were used as mechanisms in 
drug policies in a number of developing countries. This typically involved the government 
creating a list of medicines for which they were willing to partially or fully reimburse. In China, 
an important goal of the NEMP was to increase the use of primary health centres where 
patients would be able to access essential medicines at low-cost (Zhang et al, 2014; Yao et 
al, 2015; Yi et al, 2015; Zhou et al, 2015; Ding et al, 2017; Gou et al, 2017; Xi et al, 2018; 
Huang et al, 2018).  Key components of the policy were higher reimbursement rate for 
essential medicines; a restriction on physicians prescribing non-essential medicines and 
prohibiting primary health clinics from profiting off the sales of essential medicines.  Majority 
of studies reported a lack of effectiveness of the NEMP in achieving its goals. Rather than 
increasing outpatient visits, where patients can access low-cost essential medicines, there 
was evidence that patients shifted utilization behavior from primary health centres in favor 
of secondary and tertiary facilities (Ding et al, 2017; Guo et al, 2017; He at al, 2018). One 
explanation given for this change was because the EML restriction did not apply to 
secondary care facilities (Ding et al, 2017; He at al, 2018). Other studies reported no change 
in outpatient utilization behaviour as a result of the NEMP (Zhang et al, 2014; Yi et al, 2015).   
These conflicting results may be due to a number of factors including, differences in study 
design and population studied. There was also evidence that out-of-pocket payments after 
reimbursement did not decline after the policy was implemented (Ding et al, 2017).   
Furthermore, Huang et al (2018) and Zhang et al (2017) evaluated the three National Health 
Insurance schemes, which had a goal of improving access to essential medicines.  They 
found that the health insurance schemes have not been effective in making medicines 
affordable in outpatient clinics. Huang et al (2018), Xi et al (2018) and Yao et al (2015) 
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identified systematic barriers in China, such as, disparity in socioeconomic development, 
rural vs urban setting and the organizational structure of National Policies in China, that 
have confounded their effectiveness. 
 
Brazil’s constitution guarantees free access to essential medicines in public clinics.  Due to 
the limited availability of medicines in these clinics, the government also implemented 
various programs in private pharmacies to increase access to medicines for chronic 
diseases. Two such programs are, the “Popular Pharmacy Program” and the “Health has 
No Price Program”.  In public clinics where medicines are provided free, Bertoldi et al (2009, 
2012) reported that even the poorest segment of the population had to pay out-of-pocket for 
their medicines. It was also reported that upper income families spent more money on 
medicines compared to lower income families (Monteiro et al, 2016; Bertoldi et al, 2011). 
Likely because people in the upper income brackets can afford to pay for their medicines in 
private pharmacies, where there is better supply and fewer restrictions.  Free access to 
chronic disease medicines was reported to have improved as a result of Brazil’s 
pharmaceutical policies (Paniz et al, 2010; Bertoldi et al, 2011; Arauja et al, 2014).  This is 
important because of the financial burden that long-term medicines can place on 
households. Disparities in access was evident.  For example, some cities and regions 
reportedly had better access to medicines and utilization patterns were different among the 
rich versus the poor, and persons with health insurance (Bertoldi et al, 2009; Bertoldi et al, 
2011; Bertoldi et al, 2012; Mengue et al, 2016). Although access to medicines improved in 
Brazil, the limited supply of low-cost medicines in public clinics was still a barrier. This likely 
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created socio-economic inequities in access, because the poor may be forced to purchase 
medicines in private pharmacies or forego treatment if they cannot pay.   
 
Mexico’s Seguro Popular (SP) was implemented with a goal of achieving access and equity 
to universal healthcare and required no fees for accessing medicines.  Rivera-Hernandez 
et al (2016) evaluated the effect of Mexico’s Segura Popular (SP) on access to diabetes and 
hypertension treatment and found that it only had a marginal effect on access to medicines 
for diabetes and no effect on access to medicines for hypertension. Moye-Holtze et al (2018) 
reported that innovative cancer medicines for beneficiaries of SP were less accessible 
compared to patients enrolled in work-based health insurance schemes. Considering that 
SP was primarily designed to cover the poorer population, this evidence suggests that it has 
not been effective reducing inequities. One explanation for the observed inequity is that 
larger cities were able to implement the policy more fully, because they had better 
infrastructure (Rivera-Hernandez et al, 2016; Moye-Holtze et al, 2018).  
Prescribing behavior 
Policies aimed at influencing prescribing behaviour tended to have two main goals:  1) to 
reduce the burden of medicine expenditure on the health system and 2) to improve the 
quality of treatment with prescription medicines.  Irrational prescribing is a major cause of 
over expenditure on medicine and poor-quality treatment in developing countries.   Sun et 
al (2009) showed that the National Cooperative Medical Scheme (NCMS) designed to 
increase access to primary care in rural China, inadvertently resulted in irrational prescribing 
among village doctors.  In an attempt to address irrational prescribing, China’s NEMP policy 
included the Zero Markup Drug Policy, which removed the financial incentive for healthcare 
   
 
 52 
providers to prescribe irrationally.  However, this policy was not found to be effective in 
curbing their behaviour, as providers sought new and inappropriate ways to increase 
revenue from the sale of medicines (Yang et al, 2013; Chen et al, 2014; Song et al, 2014; 
Yi et al, 2015; He et al, 2018). In Taiwan, the National Health Insurance (NHI) 
reimbursement rate reduction and the drug cost-sharing policies did not have the intended 
effect of containing government expenditure on medicines, because physicians changed 
their prescribing behaviour in order to increase revenue in other ways (Chu et al, 2011; Liu 
et al, 2003).  The Bamako initiative (BI) model was also associated with inappropriate 
prescribing behaviour, such as, a tendency towards prescribing brand name and higher 
number of medicines per prescription (Uzochukwu et al, 2002; Maiga et al, 2003). Gray et 
al (2016), examined the mandatory generic substitution policy in South Africa, and found 
that it had very little effect on prescribing behaviour in South Africa. Turkey’s policy of 
removing prescription drugs to over the counter (OTC) status, in order to reduce national 
drug expenditures, resulted in inappropriate prescribing, where there was a reduction in the 
use of medicines removed from the list (Gur Ali et al, 2011). Similar concerns of over-
prescribing and irrational use of medicines was highlighted in systematic reviews of high-
income setting (Jia et al, 2014; Luiza et al, 2015; Kolasa & Kowalczyk et al, 2017). 
Consumption Patterns (adherence/compliance) 
Studies on the effects of National Drug Policies on adherence or compliance to chronic 
disease medicines were not found, which is a gap in the literature for developing countries. 
 
 





Access to medicines is the first step towards achieving quality use of medicines. Developing 
countries often face significant resource challenges when it comes to financing medicines, 
which may ultimately affect the design and effectiveness of drug policies. A major 
consideration in their policy design is to control costs related to inappropriate use of 
medicines. As a result, these policies have had varying impacts on access and use of 
chronic disease medicines. 
 
A range of policies have been implemented by developing countries to improve access to 
medicines. Financial mechanisms to influence patients’ or providers’ behavior, was a 
common tool used to achieve these goals.  They included cost recovery and financial 
incentives tied to essential medicines policies. Cost-recovery was in the form of user-fees, 
while financial incentives included reimbursement and subsidies for low-cost medicines. 
However, these policies did not always have the intended effects and sometimes led to 
undesirable outcomes. Some unintended effects were an increase in irrational prescribing, 
inappropriate use of healthcare services, and increase in out-of-pocket payments for 
medicines. These findings are consistent with previous systematic reviews that evaluated 
policies in high-income countries (Jia et al, 2014; Luiza et al, 2015; Kolasa & Kowalczyk et 
al, 2017). 
 
Drug policies were also strongly motivated by the government’s goal of reducing the burden 
of pharmaceutical expenditure on the health system and ensuring a sustainable supply of 
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essential medicines. To achieve this, government policies targeted provider prescribing 
behaviour, including removing drugs from the reimbursement list or reducing the rate of 
reimbursement for non-essential medicines, removing profit from the sale of medicines, and 
encouraging prescription of generic medicines. None of these strategies proved to be 
effective at engendering the intended prescribing behaviour. The underlying reasons for 
some of these observed behaviours may need further exploration in order to find more 
sophisticated ways of addressing prescriber and patient behavior around inappropriate use 
medicines. 
 
Additionally, health system infrastructure, such as, supply of medicines and organization 
and implementation of drug policies, were key determinants of access to medicines. 
Oftentimes these infrastructures were poorly developed and were not properly factored into 
drug policies in developing countries. As a result, inequities in access to medicines was still 
a problem and had a greater impact on the socio-economically disadvantaged. For example, 
in China, access to medicines was poorer among rural populations because of challenges 
with drug supply logistics in rural areas (Yao, 2015). As a result, urban residents paid less 
for medicines because those facilities benefit from lower logistics costs (Yao, 2015). 
Although this study was rated as having weak methodological quality, it highlights the 
accessibility dimension of access, where physical barriers such as geographical location are 
key determinants of access to medicines.  
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4.8 Limitations of the systematic review 
 
Due to observed heterogeneity in population, context and study designs, analysis of pooled 
results was not possible in this review. Majority of studies included in this review had weak 
methodological quality. Notably, confounding, data collection and blinding were rated as 
having ‘weak’ quality, which limits the application and validity of this review to other settings. 
This finding is consistent with a previous systematic review by Ratanawijitrasin et al (2001), 
who concluded that poor study designs in developing countries makes it difficult to evaluate 
the effectiveness of pharmaceutical policies in those settings.   Considering Ratanawijitrasin 
et al (2001) was done almost 20 years ago, there has been little change in the past two 
decades when it comes to the quality of research on this subject in developing countries. 
This is likely due to the difficulty in designing studies to measure drug use outcomes and 
lack of information systems in developing countries to reliably collect data on drug use on a 
population scale. 
 
The inclusion of qualitative research may have enhanced the findings and or interpretation 
of the findings of this review, however due to several  documented challenges with searching 
for qualitative studies (e.g. variation in of qualitative methods, non-standardized terminology, 
and absence of research methods from abstracts) (Booth, A., 2016), a decision was made 
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5 Summary of the literature review 
 
5.1 Factors associated with access and adherence to chronic disease 
medicines in developing countries 
 
Access to medicines is a multidimensional concept, which is not defined consistently in the 
literature in developing countries. There is a paucity of high-quality studies examining what 
factors are associated with access to chronic diseases medicines in developing countries. 
Studies published in the last decade tended to focus on affordability and availability of 
essential medicines, which are factors controlled at the global or health system level. 
However, the literature review identified multiple factors outside of the health system that 
are also affecting access to chronic disease medicines, such as patient, socio-economic, 
drug therapy, cultural, patient and provider awareness, geography and other contextual 
factors.  These factors varied across countries and regions and highlights the need for 
country-specific research on access to medicines to inform effective policies and 
programmes.   
 
5.2 A Systematic review of developing countries experience with 
policies aimed at influencing access to medicines 
 
Developing countries often face significant resource challenges when it comes to financing 
medicines, which may ultimately affect the design and effectiveness of drug policies. A major 
consideration in their policy design is to control costs related to inappropriate use of 
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medicines. As a result, these policies have had varying impacts on access to medicines. 
The systematic review highlights the challenges developing countries face to design 
effective policies in order to reduce inequities in access to chronic disease medicines 
(Huang et al, 2018; Xi et al, 2018, Yao et al, 2015; Bertoldi et al, 2009; Bertoldi et al, 2011; 
Bertoldi et al, 2012; Mengue et al, 2016; Rivera-Hernandez et al, 2016; Moye-Holtze et al, 
2018). This is likely because policies tended to use financial mechanisms with a goal of 
reducing national pharmaceutical expenditure, without due consideration given to the 
multiple dimensionalities of access. The review also highlights several gaps in the literature 
related to developing countries that have implemented policies to improve access to 
medicines. Firstly, while studies were found in different geographic regions, they were 
concentrated in specific countries; the majority were located in Asia. Only a small number 
of studies were found in the Latin American and Caribbean region, and they were all related 
to policies in Brazil and Mexico. Secondly, even within these countries, there was a paucity 
of literature related to the effect of policies on access and use of medicines. Thirdly, there is 
also a gap in research on the effect of these policies on adherence to medicines (which is 
an important quality outcome related to access and use of medicines).  Finally, the majority 
of studies examining the effect of government policies on access to chronic disease 
medicines had poor methodological quality, highlighting the need for high quality country-
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CHAPTER 3 - CONCEPTUAL FRAMEWORK 
1 Chapter introduction 
 
The goal of this chapter is to describe the research approach and the conceptual frameworks 
that will be used to guide the research project and to formulate testable hypotheses for the 
three research objectives below:  
1) Research objective one aims to understand factors associated with enrollment in the 
NHF Drug Benefit among adults with diabetes or hypertension. 
2) Research objective two aims to understand drug utilization patterns and factors 
associated with adherence among diabetic and hypertensive adults who were 
enrolled in NHF Drug Benefit programme.   
3) Research objective three will examine whether the national health policy to remove 
user fees from public health facilities in 2008, had an impact on utilization of the NHF 
Drug Benefit programme among adults with diabetes or hypertension.   
 
The chapter begins by discussing the research approach and metatheory, followed by an 
exploration of theories of health seeking behaviour, which lays the groundwork for how 
health services utilization can be perceived and evaluated.  Finally, the two conceptual 
frameworks that will be used in this study are discussed - the Andersen-Newman 
Behavioural Model and the Quasi-Experimental Approach. The conceptual frameworks will 
be used in this research to help with the analysis, interpretation and translation of the 
research findings (Paradies & Stevens, 2005).  This is to ensure that the research findings 
have relevance to health policy makers in Jamaica. 
   
 
 59 
2 Research approach 
 
The research project will use multiple secondary data sources and quantitative research 
methods to achieve the overall goal of the study.  With this approach it is possible to assess 
varying outcomes related to access to the NHF Drug Subsidy among diabetics and 
hypertensives.  Quantitative research is deductive and takes a positivist epistemological and 
ontological philosophical position (Bryman A., 2001, p.62). Positivism advocates for 
objectivism in scientific investigation, and the use of natural science methods to the study 
of social phenomena (Bryman, A., 2001, p.12). Positivist theories in health research tend to 
be concerned with causal inference, thus its purpose is to generate hypotheses that can be 
tested (Bryman, A., 2001, p.12).   Positivism has been widely criticized for its claims of 
objectivity, due to inherent limitations in applying natural science methods to social 
phenomena (Goldenberg, 2006). While these are valid criticisms, it is the dominant 
philosophy underlying quantitative scientific methods (Bowling, A., 2009, p. 129).  The 
present study will therefore be conducted with the assumption that the outcomes 
investigated reflect human behaviour which were externally observed and measured using 
the principles of natural sciences (Bowling, A., p. 129).  Recognizing that access to 
medicines is a complex and a multidimensional concept, the study also assumes that 
multiple explanatory factors are related to access to medicines, and these factors can be 
externally observed and measured (Bowling, A., p.129). Although it is difficult to claim the 
same level of value-free research as in the natural sciences, the use of secondary data 
supports the position of objectivity in the design phase of the research.  There is also an 
awareness that social, political and cultural values may influence interpretations and 
   
 
 60 
precautions will be taken against such influences.  Based on these assumptions, the next 
section focuses on defining a roadmap (conceptual framework) to characterize the 
relationship between the explanatory and outcome variables in this study.   
 
3 Theories of health seeking behaviour 
 
Early theories revealed that health-seeking behaviour is a central concept to the 
understanding of health services utilization. It is important to study these behaviours, 
because they help to identify gaps in services, target appropriate patients and understand 
patterns of health practice and adherence with medical advice (Mechanic, 1995).    
 
Khoso et al (2016) defined health-seeking behaviours as, “people’s response to symptoms 
of a disease within their socio-cultural environment”. A number of theoretical frameworks 
have evolved to explain the factors that influence health-seeking behaviour. These theories 
have been grounded in multiple disciplines including sociology, psychology and economics 
(Young, JT, 2004; Khoso, 2016). Health seeking behaviour is also referred to as Illness 
behavior and has been distinguished in the literature from health behaviour (Khoso et al, 
2016). This distinction is important, as it is conceivable that behaviours of ill individuals are 
quite different from that of healthy individuals. Whereas health seeking/illness behaviour has 
to do with behaviours of people who know themselves to be ill and take certain actions to 
get well, health behaviours relates to people who want to maintain good health and aligns 
more with health promotion, prevention and protection (Khoso et al, 2016).  Predominant 
theoretical explanations of health behaviour such as the Health Belief Model (HBM), Theory 
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of Reasoned Action (TRA), Theory of Planned Behaviour (TPB) and Health Locus of Control 
(HLC) are associated with health behaviours and thus commonly used to examine disease 
prevention programs. Therefore, they were not considered appropriate models for analyzing 
patients diagnosed with chronic diseases or who may require long-term medical treatment, 
and excluded from further discussion (Khoso et al, 2016).  
 
The concept of health seeking behaviour was proposed in the early 1950’s by Talcott 
Parsons who wrote about health seeking behaviour in terms of the ‘sick role’ (Khoso et al, 
2016; Young JT., 2004).  Later the concept of ‘illness behaviour’ was proposed in the 1960s 
by Mechanic and Volkart who were interested in understanding the behaviour of patients 
who were sick (Khoso, et al 2016).  The early theories of health seeking behavior have 
guided much of the present-day research around health services use (Young, JT, 2004).  
 
3.1 Early Theories 
 
Parsons’ sick role theory (1951) dates back to the early 1950’s and is one the first theories 
to explain factors associated with health services use (Varul, MZ, 2010, Heidarnia, MA, 
2016).  It is a sociological theory, based on the assumption that all individuals have specific 
roles within the society. Parsons saw illness as more than a biological condition, but also a 
social phenomenon. He postulated that illness was an undesirable state causing the 
individual to assume a ‘sick role’, which precluded them from normal daily activities 
(Heidarnia, MA, 2016). In an effort to return to ‘normal’ functioning, the individual is 
motivated to seek out healthcare services (Heidarnia, MA, 2016).  From Parsons’ (1951) 
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perspective, the patient’s decision to seek care was so they could return from their 
temporary ‘sick role’ to their institutional roles for which they were socialized. This theory 
was widely criticized by researchers for a number of reasons, including inadequately 
explaining observed differences in health seeking behaviour (McKinlay, J.B., 1972; Segall, 
A., 1976; Young JT, 2014; Yang & Hwang, 2016). Additionally, the ‘sick role’, which 
appeared to have been conceptualized as a temporary state, was a poor fit for the 
experience of individuals with chronic illnesses (McKinlay, JB, 1972; Segall, A., 1976).  
 
Mechanic (1968) argued that the bio-physiological approach to illness used in medicine was 
inadequate to describe the complexities of illness behaviour and the factors contributing to 
the use of formal and informal care (Young, JT., 2004). He initially postulated that 
psychological factors which were largely based on the patient’s illness experience and 
perceived need for care was driving health seeking behaviour. Later, consideration was 
given to non-psychological factors outside the control of the individual patient, such as 
affordability and patient awareness.   Mechanic’s theory of illness behaviour was initially 
criticized for emphasizing the socio-psychological factors over the institutional factors that 
can act as barriers to access. However, it introduced the notion of patient need as a 
significant predictor of health seeking behaviour.  
 
Suchman’s Stages of illness and medical care (1965) builds on Parsons’ Sick Role theory. 
He proposed that when a person becomes ill, they go through five (5) stages of critical 
decision-making points which will ultimately determine whether they will seek healthcare 
services (Suchman, EA, 1965). In his analysis of these five stages, he noted that there was 
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a natural tendency for individuals to under-emphasize symptoms of chronic diseases in their 
early stages, because they are not incapacitated (Suchman, EA, 1965).  He also found 
significant variability in how severity of illnesses was perceived by age and sex and the 
decision to seek care (Young, JT, 2004). Suchman’s model has been used to examine 
access to physicians among low-income individuals with chronic diseases (Young, JT, 2004, 
Newacheck & Butler, 1983). Newacheck & Butler (1983) highlighted significant differences 
between the poor and non-poor in healthcare utilization patterns and also supported 
Suchman’s argument that incapacitation had a significant influence on healthcare utilization.  
Like Parsons’ Sick Role Theory, Suchman’s model has also been criticized for not 
accounting for socio-economic and cultural influences on health seeking behaviour (Young, 
JT, 2004).  However, he highlighted the important role of the patient’s characteristics on 
illness perception by demonstrating variations among patients from different demographic 
and social profiles.   
 
Economic theories of health seeking behaviour have also been widely discussed in the 
literature (Young et al, 2004). Young JT (2004) examined several economic theories that 
have been used to study health services use and argued that economic theories are based 
on the assumptions that health seeking behaviour is largely driven by economic factors 
(Young, JT, 2004). These factors include income, cost of living, insurance, governmental 
assistance and self-payment/out of pocket costs. Young (2004) highlighted that while 
several authors have in the past reported the relationship between economic factors and 
use of health services, others have disputed these theories by showing that multiple factors 
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such as social, political and cultural factors, and not purely economics are driving utilization 
of health services (Young, JT, 2004).  
 
4 Evaluating access to medicines 
 
The theory of access described by Penchansky and Thomas (1981) and considerations for 
evaluating it described by Donabedian (1972), underscores the complexities with defining 
and evaluating access to health services. However, Donabedian (1972) stated that the 
actual utilization of health services was proof of access to healthcare.   He highlighted the 
importance of measuring the quantity as well as the distribution of health, noting that the 
distribution of health by social class was an important criterion for evaluating healthcare 
access (Donabedian, 1972). Geographic and demographic distribution was seen as 
correlated to social class and were also considered important when evaluating healthcare 
access (Donabedian, 1972). Therefore, inequities can be identified by observing patterns of 
health service utilization which is a reflection of health seeking behaviour.  It is well known 
that the poorer social class face greater access barriers. According to Tudor Hart’s Inverse 
Care Law, the availability of medical care services is inversely related to patient needs (Hart, 
T., 1971 in Dalrymple, T., 2012).  This suggests that there may be inherent inequities built 
into healthcare systems. Based on the above arguments, when evaluating healthcare 
access consideration must be given to equity in order to identify barriers.  
 
To account for the multiple complex relations affecting access to medicines, Bigdeli et al 
(2013) proposed a framework for evaluating access to medicines, which takes a holistic 
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health system approach. Two (2) studies included in the literature review used this 
framework to examine the factors associated with access to chronic disease medicines in 
developing countries (Elias et al, 2017; Vialle-Valentin et al, 2015). However, the practical 
application of this framework for research purposes had many identified challenges, which 
the authors acknowledged could not easily be overcome (Bigdeli et al, 2013). That being 
said, important criteria for selection of a framework for this study were theoretical as well as 
practical applicability.  
 
5 Conceptual framework: Andersen-Newman Behavioural Model 
of Health Service Utilization (Research Objectives 1 and 2) 
 
Andersen & Newman (2005) stated that access and use of health services can be 
considered a type of individual behaviour.  Andersen’s model builds on previous work done 
by Mechanic (1968) and Suchman (1965) and predominantly reflects a sociological 
approach to health seeking behaviour. This framework, known as the ‘behavioural model of 
health service utilization’, was developed primarily to understand health service utilization 
patterns of the family unit; and to promote equitable access to services across population 
groups (Andersen, 1968). The framework conceptualizes health services utilization as 
behaviour influenced by micro and macro-level factors (Shaikh & Hatcher, 2004).   The 
micro-level factors are patient and family characteristics, and macro-level factors represent 
the context in which patients seek health care. It aligns with Penchansky and Thomas (1981) 
theory of access, who noted similarities with their theory and the Andersen-Newman Model. 
The initial model explained health service utilization as a function of predisposing, enabling 
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and need factors and hypothesized that equitable access exists when utilization is largely 
determined by predisposing and need factors and less so by enabling factors such as 
income (Andersen, 1968).  Since then, the model has gone through several iterations to 
account for inputs such as the health care system and the external environment as well as 
to include measures such as perceived and evaluated health status as outcomes related to 
health services use (Aday & Andersen, 2005; Phillips et al, 1998; Aday & Andersen, 1974; 
Andersen & Newman, 1973). Over time, the focus of analysis has shifted from the family to 
the individual as the unit of analysis to account for heterogeneity among family members 
(Andersen, 1995). Contextual or environmental variables were also highlighted by Phillips 
et al (1998) and Andersen (2008) as important determinants of health services use and to 
help understand the barriers that exist within the health system or communities. The most 
recent model has retained most of its initial tenets of predisposing, enabling and need factors 
but also emphasizes contextual or environmental factors influencing health service use 
(Phillips et al, 1998; Evans and Stoddart, 1990 in Andersen, 1995; Andersen, 2008). 
 
Predisposing factors include biological factors such as age and sex, socio-structural factors 
such as education and ethnicity, and cultural factors such as health beliefs (Andersen & 
Newman, 2005).  According to Andersen & Newman (2005), these are individual 
characteristics which exist prior to illness and represent the propensity of individuals to use 
health services more than others.  Enabling factors or resources include income, insurance 
coverage, physical access to services such as transportation and distance to care and 
community resources such as availability and region of the country (Andersen & Newman, 
2005). These variables include family and community characteristics and represent the 
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conditions that make health services resources available (Andersen & Newman). Perceived 
need refers to an individual’s perception about their illness or level of need for care 
(Andersen & Newman, 2005). Perceived need includes factors related to the individual’s 
attitudes, knowledge or values towards their illness and represent the most immediate cause 
of health service use (Lo and Fulda, 2008). While assessed need is based on clinical 
evaluation of the individual’s level of impairment (Andersen & Newman, 2005; Cohen-
Mansfield & Frank, 2008). Assessed needs are more objective measures and include factors 
such as actual illness experience of the individual and illness severity (Andersen & Newman, 
2005). Predisposing, enabling and need factors are measures of individual characteristics.   
Contextual factors include health organization, provider-related factors and community 
characteristics.  According to Andersen (2008), contextual factors can be measured at an 
aggregate level and can include measures such as, age-structure, healthcare resources, 
mortality and disability rates and community health resources and area level health planning 
(Andersen R, 2008; Morgan et al, 2010).  
 
The final component of the model is the use of health services, which is the measured 
outcome related to health seeking behaviour.  Equitable access to healthcare services was 
defined by Andersen (2008) as occurring when need and predisposing characteristics are 
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5.1 Hypotheses (Research Objective one) 
 
Research objective one will examine the factors associated with enrollment in the NHF 
among adults diagnosed with diabetes or hypertension in Jamaica. The NHF Subsidy was 
established to ensure equal access to all Jamaicans with specific chronic diseases, 
regardless of age, sex or socio-economic status. Therefore, it will be important to examine 
the extent to which this occurs from the point of initial access.  The Andersen-Newman 
Behavioural model of Health Services Utilization will allow for the examination of multiple 
individual and contextual factors to determine if enrollment reflects equitable access to the 
NHF drug benefits program (figure 2).  As NHF enrollment is dependent on access to 
primary care, it relates to all six (6) dimensions of access - awareness, acceptability, 
availability, accommodation, acceptability, affordability and accessibility.  
 
Figure 2: Conceptual framework for enrollment in the NHF Drug Subsidy 
 




Accordingly, the following hypotheses were proposed for research objective one: 
1) H0: Initial access to the NHF subsidy is equitable among adult Jamaicans (18 to 59 
years) with diabetes or hypertension i.e., need, and predisposing factors were the 
strongest predictors of enrollment in the NHF Subsidy. 
 
Ha: Initial access to the NHF Subsidy among adult Jamaicans (18 to 59 years) with 
diabetes and hypertension, was mostly predicted by contextual and enabling factors. 
 
 
5.2 Hypotheses (Research Objective two) 
 
For individuals with chronic diseases, continuous access to medicines over time is 
necessary to ensure medication adherence and quality of care.   Research objective two will 
examine patterns of drug utilization, the level of adherence and the factors associated with 
medication non-adherence among adults enrolled in the NHF subsidy. Medication 
adherence is indicative of continued access to medicines, which is necessary for the 
treatment of chronic disease like diabetes and hypertension. The extent to which the NHF 
is ensuring continuous access to medicines for adults with diabetes or hypertension needs 
to be examined. The factors being investigated will be organized according to the Andersen-
Newman Behavioural Model into predisposing, enabling, need and contextual factors (figure 
3). This will allow for the identification of barriers to medication adherence and to determine 
whether those barriers were predominantly related to predisposing and need factors such 
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as age and condition severity versus enabling and contextual factors such as out-of-pocket 
cost and geography. By using the Andersen-Newman Behavioural Model, it will be possible 
to identify medication non-adherence barriers that are potentially inequitable. Adherence 
was viewed from the perspective of continued access to medicines and relates to all six 
dimensions of access, affordability, accessibility, acceptability, accommodation, awareness 
and availability. 
 
Figure 3: Conceptual framework for medication adherence among patients enrolled 
in the NHF Drug Subsidy with diabetes or hypertension 
 
 
Accordingly, the following hypotheses were proposed for research objective two: 
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1) H0: Adherence/continued access to medicines among adult Jamaicans (18 to 59 
years) enrolled in the NHF Drug Subsidy in Jamaica was equitable i.e. need and 
predisposing factors were the strongest predictors. 
 
Ha: Adherence/continued access to medicines among adult Jamaicans (18 to 59 
years) enrolled in the NHF Drug Subsidy in Jamaica, was mostly predicted by 
enabling and contextual factors. 
 
6 Conceptual framework: Quasi-experiments (Research objective 
three) 
 
Quasi-experiments are quantitative methods that test causal hypotheses by using 
experimental designs, but do not use random assignment to create treatment and control 
groups, from which the treatment effect can be inferred (Cook & Campbell, 1979, p. 7). 
These types of experiments are characterized as one where the exposure to the intervention 
of interest has not been manipulated by the investigator and are considered observational 
studies (Craig et al, 2017; Craig et al, 2012; Dunning, T., 2008).   The Randomized 
Controlled Trial (RCT) is considered the gold standard research design for determining 
cause and effect relationships in health care interventions. However, when the objective of 
the research is to understand the impact of large-scale interventions on an entire population, 
RCTs may be neither practical nor feasible (Craig et al, 2012; Craig et al, 2017).  In such 
circumstances, quasi-experiments can be used to understand the impact of a population-
level intervention such a change in national policy (Craig et al, 2012). They are very useful 
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for examining real life interventions in real world settings. The specific type of quasi-
experiment that can be used in these circumstances is known as a natural experiment 
(Bryman et al al, 2001, p.39). An important feature of this design is, the exogenous variation 
induced by the public health intervention or change in policy mimics that of a laboratory 
experiment and identify treatment and control groups (Meyer, D., 1995).  As such, causal 
inference can be established, because assignment of treatment and control subjects are 
presumed to be random (Dunning T., 2008). There are many advantages to using this 
approach over planned experiments, such as, it allows for the analysis of the intervention 
on entire populations, and they tend to be logistically and economically more feasible than 
planned experiments (Craig et al, 2012). They have the potential to evaluate a wide range 
of public health interventions that could not realistically be evaluated using an RCT (Craig 
et al, 2012). As a result, policymakers and researchers have advocated for their use to 
evaluate the impact of national policies or legislation (Craig et al, 2012).   In health services 
research, the data used in natural experiments are collected in real world settings, during 
the course of actual patient care and in the context of their social and political environment 
(Dunning, T., 2008).  Another terminology used to describe the type of data used in natural 
experiments is real world data (RWD). With the development of the quasi-experimental 
approach, RWD are being recognized more and more as valuable sources of data within 
health services research. However, this approach is not without limitations and criticisms, 
which impacts their ability to make valid causal inference. Some of the key limitations are, 
they are more susceptible to bias and confounding which ultimately affects internal validity 
(Craig et al, 2012; Sekhon & Titiunik, 2012). To overcome some of the inherent 
methodological challenges, a number of statistical approaches are recommended to 
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evaluate quasi-experiments. The interrupted time series is one such approach. This is a 
model built on continuous sequence of observations on a population overtime (Bernal et al, 
2017).  It is used to evaluate trends in the outcome in the pre-intervention and post-
intervention period (Craig et al, 2017). A comparison is then made between the observed 
trend in the pre-intervention and post-intervention periods, assuming that the trends in the 
outcome would be the same if not for the intervention between those two time periods (Craig 
et al, 2017; Kontopantelis et al, 2015).  The model is known as a single group pre-post 
design when used on a single population without a comparison group.  This particular design 
is useful for evaluating policies using time-series data.  
 
6.1 Hypotheses (Research Objective 3) 
 
The Jamaican Ministry of Health’s policy to remove user-fees from publicly funded primary 
care clinics, was intended to improve access to primary care, secondary care and 
medicines.  This was a large-scale national policy to alleviate the financial barrier to 
accessing primary care services in the public sector.  It has been reported that the removal 
of user fees made primary care visits more affordable thus improving access (Campbell A., 
2013).  Using a mixed-methods approach Campbell (2013) reported that patient utilization 
of the public health system increased immediately following the removal of user fees and 
remained above the pre-policy levels. Since primary care is the gateway to accessing the 
NHF, it can be assumed apriori that access to chronic disease medicines through NHF 
would also increase following the removal of user fees from primary care.  The extent to 
which this policy increased access to chronic disease medicines among adults with diabetes 
   
 
 74 
or hypertension will be investigated using an interrupted time series model (figure 4).  A 
single group pre-post ITS model allows for the comparison of longitudinal trends in 
measures of access to the NHF among diabetics and hypertensives, before and after the 
removal of user fees in Jamaica. Based on the assumption that the trend in NHF access 
would remain the same if not for this policy, the impact of the policy on NHF access can be 
investigated. Access to the NHF will be assessed using two outcomes, new enrollment to 
the NHF Programme and NHFCard utilization among individuals with diabetes and 
hypertension. An ITS model also allows sub-group analysis, therefore equitable access will 
be assessed using demographic (age, sex) and geographical location (administrative health 
region, rurality) which are important indicators of the accessibility dimension. To use this 
model, data are collected over several incremental data points before and after the removal 
of user fees, as well as knowledge of the exact timing and details of the intervention (Jandoc 
et al, 2015; Hudson et al, 2019).  
 
 
Figure 4: Conceptual framework for analyzing the effect of the removal of user-fees 
at primary health centres in 2008 on access to the NHF Subsidy 
 
Model A: Number of new NHF enrollments 
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Model B: Number of NHFCard users 
 
 
The hypotheses proposed for research objective 3 are as follows: 
1) H0: The health policy to remove user-fees from public health facilities in 2008 
increased access (new enrollment and pharmacy visits) to medicines through NHF 
Individual Drug Benefit Programme, among adults with diabetes and hypertension in 
Jamaica. 
 
Ha: There was no difference in access (new enrollment and NHFCard use) to 
medicines through the NHF Individual Drug Benefit Programme among adults with 
diabetes and hypertension, following the health policy to remove user-fees from 
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7 Justification for selection of models 
 
The first two research objectives aim to understand the range of factors influencing utilization 
of a healthcare benefit – The NHF Individual Benefit Programme. The Andersen-Newman 
Behavioural Model of Health Services Utilization was selected because it allows 
investigation of the individual and contextual factors that may be influencing the use of the 
NHF Programme.  This model is also very flexible in handling data from multiple data 
sources. It’s been applied in studies using survey data, where the researcher has a high 
level of control over the variables being collected as well in studies utilizing secondary 
administrative data, where the researcher has no control over the data being collected 
(Clewley et al, 2018; Morgan et al 2010; Andersen RM, 2008; Blalock et al, 2005).  Thirdly, 
the model has been applied in similar research examining drug utilization patterns in a 
variety of settings and has been shown to facilitate ease of translation of study findings into 
health policy (Morgan et al, 2010; Blalock et al, 2005). This model is also said to be useful 
for exploratory analysis when there is not a lot of previous research in the area (Kim et al, 
2016). Finally, the Andersen-Newman Behavioural Model of Health Services Utilization was 
recognized as being the most influential model used to guide much of health services 
research on access and utilization of health care services (Khoso et al, 2016).   
 
The third research objective is to determine if the National Policy to remove user fees from 
primary health centres in 2008, had an impact on enrollment of the NHF subsidy. The 
interrupted time series (ITS) approach is the most common method used to evaluate policy 
interventions in drug utilization research (Jandoc et al, 2015).  This model is also commonly 
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used to evaluate policies when using observational data from administrative sources 
(Jandoc et al, 2015).  Biglan et al (2000) highlights the value of these designs in evaluating 
population interventions in multiple disciplines such as education and healthcare. Since the 
data and nature of the policy implementation is known, the ITS model is considered 
appropriate for evaluating this policy (Bernal et al, 2017). Another strength of the ITS model, 
is that the confounding effects of socio-economic status and other population characteristics 
are accounted for, as these are expected to change relatively slowly over time (Bernal et al, 
2017).  From the literature review in the previous chapter, which examined the effect of 
government policies on access to chronic disease medicines, three studies also used ITS 
models to evaluate their policies (Garabedian et al, 2012; Gray et al, 2016; He et al, 2018). 
Additionally, Li et al (2017) demonstrated the usefulness of an ITS model to evaluate and 
quantify the impact of the removal of user fees in Jamaica on healthcare utilization among 
children < 18 years old.
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CHAPTER 4 - METHODOLOGY 
1 Chapter Introduction 
 
The study aimed to understand the factors contributing to or impeding access and utilization 
of the NHF among adults with diabetes or hypertension in Jamaica.  In order to achieve this 
study aim, three research objectives were proposed.  This chapter outlines the details of the 
study design, study population and statistical approach used to achieve the proposed study 
objectives. 
 
2 Study design and setting 
 
This study used a retrospective observational study design that combined self-reported 
cross-sectional survey data from the Jamaica Health and Lifestyle Survey II (JHLS II), and 
pharmacy claims administrative data from the National Health Fund (NHF). The study was 
based on community-dwelling adults (18-59 years) with diabetes or hypertension, who were 
eligible to use the NHF Drug Benefit Programme for prescription medication. The samples 
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3 Data sources 
 
The research involved the use of two secondary data sources. The Jamaica Health and 
Lifestyle Survey II (JHLS II), and pharmacy claims data from the National Health Fund 
(NHF).  Both datasets are rich sources of data on medication use among patients with 
diabetes and hypertension within the Jamaican population. 
 
3.1 The Jamaica Health and Lifestyle Survey II (2008) 
 
Cross-sectional surveys are frequently used for conducting social and healthcare research 
(Bowling, A., 2005). The JHLS II is a national population-based cross-sectional survey which 
was coordinated by the Epidemiology Research Unit at the University of the West Indies in 
Kingston, Jamaica. Administration of the survey began in 2007 and was completed in 2008. 
The primary purpose of this survey was to determine the health and nutritional status, health 
seeking and lifestyle behaviour, and burden of risk factors of Jamaicans (Wilks et al, 2008).  
The survey is also a rich source of data on a range of social, cultural and environmental 
factors (Wilks et al, 2008).  This was the second national health survey of its kind in Jamaica, 
and the only population survey which included data on the use of the NHF Drug Benefit 
Programme along with several other measured demographic, socio-economic and 
biomedical factors.  To ensure national representation, participants were recruited using a 
random selection of clusters proportionate to the population of the 14 geographic regions 
(parishes) of Jamaica. Clusters were based on enumeration districts (EDs), which are lower-
level geographic areas within each parish consisting of up to four hundred households (Wilks 
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et al, 2008).  EDs are grouped within parishes to form sampling regions, within which primary 
sampling units were created to form clusters for random sampling (Wilks et al, 2008). The 
survey sample consisted of 2,914 individuals 15-74 years, of which 2,848 completed the 
survey, giving a low non-response rate of 1.7% (n=50). The survey was completed by 
experienced and trained interviewers using a face-to-face mode of data collection (Wilks et 
al, 2008).  Face-to-face interviewer administered surveys are known to yield high response 
and item/questionnaire completion rates when compared to self-administered and telephone 
interviews (Bowling, A., 2005).  Additionally, respondents tend to prefer this mode of 
administration compared to telephone interviews or self-administered because they are less 
burdensome (Bowling, A., 2005). However, face-to-face interviewer administered survey 
questionnaires can lead to other biases such as social desirability bias, ‘yes-saying’ bias 
and interviewer bias which can have serious implications on the validity and reliability of the 
survey (Bowling, A., 2005).  However, a number of quality control checks were done to 
ensure quality and reliability of the data collected on the JHLS II.  These measures included, 
checking for errors or omissions on completed questionnaires and partially re-interviewing 
10% of respondents (Wilks et al, 2008). The survey was approved by the Jamaican Ministry 
of Health and the University of West Indies Ethics Committees. All participants provided 
written informed consent.  Full details of the survey methods can be found in Chapters 2 
and 3 of the survey report by Wilks et al (2008).   
 
The JHLS II has supported a large number of health research projects and health policy 
decisions in the country. More specifically for the purposes of this research, it contained the 
necessary explanatory variables and the outcome variable of interest to examine equitable 
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access to the NHF Individual Benefit Programme among Jamaicans with diabetes and 
hypertension.   
 
The JHLS II household survey was used to test the hypothesis related to research objective 
one: 
1) Research hypothesis one: 
H0: Initial access to the NHF subsidy is equitable among adult Jamaicans (18 
to 59 years) with diabetes or hypertension i.e. need, and predisposing factors 
were the strongest predictors of enrollment in the NHF Subsidy. 
 
Ha: Initial access to the NHF Subsidy among adult Jamaicans (18 to 59 years) 
with diabetes and hypertension, is mostly predicted by contextual and enabling 
factors. 
 
3.2 NHF Pharmacy Claims Database  
 
The data used in the study was extracted from the NHF pharmacy claims database. The 
NHF is a government agency that administers the NHF Individual Benefit Programme across 
the island.  They maintain an electronic population-based administrative database, which 
contains basic patient demographic data as well as the prescription history of medicines 
purchased using the NHFCard. The patient data is collected at the time of enrollment. 
Enrollment is necessary for all patients who wish to receive medicines free at public 
pharmacies or at a subsidized cost at private pharmacies, for any of the 16 eligible chronic 
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conditions. To enroll, patients must complete an application form with their names, address, 
sex and their date of birth and have it signed by their physician confirming the diagnosis(es). 
Once enrolled, individuals receive a NHFCard with a unique identifier, which they present 
to the pharmacy at each visit.  The purchase is then linked back to the patient record using 
the unique identifier tied to the NHFCard. The enrollment and disease information for which 
the patient sought subsidization is captured in the NHF database, along with their drug claim 
history. Drug information is also coded using a unique identifier called the Generic Product 
Identifier (GPI). The GPI is a standard coding system consisting of a 14-digit code used to 
identify critical information about the medicine, such as the drug class, drug name, dosage 
form and strength. At the time the drug is dispensed, the quantity and number of days of 
supplies received by the individual is also captured in the database. The database therefore 
contains all the patient, disease and drug claim history related to the use of the NHF Card. 
As a result of this electronic data capture, the NHF database is a rich source of secondary 
data and contains over 240,000 patients currently receiving subsidies and over 4 million 
drug claims per year (NHF Annual Report, 2018).  While, the database captures the 
dispensation of medicines to Jamaicans enrolled in the NHF, it is important to note that a 
limitation of this database is, it does not include prescriptions that were written but not 
dispensed; prescriptions not eligible for NHF subsidy nor does it include information on 
prescriptions that were dispensed and not taken. Two cohorts consisting of patient level 
data were extracted from the NHF pharmacy claims data for the years 2008 and 2017 to 
address research objective two.  Two cohorts consisting of aggregate data were also 
extracted for the years 2007 to 2009 and was used to address research objective three.  
The specifications for the extracts are provided in Appendices 4.1 to 4.5. 
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The idea that health care administrative data, although designed for operational use, can be 
leveraged for research is not new. Several researchers, particularly in developed countries 
have used administrative data to address important health research questions (Tricco et al, 
2008; Cadarette et al, 2012; Cadarette & Wong, 2015). Administrative data sources used to 
manage pharmacy claims have been shown to provide valuable information related to 
prescribing and dispensing patterns, adherence to drug therapy and drug safety and 
effectiveness (Cadarette & Wong, 2015; Gazmararian et al, 2006, Sinott et al, 2017). The 
benefit of using these data sources is, they are cost-efficient, and their representation of 
routine clinical care makes it possible to investigate actual utilization patterns in real-world 
settings (Schneeweiss & Avorn, 2005; Andrade et al, 2006). Because pharmacy claims data 
need to be complete and up to date for reimbursement purposes, they are generally 
considered to be accurate and of good quality (Schneeweiss & Avorn, 2005, Sinnott et al, 
2017, Strom et al, 2013, p.119).  
 
The NHF pharmacy claims was used to test the hypotheses related to research objectives 
two and three: 
1) Research Hypothesis two: 
a) H0: Adherence/continued access to medicines among adult Jamaicans (18 to 
59 years) enrolled in the NHF Drug Subsidy in Jamaica was equitable i.e. need 
and predisposing factors were the strongest predictors. 
Ha: Adherence/continued access to medicines among adult Jamaicans (18 to 
59 years) enrolled in the NHF Drug Subsidy in Jamaica, is mostly predicted by 
enabling and contextual factors. 
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2) Research Hypotheses three: 
a. H0: The health policy to remove user-fees from public health facilities in 2008 
increased access (new enrollment and NHFCard use) to medicines through 
NHF Individual Benefit Programme, among adults with diabetes or 
hypertension in Jamaica  
 
Ha: There was no difference in access (new enrollment and NHFCard use) to 
medicines through the NHF Individual Drug Benefit Programme among adults 
with diabetes and hypertension, following the health policy to remove user-
fees from public health facilities in 2008  
 
4 Data management 
 
The JHLS II raw data was received in CSV format and imported directly into SPSS for coding 
and analysis.  The raw data from the NHF pharmacy claims database was received in CSV 
format. The data was then imported into SQLITE, a software package which provides 
relational data management capabilities. SQLITE has the ability to process complex queries 
using structured query language (SQL) and was used to create the cohorts, the explanatory 
and outcome variables used in the study. The SQL codes used to create the study cohorts 
are included in appendix 4.6.  
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5 Study population and sampling 
 
A retrospective cohort study was conducted among adults (18 to 59 years old) with diabetes 
or hypertension in Jamaica.  The government of Jamaica also provides chronic disease drug 
subsidies for seniors (60+ years) through a separate programme called the Jamaica Drug 
for the Elderly Programme (JADEP). Individuals over 60 years can be enrolled in both the 
NHF and JADEP programmes and access their medications through either programme. 
However, because of the absence of a unique identifier it was not possible to link claims 
data under both programmes in persons over 60 years old. The analysis was therefore 
limited to persons under 60 years old who would only have been eligible for the NHF 
programme.  All cohorts included individuals from the 14 parishes in Jamaica. 
 
5.1 Inclusion/exclusion criteria 
Research objective one – Factors associated with NHF enrollment among adults with 
diabetes or hypertension 
Only a sub-sample of adults (18 to 59 years old) who responded ‘yes’ to the question on the 
JHLS II, “Have you ever been told by a doctor, nurse or other health professional that you 
have diabetes (sugar)?” or “Have you ever been told that you have high blood pressure?” 
Based on these criteria a total of 626 respondents were included in the data extracted for 
this study. This represented 22% of the total sample recruited from the JHLS II Household 
Survey (2008). 
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Research objective two – Factors associated with medication adherence among NHF 
enrollees with diabetes or hypertension 
Two cohorts of patients were extracted from the NHF pharmacy claims data (2008 and 
2017). Each cohort included adults (18 to 59 years old) enrolled in the NHF with a diagnosis 
of diabetes or hypertension, and who used their NHFCard to purchase chronic disease 
medicines (antidiabetics, antihypertensive, antihyperlipidemics) at any of the participating 
pharmacies in Jamaica. Additionally, to ensure a long enough adherence assessment 
period, only individuals who had a minimum of 6 months between their first and last 
prescription fill date in the assessment years (2008 and 2017) were included in the analysis.  
Individuals who purchased insulin were excluded, because of the difficulty deriving an 
appropriate adherence metric for injectable medicines from pharmacy claims data (Stolpe 
et al, 2016). Based on these criteria, 20,264 individuals were included for analysis in 2008 
and 77,454 were included in 2017. 
Research objective three – Effect of removal user-fees on NHF enrollment and use of 
the NHFCard 
Two cohorts were extracted from the NHF pharmacy claims database, one for each outcome 
measure examined. The first cohort consisted of adults (18 to 59 years old) who enrolled in 
the NHF with a diagnosis of diabetes or hypertension between January 1, 2007 and 
December 31, 2009. The second cohort consisted of adults (18 to 59 years old) who used 
their NHFCard to purchase medicines between January 1, 2007 to December 31, 2009.  
Based on these criteria, 49,559 individuals were included in the final cohort for the analysis 
of New NHF enrollment and 74,520 individuals were included in the final analysis of 
NHFCard utilization. 
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6 Study variables 
 
6.1 Research Hypothesis One - Factors associated with NHF 
enrollment among adults with diabetes or hypertension 
Dependent variable: 
Are you enrolled in the NHF (Yes/No?)? – This variable captures NHF enrollment status 
of adults in Jamaica with diabetes and hypertension who were eligible to receive subsidized 
medicines through the NHF Drug Benefit Programme.  Enrollment status was used as a 
measure of access to the NHF and was based on the survey question, “are you enrolled for 
an NHFCard?”  Possible responses to that question were, ‘Yes’, ‘No’, ‘Don’t Know’ or ‘No 
response’.  As the research objective was to compare factors influencing NHF enrollment, 
responses of ‘Don’t Know’ or ‘No response’ were excluded from the analysis (n=90). 
Response bias is a known challenge for survey questionnaires and may have impacted the 
validity of this dependent variable. These biases were mitigated by the quality control 
measures used by the survey administrators, such as re-interviewing a sample of the survey 
respondents.   
 
The intent of this dependent variable was to evaluate access to the NHF at the level of 
enrollment, where the patient is required to seek medical care and have their condition 
certified by their physician.  Following certification by a physician, they are required to enroll 
in person at one of many locations across the island. It effectively indicates whether the 
patient was diagnosed by a physician with hypertension and/or diabetes and has enrolled 
and received an NHFCard. Enrollment in the NHF Programme directly reflects three 
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dimensions of access, namely accessibility, accommodation and awareness. Accessibility 
relates to the physical or geographical location of primary care services and the location of 
NHF enrollment sites. Accommodation relates to the operational and administrative 
components such as hours of operation of private and public health physicians as well as 
NHF enrollment sites. Awareness relates to awareness of physicians who are required to 
confirm the diagnosis, and patient awareness to seek appropriate medical care.  However, 
this measure of access does not indicate whether the patient purchased any drugs using 
the NHF card.  
 
Explanatory variables 
In addition to information on the dependent variable (enrollment in the NHF), the JHLS II 
survey contained a wide range of explanatory variables to address research objective one.    
The Andersen-Newman Behavioural Model of Health Service Utilization was used to identify 
key explanatory variables to address the research objective regarding the factors predicting 
enrollment in the NHF among diabetics and hypertensives in Jamaica. The variables were 
grouped into the different categories of predisposing, enabling, need and contextual 
variables according to the definition of these categories found in the literature. These 
variables are described in table 4 below. A key limitation is that the data was collected in 
2008, however this was the first population health survey to include data on the use of the 
NHF drug subsidy programme along with several other measured demographic and socio-
economic factors and was directly relevant to the research objective. While a similar survey 
was completed in 2016, it did not include questions to allow examination of access and use 
of the NHF programme. 
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Table 4: Description of explanatory variables (Factors associated with NHF 
enrollment among adults with diabetes or hypertension) 
Variable Category Variable name Description 
Predisposing Age (years) 5 groups: 
18-391; 40-44; 45-49; 50-54;55-59 
 Sex 2 groups: 
Female1; Male 




 Education 3 groups: 
Less than secondary1; Secondary; Post-
Secondary 
Enabling Employment status 3 groups: 
Unemployed/student1; Part-time/seasonal; 
Full-time 
 Weekly Household income2 3 groups: 
 <$10,0001; $10,000-$20,000; >$20,000 
Private Health Insurance 2 groups: 
Yes1; No 
 Interviewer observed Socio-
Economic Status (SES) 
3 groups: 
Low income1; Middle Income; High Income 
Need  Sick in the past 12 months 2 groups: 
Yes1; No 
Individual has both conditions 
(diabetes & hypertension) 
2 groups: 
Yes1; No 
 Suffered a stroke or a heart 
attack in the past 
2 groups: 
Yes1; No 
Contextual Health Administrative Region 4 groups: 
South East Regional Health Authority 
(SERHA)1; North East Regional Health 
Authority (NERHA); Southern Regional 
Health Authority (SRHA); Western Regional 
Health Authority (WRHA) 
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Primarily rural surroundings or 
living conditions (reside in a 
parish with > 50% households 
in rural areas (St. Ann; 
Clarendon, St. Mary, St. 
Elizabeth, Manchester, 
Portland, Westmoreland, St. 
Thomas, Hanover, Trelawny) 
2 groups: 
Yes1; No 
1. Reference group 
2. Excluded due to >5% missing responses 
 
6.2 Research objective two - Factors associated with medication 
adherence among NHF enrollees with diabetes or hypertension 
Dependent variable 
Medication adherence (Y/N) – Measuring medication adherence (Dependent variable) 
Adherence was measured using the medication possession ratio (MPR). It is an indirect 
measure of adherence, which quantifies possession of medicines based on the number of 
days of supplies dispensed over a period of time (Hess et al, 2006). The medication 
possession ratio (MPR) was derived from the prescription re (fill) data available in the NHF 
pharmacy claims database. The specific calculation for the MPR was as follows: 
 
𝑀𝑃𝑅 (%) =
𝑡𝑜𝑡𝑎𝑙 𝑑𝑎𝑦𝑠′𝑠𝑢𝑝𝑝𝑙𝑦 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑡ℎ𝑒 1𝑠𝑡 𝑎𝑛𝑑 𝑙𝑎𝑠𝑡 𝑝𝑟𝑒𝑠𝑐𝑟𝑖𝑝𝑡𝑖𝑜𝑛 𝑓𝑖𝑙𝑙 𝑑𝑎𝑡𝑒 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑎𝑦𝑠 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑡ℎ𝑒 1𝑠𝑡 𝑎𝑛𝑑 𝑙𝑎𝑠𝑡 𝑝𝑟𝑒𝑠𝑐𝑟𝑖𝑝𝑡𝑖𝑜𝑛 𝑓𝑖𝑙𝑙 𝑑𝑎𝑡𝑒 +  𝑙𝑎𝑠𝑡 𝑝𝑟𝑒𝑠𝑐𝑟𝑖𝑝𝑡𝑖𝑜𝑛 𝑠𝑢𝑝𝑝𝑙𝑦
 𝑥 100 
 
The MPR falls within a range of 0 to 100%, where 0 is no adherence and 100% is total 
adherence (Sperber et al, 2017). It was capped at 100% to account for overestimation of 
adherence due to early refills. The MPR was dichotomized, where 80% or more MPR was 
considered adherent, and < 80% MPR non-adherent.  According to Karve et al (2009), a 
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cut-off point of 80% is reasonable and often used in research, for stratifying patients into 
adherent and non-adherent when they have prevalent chronic conditions.  The average 
MPR for three therapeutic classes (antidiabetics, antihypertensives and antihyperlipidemics) 
was used to determine if the patient met the adherent threshold of >= 80%. 
 
This measure is the most common measure of adherence when using pharmacy claims 
administrative data (Hess et al, 2006; Friedman et al, 2007; Wong et al, 2012; Margolis et 
al, 2017).  The MPR is identical to other commonly used measures of adherence such as 
Continuous Measure of Medication Acquisition (CMA), the Continuous Multiple Interval 
Measure of Oversupply (CMOS) and Medication Refill Adherence (MRA) (Hess et al, 2006). 
The values are also close to measures that report more conservative estimates such as the 
proportion of days covered (PDC). The MPR is not a direct measure of adherence and does 
not measure consumption, rather it measures possession of medicines and therefore 
directly reflects access to medicines among individuals enrolled in the NHF. 
 
The MPR was intended to capture continuous access to chronic disease medicines and 
represents all six dimensions of access (awareness, acceptability, affordability, accessibility, 
accommodation and availability). 
Explanatory variables 
The Andersen-Newman Behavioural Model was used to identify key explanatory variables 
to address the factors associated with adherence to antidiabetic and cardiovascular disease 
medicines among diabetics and hypertensives enrolled in the NHF. These variables were 
captured from the NHF pharmacy claims database and are described in table 5 below. A 
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key strength of the data is, there were no missing variables pertaining to any of the 
explanatory variables used in the analysis. However, the database does not capture some 
important explanatory variables known to be associated with use of health services, such 
as patient’s socio-economic status. It is well known that patients’ socio-economic status are 
important enablers to health service utilization and is often explored in health services 
research.  Notwithstanding this limitation, there were important explanatory variables found 
in this data source that were related to the conceptual model used in the study, and thus 
relevant to this research objective. 
 
Table 5: Description of explanatory variables (Factors associated with medication 
adherence among NHF enrollees with diabetes or hypertension) 
Variable category Variable name Description 
Predisposing Sex 2 groups: 
Female1; Male 
Age Group (at first prescription 
fill in the year 2017) 
5 groups: 
18-391; 40-44; 45-49; 50-54; 55-
59 
Enabling Average monthly out-of-pocket 
expenses (J$) 
3 groups: 
<5,0001; 5000-10,000; >10,000 
Need Polypharmacy (number of 
distinct therapeutic classes 
prescribed during the period) 
5 groups: 
One1; Two; Three; Four; Five; > 
5 
Diabetes and hypertension 
comorbidity status 
3 groups: 
Diabetes AND hypertension1; 
Hypertension without diabetes; 
Diabetes without hypertension  
Diagnosis of high cholesterol (at 
the time of enrollment) 
2 groups: 
Yes; No1 
Number of years enrolled 6 groups: 
< 11; 1-2; 2-3; 3-4; 4-5; > 5 
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Contextual Health Region 4 groups: 
Southeast Region1: Southern 
Region; North East Region; 
Western Region 
Primarily rural surroundings or 
living conditions (reside in a 
parish with > 50% households in 
rural areas (St. Ann; Clarendon, 
St. Mary, St. Elizabeth, 
Manchester, Portland, 





1. Reference group 
 
6.3 Research objective three - Effect of removal user fees on NHF 
enrollment and use of the NHFCard 
Dependent variables 
A. New NHF enrollees with diabetes or hypertension  
This was the number of new NHF enrollees with diabetes or hypertension. New 
enrollments were identified using the enrollment date from the NHF pharmacy claims 
database. The value for this outcome variable was the aggregate number of NHF 
enrollees with diabetes or hypertension between 18-59 years, within the time-periods 
of interest. This was meant to capture better access to primary care in the public 
sector, which should result in the individuals being diagnosed and getting their NHF 
enrollment application signed off by a physician, subsequently leading to enrollment 
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B. NHFCard utilization among enrollees with diabetes or hypertension  
This was the number of NHF enrollees with diabetes or hypertension who purchased 
medicines using their NHFCard during the time-period.  NHFCard utilization is 
captured in the NHF pharmacy claims database each time a person purchases 
medicines using their card.  The value of this outcome variable was the aggregate 
number of NHF enrollees between the ages of 18-59 years, who purchased 
medicines using their NHFCard within the time-periods of interest.  It is intended to 
capture pharmacy visits in relation to better access to primary care in the public 
sector. 
Explanatory variables 
Removal of user fees in public health facilities in 2008 
Health facility user fees were charges paid by the patient at the point of care in health 
facilities in Jamaica. Historically, these charges have been used in developing countries to 
generate revenue and to discourage misuse of limited resources at health facilities 
(Campell, A., 2013; Li et al, 2017).  Although these fees were promoted by the World Bank 
as a means of offsetting financial burden within the health sector and promoting 
sustainability of health services, research in developing countries have shown that they have 
had a negative impact on access to basic health services (Campbell, A., 2013; Li et al, 
2017).  Changes to user fees in Jamaica have gone through many iterations since 1968 to 
its ultimate removal on April 1, 2008 (Coombs, M., 2013): 
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Table 6: History of changes to user fees at public health clinics in Jamaica 
Time 
Period/Year 
Changes to user fees in public health 
facilities in Jamaica 
1968 Fees revised 
1975 Removed user fees 
1984 Reintroduction user fees 
1993 Increase in user fees 
1999 Increase in user fees 
2005 Increase in user fees 
2007 remove user fees for < 18 years 
01-Apr-08 Remove user fees for all patients 
Source: (Coombs, M., 2013) 
 
In 1975, user fees had been removed from the public health system and then re-introduced 
in 1984. Since 1993, they had been increasing over-time before being subsequently 
removed for all patients on April 1, 2008. This policy change was a highly political and 
publicised change that received months of media attention. Thus, it had been discussed 
widely in the public sphere prior to its implementation on April 1, 2008. Following 
implementation on April 1, 2008, daily activity at public health centres and hospitals was 
also monitored by the Ministry of Health to determine the immediate effect of the policy. 
Time-period 
The total number of time-period data points used in the analysis was 36 months. January 
2007 to March 2008, represented the pre-removal of user fees, April 2008, represented the 
policy implementation period, while May 2008 to December 2009, represented the post-
removal of user fees period.   
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7 Statistical analysis 
 
Multiple statistical methods were employed in order to address the range of research 
objectives proposed in this study. This section describes the methods used for each 
research objective and provides a justification for the selection of each method. 
 
7.1  Research objectives one and two (Factors associated with NHF 
enrollment and Factors associated with medication adherence 
among NHF enrollees with diabetes or hypertension) 
Descriptive analysis 
Descriptive statistics in the form of frequency distributions and percent distribution were 
performed on all variables included in the study.  This was done to describe the 
characteristics of the population and in the case of Research Objective 2, compare the drug 
utilization patterns among NHF enrollees in 2008 and 2017. 
Bivariate analysis 
Contingency tables were used to examine the distribution of the outcome variable and how 
it changed with each level of the explanatory variables.  The Chi-squared test of 
independence was used to test each explanatory variable against the outcome variable of 
interest. The Chi-square test is a non-parametric test used to analyze group differences 
when the outcome variable is measured at the nominal and ordinal level (McHugh, M.L., 
2013). The assumptions of the Chi-square include (McHugh, M.L., 2013): 
1) The data in the cells must be frequencies or counts 
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2) Each study respondent should fit into only one cell and  
3) The study groups are independent of each other 
4) Like the outcome variable, the explanatory variables must be categorical. If there are 
ratio or interval, they can be collapsed into ordinal categories 
5) 80% or more of the cells have expected frequencies of five (5) or greater and no cell 
should have expected frequencies less than one (1) 
 
The null hypothesis of the chi-squared test is that the outcome variable tested in a bivariate 
relationship is independent of the explanatory variable. The alternative hypothesis being that 
the distribution of the outcome is determined by the explanatory variable. For research 
objective one, the outcome variable of interest was ‘NHF Enrollment’ which was a 
dichotomous variable reported by the respondent as ‘yes’ or ‘no’ in JHLS II Survey. For 
research objective two, the dependent variable of interest was ‘medication adherence’ which 
was also a dichotomous variable transformed from the medication possession ratio (MPR). 
The MPR was calculated from the NHF Pharmacy Claims data, where a patient with an 
MPR of 80% or more was categorized as ‘adherent’ and a patient with less than 80% MPR 
was categorized as ‘non-adherent’.  
 
With all the conditions and assumptions of the chi-squared test satisfied, it was considered 
appropriate for bivariate analyses in research objectives one and two. A p-value of 0.05 or 
less was used to determine statistical significance in the bivariate analysis. The chi-squared 
test will be followed up by the Cramer’s V test to measure the strength of the association 
(McHugh M.L., 2013). It is calculated using the following formula: 










Where, X2 is the chi-square, n is sample size and k is the lesser of the number of rows or 
columns (McHugh M.L., 2013). A Cramer’s V test value of 0.1 to less than 0.2 is considered 
a weak association, 0.2 to less than 0.4 is considered moderate  and 0.4 and greater is 
considered a strong association (Kotrlik et al, 2011).  It should be noted that a weak 
association is not an indication of practical or clinical insignificance, as there is an 
expectation that weak associations will be observed in real world settings, where each 
predictor variable is only partially explaining the complex outcomes being investigated in 
this study (McHugh M.L., 2013). 
Multivariate analysis 
Binary logistic regression was used to model the relationship between the outcome and 
explanatory variables.  This statistical method is commonly used in healthcare research to 
test the relationship between a dichotomous outcome variable and multiple continuous or 
categorical explanatory variables. It is frequently used for predictive analysis in order to 
model the probability of the outcome as a function of the explanatory variables. It resembles 
ordinary linear regression in many ways in that it allows for a combination of quantitative 
and categorical explanatory variables and it allows for the inclusion of interaction terms 
between explanatory variables (Peng et al, 2002). The fundamental characteristic of logistic 
regression modeling is, the application of the logit transformation to the odds of the outcome 
variable makes the relationship between the dichotomous outcome variable and its 
explanatory variables linear (Peng et al, 2002). Thus, allowing for the prediction of the 
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outcome based on the values of the explanatory variables (Peng et al, 2002). As a result, 
the relationship between the outcome and explanatory variables can be represented in the 
form of an ordinary linear regression equation. Other key assumptions underlying logistic 
regression method is that all observations are independent i.e. it should not be used with 
data collected from repeated measurements or matched data and there should be little or 
no correlation between explanatory variables in the model (multicollinearity). The 
mathematical concept underlying logistic regression is the natural logarithm of the odds 
(logit), where the odds of the outcome being investigated is equal to the ratio of the 
probability of the ‘success’ to the probability of ‘failure’ (Peng et al, 2002).   
 
𝐿𝑜𝑔𝑖𝑡 (𝑝) = 𝑙𝑛 (
𝑝
1−𝑝
) = 𝛼 +  𝛽𝑋1 
 
Where p is the probability of the outcome, 𝑋1  represents an independent variable, 𝛼 is the 
intercept when 𝑋1 = 0, 𝛽 is the regression coefficient.   Logistic regression allows for the 
examination of multiple covariates in a single model as follows (Peng et al, 2002): 
 
𝑙𝑜𝑔𝑖𝑡 (𝑝) = 𝛼 + 𝛽1𝑋1 + ⋯ 𝛽𝑘𝑋𝑘 
 
Where 𝛼 is the y-intercept, 𝑝 is the probability of the outcome, 𝑋1 𝑡𝑜 𝑋𝑘  are a set of 
predictor variables and 𝛽1to 𝛽𝑘 are the regression coefficients.  
 
Based on the literature review which indicated that multiple factors impact on health service 
utilization, a logistic regression model was used to examine the relationship between the 
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outcome (enrollment in the NHF and adherence), and the predisposing, enabling, need and 
contextual factors. Forward logistic regression was performed to identify the model with the 
best explanatory variables of the likelihood of the outcomes investigated (NHF enrollment 
and adherence among NHF enrollees).   
 
The logistic regression models for research hypotheses one and two are represented by the 
equations below: 
 
1. Research hypothesis one: 
Logit(enrol) = 𝛼 + β1age + β2sex  + β3mar+ β4ed + β5sym + β6mor + β7str + β8inc 
+ β9ses + β10hi + β11hr + β12rur + μ… (equation 1) 
 
where: 
a. enrol = response to the question “are you enrolled in the NHF” 
b. 𝛼 = y-intercept 
c. β1 to β9  = regression coefficients 
d. age = age of respondent 
e. sex  = sex of respondent 
f. mar = marital status 
g. ed = education level 
h. sym = symptoms in the last 12 months 
i. mor = Diabetes and hypertension comorbidity 
j. str = suffered a stroke/heart attack 
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k. inc = reported income 
l. ses = interviewer observed socio-economic status 
m. hi = respondent has private health insurance 
n. hr = administrative health region of residence 
o. rur = lives in predominantly rural geography 
p. μ = unobserved covariates 
 
2. Research hypothesis two: 
Logit(adhere) = 𝛼 + β1age + β2sex   + β3ye + β4mor +  β5oop + β6ntc +  β7hr + β8rur + 
β9hc  + μ… (equation 2) 
 
where: 
a. adhere = adherent (>= 80% MPR) vs nonadherent (<80% MPR) 
b. 𝛼 = y-intercept 
c. β1 to β11 = regression coefficients 
d. age = age (years) at the time of first prescription (2008, 2017) 
e. sex = sex of respondent (male/female) 
f. ye = Number of years enrolled in the NHF 
g. mor = Diabetes and hypertension comorbidity status 
h. hc = High cholesterol comorbidity 
i. oop = Average monthly out-of-pocket expenses 
j. ntc = Number of therapeutic classes (polypharmacy) 
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k. hr = administrative health region of residence 
l. rur = lives in predominantly rural geography 
m. μ = unobserved covariates 
 
All explanatory variables were entered in the logistic regression model. According to the 
above equations, the null hypothesis underlying the overall model states that all βs are equal 
to zero, meaning there is no relationship between the outcome variable and explanatory 
variables. A rejection of this null implies that at least one β does not equal zero in the 
population, which means the logistic regression model predicts the probability of the 
outcome better than the mean of the outcome variable Y (Peng et al, 2002). 
 
7.2 Research objective three – Effect of removal user fees on NHF 
enrollment and use of the NHFCard 
Descriptive analysis 
The mean was used to describe the population characteristic for each level of the 
explanatory variable analyzed.  Frequency tables were used to present the results of the 
descriptive analysis. 
Multivariate analysis 
With the exact timing and nature of the policy change known, an Interrupted Time Series 
(ITS) model was used to test whether the removal of user fees from public health facilities 
improved access to the NHF Individual Benefit Programme. In order to utilize an ITS model, 
data for equal increments of time-periods was also available before and after the removal 
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of user-fees from public health facilities. A single group pre-post ITS model was constructed 
to determine whether new enrollments to NHF and NHFCard use increased.  Based on the 
a priori assumption that the removal of user fees from public health facilities increased new 
NHF enrollments and NHFCard use, segmented linear regression was used to model these 
outcome measures before and after the implementation of the policy. Segmented Linear 
Regression also known as Piecewise Regression, is a statistical technique used to model 
temporal trends and is ideal for use with retrospective data for which there is sufficient 
number of data points before and after a policy implementation (Wagner et al, 2002; 
Valsamis et al, 2019). Segmented Linear Regression fits a least squares regression line to 
each segment of the explanatory variable (time) and assumes a linear relationship between 
the outcome and time (Wagner et al, 2002).   
 
To construct a segmented regression model, the following three parameters are needed in 
addition to the explanatory and outcome variables. 
1) The breakpoint or knot represents the point at which the linear function is expected 
to change. In this model, the knot value is known as the data point of the policy 
implementation (Xk).   
2) A dichotomous dummy variable (T) which represents each side of the knot.   
3) An interaction term between the dummy variable and the explanatory variable (XT). 
The values for the interaction term between the dummy variable and the values of 
the explanatory variables were calculated using the following equation: 
 
X*T (interaction term) = (X- Xk) T… (equation 3) 
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Below are the Segmented Linear Regression equations for the outcomes, number of new 
NHF enrollments (equation 4) and number of NHFCard users (equation 5) among diabetics 
and hypertensives, following the removal of user fees from public health clinics in Jamaica: 
 
1. new_enrolt = 𝛼 + β1X + β2T + β3(X - Xk) T... (equation 4) 
2. presct = 𝛼 + β1X + β2T + β3(X - Xk) T ……... (equation 5) 
 
 Where: 
a. new_enrolt = Number of new NHF enrollment with diabetes or hypertension 
per quarter 
b. presct = Number of individuals who used their NHFCard per quarter 
c. X = A continuous variable indicating time in months from the start of the study 
period 
d. T= A dichotomous dummy variable indicating the pre-policy period (coded 0) 
or the post-policy period (coded 1). 
e. 𝛼 = Baseline level at time X = 0 (y-intercept in the pre-policy period) 
f. β1 = Slope of the regression line in the pre-policy period 
g. β2 = Level of change following the policy implementation (change in y-intercept 
in post policy period) 
h. β3 = Change in slope following the policy implementation 
 
The linear regression model estimated the level and trend in the number of new NHF 
enrollment and the number of NHFCard use before the policy, and the changes in level and 
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trend following the policy.  To examine whether the policy had an impact on equitable access 
to medicines, the analysis was stratified by demographic (age, sex) and contextual variables 
(health region, rurality). These were independent sub-group analysis intended to analyze 
whether the policy had an effect on specific sub-groups. 
Controlling for confounding 
Controlling for autocorrelation between values of the outcome measures over time 
A key assumption of linear regression with time series data is the absence of autocorrelation 
between error terms. Serial autocorrelation is said to exist when the observation at a 
particular time point is correlated to observations in the previous time points (Wagner et al, 
2002). This is a known problem with time series data, which can lead to unreliable estimates.  
The Durbin-Watson Test was done to detect the most common type of serial autocorrelation, 
known as first order serial autocorrelation. First order serial autocorrelation is when there is 
correlation between the error terms of adjacent time points (Wagner et al, 2002).  The null 
hypothesis for this test is that the error term in one time is not correlated to the error term in 
the previous time. A failure to reject the null indicates that no autocorrelation was detected 
in the time series data. The values for the Durbin-Watson statistic fall between zero (0) and 
four (4) (Savin & White, 1991).  To determine if autocorrelation exists, the Durbin-Watson 
test statistic (D) is compared to the lower (dL) and upper bounds (du) in the critical values of 
the Durbin-Watson Test Statistic (Savin & White, 1991). The values of dL and du   are based 
on the number of observations (n) and the number of regressors (k) in the analysis (Savin 
& White, 1991). If there is no autocorrelation in the time-series data, then D>Du; if D<DL, 
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then there is evidence of autocorrelation; if D falls between the dL and du, then the test is 
inconclusive. 
Testing for bias due to exogenous events 
Events occurring in the pre and post-policy periods and which are related to the outcomes 
being measured can bias the results of a single ITS design (Svoronos, T., 2016). As a result, 
changes detected in the outcome will be incorrectly attributed to the policy being evaluated. 
Cook & Campbell (1979) highlighted this issue as a major threat to internal validity of single 
ITS designs. To overcome these biases, it was recommended that a control group be used 
(Cook & Campbell, p. 211; Wagner et al, 2002), or to carry out an evaluation of a related 
outcome that was not affected the policy (Wagner et al, 2002).  However, due to the design 
of the study, a control group was not available. Likewise, the evaluation of a related outcome 
measure that was unaffected by the policy was not in scope for this study. In order to test 
for the existence of external influences, falsification tests are recommended when using 
single ITS designs (Svoronos, T., 2016). One such test is the Chow Test for structural break 
points in the time series data (Svoronos, T., 2016).  Based on the null hypothesis that there 
were no significant events related to access to the NHF directly before and after the removal 
of user fees, Chow Tests were conducted in SPSS. Structural breaks were chosen apriori 
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8 Approach to missing variables 
 
Missing data as a result of non-response can lead to inaccurate conclusions (Sterne, 2009). 
This type of missing data is known as item non-response, where a proportion of the 
respondents provide a response to only some of the items in the questionnaire (Schlomer 
et al, 2010).  Population health surveys are known to be prone to item non-response, 
especially to questions that respondents may deem sensitive or personal. Therefore, a 
missing variable approach was required for research objective one, which utilized the JHLS 
(II). 
8.1 Research objective one – Factors associated with NHF enrollment 
among adults with diabetes or hypertension 
 
A two-staged approach was taken to understand and deal with missing data.  First a 
univariate missing variable analysis (MVA) was performed in SPSS on all variables to 
examine the extent of missing data. The approach to handling variables with less than 5% 
missing values in the dataset was to do complete cases analysis, in which only the records 
that do not have missing values are retained in the analysis. No further missing variable 
analysis was performed on these variables. Variables with > 5% item non-response were 
further analyzed to examine their pattern of missingness. The variable income had 33% 
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Table 7a: Missing Values Analysis 
Variables N Missing % Missing 
Sex 626 0 0.0% 
Patient has both conditions 
(Diabetes & Hypertension) 
626 0 0.0% 
Has health insurance 624 2 0.3% 
Age 626 0 0.0% 
Marital Status 624 2 0.3% 
Education 607 19 3.0% 
Employment Status 608 18 2.9% 
Socio-economic status 623 3 0.5% 
*Income 415 211 33.7% 
Suffered a stroke/heart attack 626 0 0.0% 
Have you been sick in the 
past 12 months 
626 0 0.0% 
Diagnosed with a mental 
health problem 
626 0 0.0% 
Rural 626 0 0.0% 
Health Administrative Region 626 0 0.0% 
Are you enrolled in the NHF 
(dependent variable) 
626 0 0.0% 
 
To examine the pattern of missingness in the ‘income’ variable, a Chi-squared test was used 
to test the association between missingness on the ‘income’ variable and all other variables, 
where p<0.05 was considered significant. This test was performed to determine if the 
missing responses were missing completely at random (MCAR), missing at random (MAR) 
or missing not at random (MNAR).  Missingness on the ‘income’ variable was significantly 
associated with ‘employment status’, ‘interviewer observed social status’, ‘administrative 
health region’, ‘rurality’ and the outcome variable, ‘enrolled in the NHF’ (Table 7b). Based 
on its association with multiple covariates, it was assumed that the missing data pattern was 
not random (MNAR), and a decision was made to exclude the ‘income’ variable from further 
analysis.  Since the interviewer observed social status was considered a similar and more 
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objective measure of income status, excluding reported income did not compromise the 
analysis of this important variable.  
 











Female 34%   












Education     












**Interviewer Observed Social status   
6.950 
(0.031) 
High income 50% 
Middle income 32% 
Low income 31% 





Have you been sick in the past 12 months   
0.169 
(0.681) 





Patients has both diabetes and hypertension   
2.834 
(0.092) Yes 41% 
No 32% 
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CHAPTER 5 - RESULTS  
1 Chapter Introduction 
The results were presented in three sections. Each section relates to one of the three 
research hypotheses.  
 
2 Section one – What factors predicted enrollment in the NHF 
among adults with diabetes and hypertension? 
 
At the time of the survey, 154 or approximately one-quarter (25%) of adults with diabetes or 
hypertension between the ages of 18 to 59 years were enrolled in the NHF Drug benefit 
programme (figure 5).  
 
2.1 Univariate analysis 
 






Percent enrollment in the NHF
Yes
No
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Table 8: Distribution of predisposing, enabling, need and contextual factors (n=626) 
 
  enrolled (yes) enrolled (no)  
PREDISPOSING 
FACTORS 
  n % n % Total 
Sex 
Female 130 76% 410 24% 540 
Male 24 72% 62 28% 86 
Age 
18-39 18 9% 188 91% 206 
40-44 22 24% 71 76% 93 
45-49 39 34% 75 66% 114 
50-54 37 32% 80 68% 117 
55-59 38 40% 58 60% 96 
Marital Status 
Married/Common-law 97 28% 246 72% 343 
Divorced/Separated/widowed 12 46% 14 54% 26 
Single/visiting 45 18% 210 82% 255 
Education 
Less than Secondary 68 27% 184 73% 252 
Secondary 59 21% 215 79% 274 







  enrolled (yes) enrolled (no)  




Unemployed/student 63 27% 170 73% 233 
Part-time/Seasonal 13 15% 72 85% 85 
Full-time 71 25% 219 76% 290 
Interviewer Observed Social status 
Low income 34 16% 173 84% 207 
Middle income 104 29% 260 71% 364 
High income 16 31% 36 69% 52 
Have private health insurance 
Yes 30 28% 76 72% 106 
No 124 24% 394 76% 518 
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  enrolled (yes) enrolled (no)  
  n % N % Total 
NEED 
FACTORS 
Have you been sick in past 12 months 
Yes 56 28% 142 72% 198 
No 98 23% 330 77% 428 
Patients has both diabetes and hypertension 
Yes 53 53% 47 47% 100 
No 101 19% 425 81% 526 
*Suffered stroke/heart attack 
Yes 6 35% 11 65% 17 




Table 8 summarizes the characteristics of the study participants. Explanatory variables were 
summarized according to the categories of the Andersen-Newman Framework i.e., 
predisposing, enabling, need and contextual factors.  Female participants outnumbered 
males by a ratio of six (6) to one (1) and more than half (55%) of the participants were 
married.  Forty eight percent (48%) were under the age of forty-five, while 52% were in the 
older age categories (45-59 years), indicating a large proportion of middle-aged participants. 
Approximately 1 in 8 participants reported having post-secondary education, while the 
majority had either less than secondary or secondary education. Thirty three percent (33%) 
  enrolled (yes) enrolled (no)  




7 - Southeast Regional Health Authority 80 26% 227 74% 
307 
20 - Northeast Regional Health Authority 16 24% 56 76% 
72 
12 - Southern Regional Health Authority 30 23% 103 77% 
133 
18 - Western Regional Health Authority 26 23% 86 77% 
112 
Rural parishes 
Yes 71 23% 235 77% 306 
No 83 26% 237 74% 320 
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of the participants were observed by the interviewer to be in the lowest income category.  
However, the majority were in the middle-income category, while only 8% were observed to 
be of high-income status. The percentage with private health insurance was 17%. 
Almost one-third (32%) reported being sick in the past 12 months and 16% reported having 
both chronic conditions (diabetes and hypertension). Three percent (3%) had suffered a 
stroke or heart attack in the past 12 months.  
 
At the time of the survey, approximately half of the respondents lived in the Southeast 
administrative health region (SERHA) and 48% lived in a parish which was predominantly 
rural (>50% households in rural areas). 
 
2.2 Bivariate analysis 
 
Table 9: Bivariate relationship between predisposing factors and NHF Access (n=626) 
 enrolled (yes) enrolled (no)   
PREDISPOSING FACTORS n % n % Total 
Chi-squared p-
value (Cramer’s V) 
Sex 
Female 130 76% 410 24% 540 
p = 0.443 (0.03) Male 24 72% 62 28% 86 
Age 
18-39 18 9% 188 91% 206 
P < 0.001 (**0.30) 
40-44 22 24% 71 76% 93 
45-49 39 34% 75 66% 114 
50-54 37 32% 80 68% 117 
55-59 38 40% 58 60% 96 
Marital Status 
Married/Common-law 97 28% 246 72% 343 
 p < 0.001 (0.16) 
Divorced/Separated/widowed 12 46% 14 54% 26 
Single/visiting 45 18% 210 82% 255 
Education 
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Less than Secondary 68 27% 184 73% 252 
p = 0.291 (0.07) 
Secondary 59 21% 215 79% 274 
Post-Secondary 23 28% 58 72% 81 
p<0.05 is significant association 
** Moderate to strong association 
 
Table 9 presents the results of the bivariate analysis between explanatory variables and the 
outcome variable. Significant associations were observed between age and marital status 
and the participants likelihood of being enrolled in the NHF.  Participants who were never 
married (single/visiting), were less likely to be enrolled in the NHF compared to participants 
who reported being in a committed relationship at some point (married/common-law, 
separated/divorced/widowed). However, the relationship between marital status and NHF 
enrollment could be described as weak (v=0.16). From the analysis it was also observed 
that, as the age of the participants increased, the probability of enrolling in the NHF also 
increased. Only 9% of participants with diabetes or hypertension between the ages of 18-
39 years were enrolled, compared to 40% of participants between 55-59 years (p<0.001). 
The Cramer’s V measure (v=0.3) suggests a strong relationship between age and the 
likelihood of NHF enrollment.  Likelihood of enrollment in the NHF was similar for males and 
females at 28% and 24% respectively (p=0.443). Similarly, participants' enrollment in NHF 
was not significantly associated with level of education attainment (p=0.291). 
 
Table 10: Bivariate relationship between enabling factors and NHF Access (n=626) 
 enrolled (yes) enrolled (no)   





Unemployed/student 63 27% 170 73% 233 p = 0.095 (0.09) 
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Part-time/Seasonal 13 15% 72 85% 85 
Full-time 71 25% 219 76% 290 
Interviewer Observed Social status 
Low income 34 16% 173 84% 207 
 p = 0.003 (0.14) 
Middle income 104 29% 260 71% 364 
High income 16 31% 36 69% 52 
Have private health insurance 
Yes 30 28% 76 72% 106 
p = 0.342 (0.04) No 124 24% 394 76% 518 
p<0.05 is significant 
** Moderate to strong association 
 
Interviewer observed social status was associated with the likelihood of NHF enrollment, 
with higher proportions of participants in the high- and middle-income category being 
enrolled compared to those in the low-income group (p = 0.003), although the strength of 
that association could be described as weak (v=0.14). NHF enrollment was not significantly 
associated with employment status (p=0.095) and having private health insurance (p= 
0.342). 
 




(no)   
NEED FACTORS n % n % Total 
Chi-squared p-value 
(Cramer’s V) 
Have you been sick in past 12 months 
Yes 56 28% 142 72% 198 
p=0.146 (0.06) No 98 23% 330 77% 428 
Patients has both diabetes and hypertension 
Yes 53 53% 47 47% 100 
 p < 0.001 **(0.30) No 101 19% 425 81% 526 
*Suffered stroke/heart attack 
Yes 6 35% 11 65% 17 
 p=0.299 (0.04) No 148 24% 461 76% 609 
p<0.05 is significant 
** Moderate to strong association 
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Fifty three percent (53%) of participants with both diabetes and hypertension were enrolled 
in the NHF, compared to only 19% with only one of the two conditions (p < 0.001). Based 
on Cramer’s V (V=0.30), there was strong relationship between having both diabetes and 
hypertension and the Likelihood of NHF enrollment. Being sick in the past 12 months 
(p=0.146) and having a history of stroke or heart attack (p=0.299) were not significantly 
associated with NHF enrollment. 
 
 
Table 12: Bivariate relationship between contextual factors and NHF enrollment 
(n=626) 
  enrolled (yes) enrolled (no)     
CONTEXTUAL FACTOR n % n % Total 
Chi-squared p-
value (Cramer’s V) 
Health Region 
Southeast Regional Health Authority 80 26% 227 74% 307 
p = 0.856 (0.04) 
Northeast Regional Health Authority 16 24% 56 76% 72 
Southern Regional Health Authority 30 23% 103 77% 133 
Western Regional Health Authority 26 23% 86 77% 112 
Rural parishes 
Yes 71 23% 235 77% 306 
 p = 0.427 (0.05) No 83 26% 237 74% 320 
p<0.05 is significant 
** Moderate to strong association 
 
Contextual factors such as administrative health region and rurality were not significantly 
associated with NHF enrollment (table 12). Administrative Health Region represents 
differences in health system inputs and organization of health services, while rurality 
represents the community level factors such as availability of primary care, socio-economic 
conditions, such as rates of post-secondary education and average income and overall 
population health. 
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2.3 Multivariate analysis 
 
Table 13: Relationship between NHF Enrollment and predisposing, enabling, need 
and contextual covariates (n=600) 
 
p<0.05 is significant 
 
 
The logistic regression model identified age, marital status and the presence of both 
diabetes and hypertension as significant factors associated with enrollment in the NHF (p < 
0.001, chi-square 93.23, df=7).  The odds of NHF enrollment among older Jamaicans with 
diabetes or hypertension between the ages of 40-44 years was 3.19 times that of the 18 to 
39 years age group (95% CI, 1.56-6.55, p=0.002). While the odds of enrollment were 5.33 
times higher in the 55 to 59 years age group (95% CI, 2.65-10.71). Compared to individuals 
who were single or in visiting relations, the odds of enrollment were 1.76 (95% CI, 1.14-
2.72) times higher among respondents who were married or in common-law relationships 
and 2.54 (95% CI,1.08-6.73) times higher among the group that were previously married 
(divorced/widowed/separated).  The odds of enrollment were 3.81 (95%CI, 2.31-5.99) times 
higher among respondents who reported being diagnosed with both conditions compared 
to those diagnosed with only one.  Socio-economic status, which was significant on bivariate 
analysis, was not significant in the multivariate model. Both age and comorbid status were 
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determined in the bivariate analysis as having a strong effect on NHF enrollment, while 
marital status was determined to have a small effect.  
 
3 Section two: NHF utilization patterns and the factors 
associated with adherence among NHF enrollees with diabetes 
or hypertension 
 
3.1 Univariate analysis 
 
Table 14: Prevalence of drug use among diabetics and hypertensives by therapeutic 












ANTIHYPERTENSIVES 20,699 83% 19,475 97% 1,333 21% 




8,460 34% 8,957 45% 0 0% 
CALCIUM CHANNEL 
BLOCKERS 
7,386 29% 7,676 38% 0 0% 
BETA BLOCKERS 
CARDIO-SELECTIVE 
3,767 15% 4,310 22% 16 0% 
ANTIHYPERTENSIVE 
COMBINATIONS 




3,211 13% 3,044 15% 144 2% 
LOOP DIURETICS 1,302 5% 1,005 5% 28 0% 
BETA BLOCKERS NON-
SELECTIVE 
1,207 5% 1,268 6% 27 0% 
ANTIADRENERGIC 
ANTIHYPERTENSIVES 
1,173 5% 1,356 7% 10 0% 
VASODILATORS 640 3% 567 3% 0 0% 





87 0% 81 0% 19 0% 
ANTIDIABETICS 19,005 76% 0 0% 6,144 97% 
BIGUANIDES 
(METFORMIN) 
14,549 58% 0 0% 4,317 68% 
SULFONYLUREAS 10,888 43% 0 0% 3,309 52% 
INSULIN 4,236 17% 0 0% 1,830 29% 
THIAZOLIDINEDIONES 
(PIOGLITAZONE) 
1,840 7% 0 0% 544 9% 
ALPHA-GLUCOSIDASE 
INHIBITORS 
1,829 7% 0 0% 579 9% 
DIABETIC OTHER 587 2% 0 0% 192 3% 
MEGLITINIDE 
ANALOGUES 
63 0% 0 0% 26 0% 
DIPEPTIDYL PEPTIDASE-4 
(DPP-4) INHIBITORS 
22 0% 0 0% 3 0% 
ANTIHYPERLIPIDEMICS 7,882 31% 4,623 23% 1,245 20% 
HMG COA REDUCTASE 
INHIBITORS (STATIN) 
7,451 30% 4,254 21% 1,183 19% 
ANTIHYPERLIPIDEMICS - 
MISC. 
728 3% 591 3% 105 2% 
**Excluded from adherence analysis 
 
Table 15: Prevalence of drug use among diabetics and hypertensives by therapeutic 











ANTIHYPERTENSIVES 40,673 88% 63,267 98% 3,958 28% 
CALCIUM CHANNEL 
BLOCKERS 
18,315 40% 28,593 44% 66 0% 








12,025 26% 17,634 27% 1,148 8% 
ANTIHYPERTENSIVE 
COMBINATIONS 
9,125 20% 17,387 27% 316 2% 
BETA BLOCKERS 
CARDIO-SELECTIVE 
5,030 11% 8,111 13% 37 0% 
BETA BLOCKERS NON-
SELECTIVE 
4,809 10% 6,100 9% 54 0% 
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LOOP DIURETICS 2,743 6% 2,676 4% 29 0% 
POTASSIUM SPARING 
DIURETICS 
1,262 3% 1,534 2% 0 0% 
VASODILATORS 1,242 3% 1,539 2% 0 0% 
ANTIADRENERGIC 
ANTIHYPERTENSIVES 
717 2% 1,336 2% 10 0% 
DIURETIC 
COMBINATIONS 
227 0% 366 1% 0 0% 
CARBONIC ANHYDRASE 
INHIBITORS 
151 0% 185 0% 35 0% 
ANTIDIABETICS 39,274 85% 5 0% 13,520 97% 
BIGUANIDES 
(METFORMIN) 
25,934 56% 0 0% 8,140 59% 
SULFONYLUREAS 19,934 43% 5 0% 6,631 48% 
INSULIN 8,085 17% 0 0% 3,761 27% 
ANTIDIABETIC 
COMBINATIONS 
7,299 16% 0 0% 2,714 20% 
THIAZOLIDINEDIONES 
(PIOGLITAZONE) 
7,188 16% 0 0% 2,478 18% 
ALPHA-GLUCOSIDASE 
INHIBITORS 
2,944 6% 0 0% 878 6% 
DIPEPTIDYL PEPTIDASE-
4 (DPP-4) INHIBITORS 
2,690 6% 0 0% 783 6% 
DIABETIC OTHER 351 1% 0 0% 110 1% 
MEGLITINIDE 
ANALOGUES 
4 0% 0 0% 1 0% 
ANTIHYPERLIPIDEMICS 20,457 44% 18,564 29% 4,003 29% 
HMG COA REDUCTASE 
INHIBITORS (STATINS) 
19,960 43% 17,960 28% 3,916 28% 
ANTIHYPERLIPIDEMICS - 
MISC. 
765 2% 880 1% 137 1% 
**Excluded from adherence analysis 
 
An analysis was conducted on all the individuals who enrolled with diabetes or hypertension 
and who used their NHFCard to purchase chronic disease medicines (antidiabetic, 
antihypertensives or antihyperlipidemics) in 2008 and 2017. In 2008, 51,451 diabetics 
and/or hypertensives used their NHFCard to purchase antidiabetics or cardiovascular 
disease medicines (antihypertensive and antihyperlipidemics), by 2017, that number 
increased by 242% (124,593). The proportion of users who were comorbid diabetes and 
hypertension at the time of enrollment differed between the two cohorts (2008 and 2017). In 
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2008, 49% of users enrolled both conditions, 39% enrolled with hypertension only, and 12% 
enrolled with diabetes only. In 2017, the proportion of comorbid users was relatively smaller 
at 37%, and the proportion with hypertension only was larger at 52%, while the proportion 
with diabetes only slightly lower at 11%.   
 
In 2017, the most prevalent antihypertensive was Calcium Channel Blockers (40%); ACE 
Inhibitors (37%); Thiazide and Thiazide-Like Diuretics (33%) and Angiotensin II Receptor 
Antagonists (26%).  The prevalence of Calcium Channel Blockers among all hypertensives 
increased relative to 2008, where ACE Inhibitors was more prevalent at that time. The use 
of antihypertensive combinations increased among all individuals with hypertension. There 
was an increase from 20% in 2008 to 27% in 2017, within the group with hypertension only, 
and from 13% to 20% within the comorbid group. Use of Beta-blockers decreased while 
Angiotensin II Receptors use increased from 2008 to 2017.  More than 1 in 5 adults who 
enrolled with diabetes only, were treated with antihypertensive medicines in 2008 and 2017. 
The most prevalent antihypertensive used among this group was ACE Inhibitors (19% in 
2017; 18% in 2008), while a lesser proportion received ARBs (8%) and antihypertensive 
combinations (2%). The likelihood that these were individuals diagnosed later with 
hypertension is strong, as those medicines are typically recommended as a first line 
treatment for diabetics with hypertension (ADA, 2020; O’Hare et al, 2015, NICE guidelines).  
 
Among diabetics, metformin and sulfonylureas were the most prevalent antidiabetics.  
However, there was a decrease in the prevalence of metformin from 68% in 2008 to 59% in 
2017. There was also a decrease in the prevalence of sulfonylureas from 52% to 48% in 
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this same group.   In 2017, the prevalence of antidiabetic combinations ranged from 16% to 
20%, whereas it was 0% in 2008. Insulin prevalence was higher among the diabetics who 
enrolled without comorbid hypertension, but it decreased slightly from 29% to 27% from 
2008 to 2017. 
 
In 2017, the prevalence of Statin was higher among the comorbid group at 43% compared 
to 28%.  There was also an overall increase in statin use among all the disease groups from 
2008 to 2017. 
 
Table 16: Percent adherent among diabetics and hypertensives who met the study 




Hypertension with no 
diabetes 











ANTIHYPERTENSIVES 8,006 63.1% 8,430 64.9% 193 32.6% 
ANTIDIABETICS 6,497 60.2% 0 --- 1,511 61.2% 
ANTIHYPERLIPIDEMICS 2,025 24.6% 1,440 24.3% 230 24.3% 
TOTAL 10,018 55.8% 8,670 59.1% 1,576 54.0% 
p<0.05 is significant 
 
Table 17: Percent adherent among diabetics and hypertensives who met the study 




Hypertension with no 
diabetes 











ANTIHYPERTENSIVES 23,573 62.8% 41,509 60.0% 1,418 23.0% 
ANTIDIABETICS 21,836 60.0% 0 -- 6,502 61.8% 
ANTIHYPERLIPIDEMICS 8,038 19.9% 8,316 17.7% 1,247 18.8% 
TOTAL 28,426 52.3% 42,277 52.4% 6,751 50.2% 
p<0.05 is significant 
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Regardless of comorbidity status, the proportion adherent in 2017 had decreased when 
compared to 2008 (Tables 16 and 17).  Proportion adherent to antidiabetics was similar in 
both years examined. However, in 2017, proportion adherent to antihypertensives and 
antihyperlipidemics decreased among all three groups when compared to 2008. Of the three 
therapeutic classes examined, percent adherent to antihyperlipidemics was the lowest in 
both years (tables 16 and 17).  
 
3.2 Bivariate analysis 
 
Table 18: Percent adherent among individuals enrolled in the NHF with diabetes or 
hypertension and who met the study criteria in 2008 (n=20,264) 
Variable 
category 






value (Cramer’s V) 
Predisposing 
Sex 
Female 14,467 71% 55% 
p<0.001(0.05) 
Male 5,797 29% 61% 
Age 
18-39 1739 9% 57% 
p=0.015 (0.03) 
40-44 2379 12% 57% 
45-49 3661 18% 58% 
50-54 5039 25% 59% 
55-59 7446 37% 56% 
Enabling 
Average monthly OOP on medicines (J$) 
< 5,000 14,907 78% 55% 
p<0.001 (0.10) 5,000 - 10,000 2,839 15% 64% 
> 10,000 1,417 7% 71% 
Need 
Number of therapeutic classes 
One 6,863 34% 61% 
p<0.001 (0.06) 
Two 6,487 32% 56% 
Three 3,921 19% 54% 
Four 1,867 9% 54% 
Five 707 3% 59% 
> 5 419 2% 58% 
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Diabetes and hypertension comorbidity status 
Diabetes and 
hypertension 









1576 8% 54% 
Diagnosis of high cholesterol 
Yes 11,257 56% 59% 
p<0.001 (0.03) 
No 9,007 44% 56% 
Number of years enrolled 
< 1 6,760 33% 56% 
p<0.001 (0.02) 
1-2 7,040 35% 58% 
2-3 2,668 13% 57% 
3-4 859 4% 56% 
>4 2,937 14% 58% 
Contextual 
Health Region   
South East 
Health Region 




1,765 9% 56% 
Southern 
Health Region 
4,380 22% 56% 
Western Health 
Region 
3,072 15% 55% 
Resides in predominantly rural parish (> 50% dwellings in rural areas) 
Yes 8,057 40% 59% 
p<0.001 (0.04) 
No 12,207 60% 55% 
p<0.05 is significant 
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Table 19: Percent adherent among individuals enrolled in the NHF with diabetes or 
hypertension and who met the study criteria in 2017 (n=77,454) 
Variable 
category 






value (Cramer’s V) 
Predisposing 
Sex 
Female 54,793 71% 51% 
p<0.001 (0.05) 
Male 22,661 29% 55% 
Age 
18-39 4,729 6% 48% 
p<0.001 (0.03) 
40-44 5,936 8% 50% 
45-49 10,227 13% 53% 
50-54 15,030 19% 53% 
55-59 41,532 54% 53% 
Enabling 
Average monthly OOP on medicines (J$) 
< 5,000 66,437 86% 48% 
p<0.001 **(0.20) 5,000 - 10,000 7,990 10% 73% 
> 10,000 3,027 4% 82% 
Need 
Number of therapeutic classes 
One 23,386 30% 54% 
p<0.001 (0.04) 
Two 21,950 28% 50% 
Three 15,712 20% 51% 
Four 9,150 12% 52% 
Five 4,277 6% 53% 
>5 2,979 4% 57% 
Diabetes and hypertension comorbidity status 
Diabetes and 
Hypertension 









6,751 9% 52% 
Diagnosis of high cholesterol 
Yes 38,999 50% 51% 
p<0.001 (0.02) 
No 38,455 50% 53% 
Number of years enrolled 
<1 6,719 9% 45% 
p<0.001 (0.07) 
1-2 5,743 7% 45% 
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2-3 4,815 6% 49% 
3-4 5,588 7% 50% 
4-5 5,371 7% 50% 
> 5 49,218 64% 55% 
Contextual 
Health Region   
South East 
Health Region 




10,564 14% 54% 
Southern 
Health Region 
16,395 21% 52% 
Western Health 
Region 
12,855 17% 53% 
Resides in predominantly rural parish (> 50% dwellings in rural areas) 
Yes 35,432 46% 52% 
 p=0.654 (0.002) 
No 42,022 54% 52% 
p<0.05 is significant association 
**Moderate to strong association 
 
Among the diabetics or hypertensives who used their NHFCard in 2017 to purchase 
antihypertensive, antidiabetic or antihyperlipidemic medicine, the majority were female 
(71%) over the age of 50 years (73%). Approximately half (49%) lived in the Southeast 
Health Region and 46% resided in parishes that were predominantly rural.  37% enrolled 
with both diabetes and hypertension; 55% enrolled with a diagnosis of hypertension without 
diabetes; and only 9% enrolled with a diagnosis of diabetes without hypertension. Half of 
this population also had a diagnosis of high cholesterol at the time of enrollment.  64% were 
enrolled for more than 5 years, and the majority (86%) spent on average less than J$5,000 
per month on medications. 42% purchased medicines in more than two therapeutic classes 
(Table 19).    
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In 2008, all explanatory variables were significantly associated with adherence on bivariate 
analysis, while in 2017 all except residing in a rural area were found to be significant (Tables 
18 and 19). However, the Cramer’s V, which measures the strength of association between 
adherence and the predictor variables suggests small differences within each variable 
tested, except in the case of Monthly Out-of-Pocket expense where moderate differences 
were observed in 2017 (0.20).  
 
3.3 Multivariate analysis 
 













<5,000 1     --- 
5,000-10,000 1.46 1.34 1.59 <0.001 




One 1     -- 
Two 0.82 0.76 0.88 <0.001 
Three 0.78 0.72 0.85 <0.001 
Four 0.73 0.65 0.82 <0.001 
Five 0.91 0.77 1.08 0.28 
> Five 0.85 0.69 1.05 0.13 
Sex 
Female 1     ---  
Male 1.20 1.13 1.28 < 0.001 
High cholesterol 
Yes 1     --- 
No 1.13 1.06 1.20 <0.001 
Predominantly 
rural parish 
Yes 1     --- 




1     -- 










0.91 0.81 1.02 0.095 
Number of 
years enrolled 
< 1 1     --- 
1-2 1.09 1.02 1.17 0.019 
2-3 1.07 0.98 1.18 0.192 
3-4 1.08 0.93 1.25 0.443 
>4 1.23 1.12 1.35 p<0.001 
Age-group 
18-39 1     --- 
40-44 1.02 0.90 1.17 0.742 
45-49 1.08 0.96 1.22 0.205 
50-54 1.10 0.98 1.24 0.098 
55-59 0.98 0.87 1.09 0.681 
p<0.05 is significant 
 











OOP on medicines 
(J$) 
<5,000 1     --- 
5,000-10,000 3.01 2.86 3.18 <0.001 
> 10,000 5.52 5.01 6.08 <0.001 
Number of 
therapeutic classes 
One 1     -- 
Two 0.78 0.75 0.81 <0.001 
Three 0.72 0.69 0.75 <0.001 
Four 0.69 0.65 0.73 <0.001 
Five 0.66 0.61 0.7 <0.001 
> Five 0.65 0.6 0.71 <0.001 
Number of years 
enrolled 
< 1 1     --- 
1-2 1 0.93 1.07 0.906 
2-3 1.14 1.06 1.23 0.001 
3-4 1.18 1.1 1.27 <0.001 
4-5 1.23 1.14 1.32 <0.001 
> 5 1.46 1.38 1.54 <0.001 
Health Region  
Southeast Health 
Region 
1     -- 





1.44 1.34 1.55 <0.001 
Southern Health 
Region 
1.2 1.12 1.29 <0.001 
Western Health 
Region 
1.26 1.2 1.33 <0.001   
High cholesterol 
diagnosis 
Yes 1       
No 1.14 1.11 1.18 < 0.001 
Sex 
Female 1     ---  
Male 1.13 1.09 1.16 < 0.001 
Age-group 
18-39 1     --- 
40-44 1.06 0.98 1.14 0.181 
45-49 1.18 1.11 1.27 < 0.001 
50-54 1.19 1.11 1.28 < 0.001 
55-59 1.13 1.05 1.19 0.001 
Predominantly rural 
parish 
Yes 1     --- 
No 1.11 1.05 1.18 0.001 
p < 0.05 is significant 
 
Multivariate analysis on the 2017 cohort identified monthly out-of-pocket expense, number 
or therapeutic class, number of years enrolled, health region, high cholesterol comorbidity, 
sex, age group and living in a rural geography as significant factors in the logistic regression 
model (p<0.001; chi-square = 3,946.15; df = 23). The characteristics associated with the 
lowest odds of adherence were, spending an average of less than J$5,000 per month out-
of-pocket on medicines (p<0.001); obtaining multiple drug therapies; residing in the 
Southeast Health Region (p<0.001); having a diagnosis of high cholesterol (p<0.001); being 
female (p<0.001); age less than 45 years old and residing in a rural parish (p=0.001) (table 
21).  Being enrolled in the NHF for more than two years was associated with an increased 
odds of adherence (p=0.001).  
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The forward logistic regression model with the 2008 cohort was also significant (p<0.001; 
chi-square = 369.06; df = 18). Consistent with the 2017 cohort, odds of adherence in the 
2008 cohort were also lower among females (p< 0.001), individuals who had lower out-of-
pocket expenditure on medicines (p<0.001), those on multiple drug therapies (p<0.001), 
those with comorbid high cholesterol and individuals who resided in rural geographies 
(p=0.001) (table 20).  Odds of adherence was found to be higher in individuals with 
hypertension only when compared to those who enrolled with comorbid diabetes and 
hypertension (p=0.005), but there was no difference between the comorbid group and those 
with diabetes only. Health region and age were not found to be significant in the 2008 model, 
diabetes and hypertension comorbidity was not significant in the 2017 model. The variable 
with the strongest effect on adherence was monthly out of pocket expenditure, where odds 
of adherence was 3 to 6 times higher among individuals with the highest monthly Out-of-
pocket expense on medicines in 2017 (table 21). Similarly in 2008, odds of adherence were 
1.5 to 2 times higher in the groups with the highest out-of-pocket expense, although the 
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4 Section three: – Effect of removal user fees on NHF enrollment 
and use of the NHFCard 
 
4.1 Descriptive analysis 
 
Table 22: Numbers of new NHF enrollees and enrollees who used their NHFCard to 




In the month of January 2007, there were approximately 1,800 new NHF enrollments with 





Number of New NHF 
enrollments with 
diabetes or hypertension 
(18-59 years)
Number of new NHF 
enrollments with 
diabetes or hypertension  
per 10,000 population (18-
59 years)
Number of NHFCard users 
with diabetes or 
hypertension (18-59 
years)
Number of NHFCard 
users with diabetes 




2007 Jan 1,449,612 1,804 12 16,210 112
2007 Feb 1,449,612 1,434 10 15,799 109
2007 Mar 1,449,612 2,161 15 18,156 125
2007 Apr 1,449,612 1,358 9 17,770 123
2007 May 1,449,612 1,776 12 19,640 135
2007 Jun 1,449,612 1,604 11 19,978 138
2007 Jul 1,449,612 1,626 11 21,412 148
2007 Aug 1,449,612 1,300 9 20,022 138
2007 Sep 1,449,612 1,274 9 21,099 146
2007 Oct 1,449,612 1,426 10 23,231 160
2007 Nov 1,449,612 1,626 11 23,275 161
2007 Dec 1,449,612 1,024 7 23,742 164
2008 Jan 1,466,273 1,282 9 24,695 168
2008 Feb 1,466,273 1,261 9 24,149 165
2008 Mar 1,466,273 1,502 10 25,526 174
2008 Apr 1,466,273 1,346 9 25,723 175
2008 May 1,466,273 1,558 11 25,773 176
2008 Jun 1,466,273 1,196 8 25,393 173
2008 Jul 1,466,273 1,380 9 27,119 185
2008 Aug 1,466,273 818 6 24,978 170
2008 Sep 1,466,273 1,391 9 27,293 186
2008 Oct 1,466,273 1,320 9 28,051 191
2008 Nov 1,466,273 1,221 8 27,415 187
2008 Dec 1,466,273 1,142 8 29,549 202
2009 Jan 1,483,830 1,135 8 29,319 198
2009 Feb 1,483,830 1,634 11 27,471 185
2009 Mar 1,483,830 1,632 11 30,721 207
2009 Apr 1,483,830 1,463 10 30,166 203
2009 May 1,483,830 1,274 9 30,898 208
2009 Jun 1,483,830 1,445 10 31,717 214
2009 Jul 1,483,830 1,404 9 32,740 221
2009 Aug 1,483,830 1,261 8 31,064 209
2009 Sep 1,483,830 1,207 8 32,218 217
2009 Oct 1,483,830 1,043 7 33,428 225
2009 Nov 1,483,830 1,153 8 31,845 215
2009 Dec 1,483,830 1,078 7 33,692 227
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been decreasing over time to 1,000 in the month of December 2009 (table 22). 
Simultaneously, the number of NHFCard users with diabetes or hypertension increased 
overtime from approximately 16,000 individuals in January 2005 to 33,000 by December 
2009 (table 22).  In April 2008, the government implemented the policy to remove user fees 
from public health facilities. At that time, there were approximately 1,300 new enrollees (9 
per 10,000 population) with diabetes or hypertension between the ages of 18 to 59 years. 
In addition, approximately 25,000 individuals (175 per 10,000 population) used their 
NHFCard to purchase medicines (table 22). 
 
Table 23: Mean number of new NHF enrollment and NHF Card Utilization per month 















Female 923 177 17,918 3,299 
Male 454 82 7,951 1,785 
Age-Group 
18-39 248 37 3,516 718 
40-44 215 43 3,522 773 
45-49 282 53 5,167 1,115 
50-54 320 69 6,665 1,297 
55-59 311 68 6,999 1,182 
Rural 
Yes 597 122 9,995 1,888 
No 780 142 15,874 3,205 
Health 
Region 
SERHA 720 133 14,370 2,901 
NERHA 152 35 2,286 428 
SRHA 303 67 5,309 1,037 
WRHA 203 48 3,904 731 
 
On average, majority of new NHF enrollees and NHFCard users were females who 
outnumbered the males by a ratio of more than 2 to 1. Individuals in the 45 years and older 
age groups outnumbered those in the younger age groups and accounted for more than 
two-thirds of new enrollments and NHFCard users. Likewise, Individuals residing in 
   
 
 134 
predominantly urban areas and those residing in the Southeast Health Region accounted 
for a higher proportion of new NHF enrollment and NHFCard users over the study period.  
 
4.2 Multivariate analysis 
 
Durbin-Watson test for autocorrelation 
The Durbin-Watson test statistic for the effect of the policy to remove user fees from public 
health facilities on ‘new NHF enrollment’ was 2.3 and on NHFCard use was 2.7. The critical 
values for the Durbin-Watson tests (n=36, k=3) were DL = 1.07 and DU = 1.44. Since D>DU, 
the null hypothesis that there is no autocorrelation in the time-series was not rejected. 
 
Table 24: Results of the Chow Test for structural breaks in the time-series data 
 
Number of new NHF 
enrollment 










Pre-policy         
12 months 1.249 0.325 0.479 0.632 
9 months 0.273 0.766 0.789 0.478 
6 months 0.281 0.76 1.112 0.363 
3 months 0.678 0.527 0.537 0.599 
Post-policy         
3 months 0.768 0.48 0.18 0.837 
6 months 0.998 0.39 0.396 0.679 
9 months 3.106 0.072 0.116 0.892 
12 months 2.108 0.154 0.585 0.569 
*significant at p<0.05 
 
The results of the Chow Test indicated that there were no significant events influencing NHF 
enrollment and use of the NHF card within the 12-month period before and after the policy 
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was implemented (table 24).  This helped to guide the decision around the observation 
period used in the analysis.  
Unstratified analysis 
Table 25: Unstratified Interrupted time series model of the impact of removal of user 





Intercept 1,784.09 118.74 15.03 <0.001 
Baseline trend -35.86 13.06 -2.75 0.01 
Level change after the policy 135.26 150.26 0.90 0.38 
Trend change after policy 30.36 15.25 1.99 0.06 
p < 0.05 is significant 
 
Interrupted time series analysis, which is summarized in table 25, indicated that prior to 
January 2007, there was an average of 1,784 new NHF enrollments per month among 
individuals with diabetes or hypertension (p<0.001).  Before the policy to remove user fees 
from public health facilities in Jamaica, new NHF enrollments decreased at a rate of 36 
individuals per month (p=0.01). After accounting for secular trends in the pre-policy period, 
there was no indication of a change in the level of new enrollments, directly following the 
implementation of the policy (p-value = 0.375) and there was no significant change in the 
rate of new NHF enrollments per month compared to the pre-policy period (p-value = 0.06). 
With the inclusion of the additional parameter, the adjusted R2  for the Segmented 
Regression Model was 0.269, compared to 0.225 for the linear model.  Figure 6 below is a 
graphical representation of the segmented time-series trend describing the effect of the 
removal of user fees in public health facilities on new NHF enrollment among individuals 
with diabetes or hypertension. Based on the graph in Figure 6, there is an observed increase 
in new NHF enrollment in the post-policy period around February 2009.  
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Figure 6: Unstratified interrupted time series chart of the trend in new NHF 
Enrollments with Diabetes or Hypertension before and after the removal of user fees 
 
 
Table 26: Unstratified Interrupted time series model of the impact of removal of user 





Intercept 15,580.47 457.42 34.06 <0.001 
Baseline trend 674.98 50.310 13.42 <0.001 
Level change after the policy -1,250.76 578.810 -2.16 0.04 
Trend change after policy -251.84 58.75 -4.29 <0.001 
p < 0.05 is significant 
 
As summarized in table 26, prior to January 2007, an average of 15,580 individuals with 
diabetes or hypertension used their NHFCard to purchase medicines per month (p<0.001). 
Before the policy to remove user fees from public health facilities, this number increased at 
a monthly rate of approximately 675 individuals (p<0.001). After accounting for secular 
trends in the pre-policy period, there was a decrease in the level of NHFCard users directly 
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following the implementation of the policy (p=0.04) and the NHFCard use increased at a 
significantly lower rate of approximately 423 individuals per month compared to 675 in the 
pre-policy period (p<0.001). Figure 7 below is a graphical representation of the segmented 
time-series trend describing the effect of the removal of user fees from public health facilities 
on NHFCard use among adults with diabetes and hypertension. 
 
Figure 7: Unstratified interrupted time series chart of the trend in NHFCard utilization 




Stratified analysis of New NHF Enrollment 
Table 27: Interrupted time series model of the impact of the removal of user fees from 
public health facilities on new NHF enrollment among adults with diabetes or 
hypertension by gender 







Intercept 1,216.43 79.88 15.23 <0.001 
Baseline trend -25.30 8.79 -2.88 0.001 
Level change after the policy 83.23 101.08 0.82 0.416 
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Trend change after policy 21.55 10.26 2.10 0.04 
Male 
Intercept 567.66 40.47 14.03 <0.001 
Baseline trend -10.56 4.45 -2.37 0.024 
Level change after the policy 52.03 51.21 1.02 0.317 
Trend change after policy 8.80 5.20 1.69 0.100 
p < 0.05 is significant 
 
Prior to January 2007, an average of 1,200 females and 560 males with diabetes or 
hypertension enrolled in the NHF each month (p<0.001). Before the policy there was a 
significant decline in the rate of NHF enrollment for females (p=0.001) and males (p=0.025). 
Immediately following the policy, there was no significant change in the level of enrollment 
for females (0.416) or males (p=0.317). However, the rate of decline in the new NHF 
enrollments among females during the post-policy period was significantly lower (p=0.04) 
compared to the pre-policy period, but there was no significant change in the rate of decline 
among males (p=0.100). 
 
Table 28: Interrupted time series model of the impact of the removal of user fees from 
public health facilities on new NHF enrollment among adults with diabetes or 
hypertension by age 







Intercept 299.96 18.17 16.51 p<0.001 
Baseline trend -4.63 2.00 -2.32 0.03 
Level change after the policy 7.04 22.99 0.31 0.76 
Trend change after policy 5.08 2.33 2.18 0.04 
40-44 
Intercept 259.37 22.67 11.44 p<0.001 
Baseline trend -3.87 2.49 -1.55 0.13 
Level change after the policy 15.65 28.69 0.55 0.589 
Trend change after policy 3.19 2.91 1.09 0.282 
45-49 
Intercept 367.34 24.79 14.82 p<0.001 
Baseline trend -8.32 2.73 -3.05 0.00 
Level change after the policy 52.86 31.37 1.69 0.10 
Trend change after policy 6.53 3.18 2.05 0.05 




Intercept 433.46 31.66 13.69 p<0.001 
Baseline trend -10.03 3.48 -2.88 0.01 
Level change after the policy 32.12 40.07 0.80 0.43 
Trend change after policy 9.10 4.07 2.24 0.03 
55-59 
Intercept 423.95 28.61 14.82 p<0.001 
Baseline trend -9.01 3.15 -2.86 0.01 
Level change after the policy 27.59 36.20 0.76 0.45 
Trend change after policy 6.45 3.67 1.76 0.09 
p < 0.05 is significant 
 
Prior to January 2007, the average number of new NHF enrollments ranged from 300 to 420 
adults with diabetes or hypertension, depending on age group (p<0.001). During the pre-
policy observation period, new NHF enrollments was declining at a significant rate in all age 
groups (table 28). Immediately following the implementation of the policy, there was no 
significant change in the level of new NHF enrollments (table 28). However, after the policy 
there was a significant increase in the rate of new NHF enrollments among the 18 to 39 
years (p=0.04), while the rates of decline in the 45 to 49 years age group (p=0.05) and the 
50 to 54 years age group (p=0.03) was lower compared to the pre-policy period. There was 
no signficant change in the rate of new NHF enrollments in the 40 to 44 years (p=0.282) and 
the 55 to 59 years age group (p=0.09) (table 28). 
 
Table 29: Interrupted time series model of the impact of the removal of user fees from 
public health facilities on new NHF enrollment among adults with diabetes or 
hypertension by rurality 







Intercept 791.50 54.65 14.48 < 0.001 
Baseline trend -16.75 6.01 -2.79 0.01 
Level change after the policy 85.88 69.15 1.24 0.22 
Trend change after policy 11.09 7.02 1.58 0.12 
Urban 
Intercept 992.58 68.79 14.43 < 0.001 
Baseline trend -19.11 7.57 -2.53 0.02 
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Level change after the policy 49.39 87.05 0.57 0.57 
Trend change after policy 19.26 8.84 2.18 0.04 
p < 0.05 is significant 
 
Prior to January 2007, new NHF enrollments among adults with diabetes or hypertension 
was an average of 790 per month in rural areas and 1,000 per month in urban areas (table 
29).  In both areas, there was a decline in the rate of new NHF enrollments during the pre-
policy observation period. Following the implementation of the policy, there was no change 
in the level of new enrollments in both areas (table 29).  However, the rate of new NHF 
enrollments increased in urban areas after the policy (p = 0.04), but there was no change in 
the rate of new NHF enrollments in rural areas (p=0.12) (table 29).  
 
Table 30: Interrupted time series model of the impact of the removal of user fees from 
public health facilities on new NHF enrollment among adults with diabetes or 










Intercept 929.95 63.83 14.57 < 0.001 
Baseline trend -19.71 7.02 -2.81 0.01 
Level change after the policy 63.66 80.77 0.79 0.44 
Trend change after policy 20.11 8.20 2.45 0.02 
Northeast 
Intercept 188.96 18.12 10.43 < 0.001 
Baseline trend -4.38 1.99 -2.20 0.04 
Level change after the policy 48.58 22.93 2.12 0.04 
Trend change after policy 2.63 2.33 1.13 0.27 
Southern 
Intercept 407.85 29.15 13.99 < 0.001 
Baseline trend -7.91 3.21 -2.47 0.02 
Level change after the policy 7.50 36.88 0.20 0.84 
Trend change after policy 6.34 3.74 1.69 0.10 
Western 
Intercept 257.32 22.67 11.35 < 0.001 
Baseline trend -3.86 2.49 -1.55 0.13 
Level change after the policy 15.52 28.69 0.54 0.59 
Trend change after policy 1.29 2.91 0.44 0.66 
p < 0.05 is significant 




Prior to January 2007, rates of new NHF enrollments with diabetes or hypertension was an 
average of 930 per month in the Southeast Health Region, 200 per month in the Northeast 
Health Region, 400 per month in the Southern Health Region and 250 per month in the 
Western Health Region (table 30). During the pre-policy period, the rate of new NHF 
enrollments was on a declining trend in all health regions. Following the implementation of 
the policy, there was a significant decrease in the level of new enrollments in the Northeast 
Health Region only. While the Southeast Health Region (p=0.02) experienced an increased 
rate of new NHF enrollments when compared to the pre-policy period (table 30). 
Stratified analysis of NHFCard Use  
Table 31: Interrupted time series model of the impact of the removal of user fees from 
public health facilities on NHF utilization among adults with diabetes or hypertension 
by gender 





Intercept 11,144.21 335.40 33.23 <0.001  
Baseline trend 453.71 36.89 12.30 <0.001  
Level change after the 
policy 
-955.31 424.40 -2.25 0.03 
Trend change after policy -182.15 43.08 -4.23 <0.001  
Male 
Intercept 4,436.26 131.51 33.73 <0.001  
Baseline trend 221.27 14.46 15.30 <0.001  
Level change after the 
policy 
-295.45 166.42 -1.78 0.09 
Trend change after policy -69.69 16.89 -4.13 <0.001  
p < 0.05 is significant 
 
 
NHFCard utilization was an average of 11,144 per month for females and 4,400 per month 
for males prior to January 2007 (p < 0.001). During the pre-policy observation period 
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NHFCard utilization was increasing at a rate of 454 female users and 222 male users per 
month. Immediately following the policy, there was a significant decline in the level (p=0.03) 
of NHFCard users among females only (p=0.03). There was also a significant decline in the 
rate of NHCard users among both genders during the post-policy observation period (table 
31). 
 
Table 32: Interrupted time series model of the impact of the removal of user fees from 
public health facilities on NHF utilization among adults with diabetes or hypertension 
by age-group 







Intercept 2,010.61 69.88 28.77 < 0.001 
Baseline trend 103.81 7.69 13.51 < 0.001 
Level change after the policy -274.13 88.43 -3.10 0.004 
Trend change after policy -43.71 8.98 -4.87 < 0.001 
40-44 
Intercept 1,982.85 65.77 30.15 < 0.001 
Baseline trend 98.59 7.23 13.63 < 0.001 
Level change after the policy -152.94 83.22 -1.84 0.08 
Trend change after policy -33.56 8.45 -3.97 < 0.001 
45-50 
Intercept 2,970.41 91.07 32.62 < 0.001 
Baseline trend 139.61 10.02 13.94 < 0.001 
Level change after the policy -229.29 115.24 -1.99 0.06 
Trend change after policy -43.20 11.70 -3.69 < 0.001 
50-54 
Intercept 4,061.68 119.82 33.90 < 0.001 
Baseline trend 168.91 13.18 12.82 < 0.001 
Level change after the policy -288.60 151.61 -1.90 0.07 
Trend change after policy -60.61 15.39 -3.94 < 0.001 
55-59 
Intercept 4,554.92 125.06 36.42 < 0.001 
Baseline trend 164.07 13.76 11.93 < 0.001 
Level change after the policy -305.79 158.25 -1.93 0.06 
Trend change after policy -70.76 16.06 -4.41 < 0.001 
p < 0.05 is significant 
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Prior to January 2007, the average NHFCard users among adults with diabetes or 
hypertension was between 2,000 per month in the youngest age group (18-34 years) to 
4,500 per month in the oldest age group (55-59 years) studied.  During the pre-policy period, 
the number of NHFCard users increased at a significant rate each month among all age 
groups (p<0.001). There was a significant decline in the level of NHFCard users among the 
youngest age group only (p=0.004) and although the monthly NHF user rates increased, the 
rate of increase was significant lower in all age groups during the post policy period (table 
32). 
 
Table 33: Interrupted time series model of the impact of the removal of user fees from 
public health facilities on NHF utilization among adults with diabetes or hypertension 
by rurality 







Intercept 5,857.43 186.61 31.39 < 001 
Baseline trend 293.25 20.52 14.29 < 001 
Level change after the 
policy 
-638.93 236.13 -2.71 0.011 
Trend change after 
policy 
-156.78 23.97 -6.54 < 001 
Urban 
Intercept 9,723.04 284.16 34.22 < 001 
Baseline trend 381.73 31.25 12.21 < 001 
Level change after the 
policy 
-611.83 359.57 -1.70 0.099 
Trend change after 
policy 
-95.06 36.50 -2.60 < 001 
p < 0.05 is significant 
 
Prior to January 2007, an average of 5,800 individuals with diabetes or hypertension in rural 
areas and 9,700 in urban areas used their NHFCard to purchase medicines on a monthly 
basis (p < 0.001). During the pre-policy policy period, that number increased by 293 in the 
rural areas and 381 in urban areas each month (p < 0.001).  Immediately following the 
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implementation of the policy, there was a decline in the level of NHFCard use in rural areas 
(p=0.011) but none in the urban areas (p=0.099) (table 33). However, after accounting for 
secular trends in the pre-policy period, there was a decline in the rates of NHFCard use in 
rural and urban areas during the post-policy period (p < 0.001). 
 
Table 34: Interrupted time series model of the impact of the removal of user fees from 
public health facilities on NHF utilization among adults with diabetes or hypertension 










Intercept 8,778.90 259.40 33.84 < 0.001 
Baseline trend 349.75 28.53 12.26 < 0.001 
Level change after the policy -619.79 328.24 -1.89 0.07 
Trend change after policy -88.79 33.32 -2.67 < 0.001 
Northeast 
Intercept 1,360.14 51.72 26.30 < 0.001 
Baseline trend 64.76 5.69 11.38 < 0.001 
Level change after the policy -119.11 65.45 -1.82 0.08 
Trend change after policy -34.81 6.64 -5.24 < 0.001 
Southern 
Intercept 3,052.23 104.28 29.27 < 0.001 
Baseline trend 158.27 11.47 13.80 < 0.001 
Level change after the policy -304.45 131.96 -2.31 0.03 
Trend change after policy -84.61 13.39 -6.32 < 0.001 
Western 
Intercept 2,389.20 74.48 32.08 < 0.001 
Baseline trend 102.20 8.19 12.48 < 0.001 
Level change after the policy -207.40 94.25 -2.20 0.04 
Trend change after policy -43.62 9.57 -4.56 < 0.001 
p < 0.05 is significant 
 
Prior to January 2007, rates of NHFCard users among adults with diabetes or hypertension 
was an average of 8,800 per month in the Southeast Health Region, 1,300  per month in the 
Northeast Health Region, 3,000 per month in the Southern Health Region and 2,400 per 
month  in the Western Health Region (p < 0.001). Prior to the policy, the NHFCard use was 
increasing significantly by 350 per month in the Southeast, 65 per month in the Northeast, 
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160 per month in the Southern and 102 per month in the Western health region (p < 0.001).  
Immediately following the policy, the number of NHFCard use dropped suddenly in the 
Southern and Western Health Regions (table 34).  After accounting for secular trends in the 
pre-policy period, there was a significant decline in the rate of NHFCard users in the post-
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CHAPTER 6 - DISCUSSION 
1 Chapter introduction  
 
Mortality from NCDs in Jamaica ranks within the top 10 highest among the 28 Caribbean 
nations (PAHO, 2018).  Drug therapy is a key component of effective chronic disease 
management. The NHF individual benefits (2003) was designed to improve access to 
medicines and quality drug therapy for chronic diseases patients in Jamaica, by subsidizing 
the cost of chronic disease medicines in private pharmacies or providing it for free in public 
pharmacies. Previous studies in Jamaica have highlighted disparities in health status and 
access to health services (Bourne et al, 2010; Scott & Theodore, 2013). Similar to other 
developing nations, there is a paucity of research on access to essential medicines in 
Jamaica to support government policies. This study explored three research questions 
related to access to medicines among adult Jamaicans with diabetes or hypertension 
through the NHF Individual Benefits programme. 
 
This chapter discusses the main findings from each of the research objectives, and the 
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2 Main findings 
 
2.1 Factors associated with NHF enrollment among Jamaicans with 
diabetes or hypertension 
 
Enrollment in the NHF is necessary for individuals with diabetes or hypertension to gain 
access to government subsidized chronic disease medicines through the NHF. This study 
found that in 2008, only 25% of adults with diabetes or hypertension were enrolled in the 
NHF.  Considering enrollment in the NHF enables access to medicines at a reduced cost in 
private pharmacies or free in public pharmacies, low levels of enrollment may be an 
indication that many adults in Jamaica with diabetes or hypertension face barriers to 
accessing their medicines.   To identify some of those barriers and determine whether they 
may be disproportionately affecting some individuals more than others, the Andersen-
Newman Behavioural Model of Health Service Utilization was used to examine the 
predictors of enrollment in the NHF.  The study hypothesized that equitable access exists 
when need and predisposing variables are the strongest predictors of access to health 
services (Andersen, MR, 2008).  The findings of this study indicate that predisposing (age 
and marital status) and need (disease burden or comorbidity status) factors were significant 
predictors of NHF enrollment.  Individuals less than 40 years with diabetes or hypertension 
were 3 to 5 times less likely to enroll in the NHF compared to those over 40 years.  This is 
consistent with studies by Christiani et al (2016) and Vialle-Valentin et al (2015), who 
reported decreased access to chronic disease medicines among younger people in some 
developing countries. Comorbid individuals are known to be at a higher risk of CVD events 
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and were 4 times more likely to enroll in the NHF.  Maquart de Terline et al (2016) considered 
comorbidity in their analysis and did not find a significant association.  This study found that 
married people/common-law relationships or those who were previously married were 
between 1.7 and 2.5 times more likely to enroll in the NHF than those who were single. This 
is consistent with the study by Srivastava et al (2015) who found that people who were 
married were more likely to seek medical care and access medicines.   
 
None of the enabling factors such as education, income, and having private health insurance 
were associated with the odds of enrollment. The contextual factors, such as administrative 
health region and rurality were also not significant. Administrative health regions are 
geography-based and represent differences in health system inputs and organization of 
health services, while rurality represents the community level factors such as availability of 
primary care, socio-economic conditions, such as rates of post-secondary education, 
average income and overall population health. This is contrary to what was found from the 
literature review, where poor accommodations in primary care, socioeconomic development 
and geographic accessibility were significant barriers to accessing medicines in some 
developing countries (Srivastava et al, 2015; Yao et al, 2015; Elias et al, 2016; Christiani et 
al, 2016; Sarayani et al, 2014; Rahmawati et al, 2018; Huang et al, 2018; Xi et al 2018).  
This is not surprising, as the systematic review of 15 developing countries conducted by 
Christiani et al (2016) also noted contrasting evidence among the included studies on 
multiple factors associated with access to chronic disease medicines. It is likely that the 
differences in observed findings between this study and the studies evaluated in the 
systematic literature review was due to methodological and contextual differences. 
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Methodological differences include study population, data sources, study design and 
outcome measures. Contextual differences include health system structure, administration 
and operation, community and culture.   
 
It should be highlighted that age and comorbid status, which are predisposing and need 
variables respectively, had a strong effect on NHF enrollment, suggesting the likelihood of 
NHF enrollment being equitable. Marital status is also a predisposing variable and was found 
to have a relatively small effect on NHF enrollment.  However, due to the increasing 
prevalence of diabetes and hypertension and the mortality from NCDs in Jamaica, a small 
effect would be considered significant because of the potential for public health gains 
resulting from even a small increase in NHF enrollment.  
 
2.2 Drug utilization patterns and the factors predicting adherence to 
medicines among NHF enrollees with diabetes and hypertension 
 
NHF pharmacy administrative claims data were used to examine utilization patterns and 
adherence to medicines on two large cohorts of Jamaicans enrolled in the National Health 
Fund with diabetes or hypertension. The cohorts consisted of adults 18 to 59 years who 
enrolled with diabetes or hypertension and used their NHFCard to purchase medicines in 
the years 2008 or 2017.  
 
There were some differences observed in the profile of NHF users and their patterns of drug 
utilization between 2008 and 2017. Firstly, the disease profile at enrollment was different 
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between the two years examined. By 2017, the proportion of NHFCard users who had just 
one of the disease conditions (diabetes or hypertension) at the time of enrollment was higher 
when compared to 2008.  This may be an indication of increased awareness to early 
initiation of drug therapy.  Secondly, the number of individuals using their NHFCard to 
purchase prescriptions increased by 242% between the two years. This is likely due to 
cumulative increase in enrollment over the years, as the programme expanded to more 
pharmacies and people.  An increase in the drug classes subsidized would have also 
contributed to the observed increase in the NHF utilization over time. Thirdly, the prevalence 
of use of the different drug class also differed between the two years. There was an increase 
in the use of Calcium Channel Blockers (CCB) and a decrease in the use of Angiotensin-
Converting Enzymes (ACE) inhibitors among persons with hypertension. Antihypertensive 
combinations also increased from 2008 to 2017. There was a notable decrease in use of 
Metformin and Sulfonylureas as well as a slight decrease in the use of Insulin and an 
increase in the use of Antidiabetic Combinations from 2008 to 2017. Statin, which is 
commonly used for treating high cholesterol, increased among all individuals in the study. 
These drug utilization patterns are likely associated with availability of drug classes within 
the private sector where 80% of medicines are accessed. They are also reflective of 
physician prescribing patterns in Jamaica. Government policies aimed at improving access 
to medicines have been shown to impact physician prescribing behaviour and in some 
instances have resulted in irrational prescribing, such as the tendency towards prescribing 
brand names or polypharmacy (Uzochukwu et al, 2002; Maiga et al, 2003). In some 
countries where physicians prescribing is tied to financial incentives, government policies 
have not been successful in curtailing irrational prescribing (Yang et al, 2013; Chen et al, 
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2014; Song et al, 2014b; Yi et al, 2015; He et al, 2018; Chu et al, 2011; Liu et al, 2003). 
These challenges with irrational prescribing can lead to poor quality treatment and are costly 
for the healthcare system, so understanding the drug utilization pattern is the first step in 
identifying if irrational prescribing is present within the Jamaican context. 
 
Individuals diagnosed with chronic diseases require continuous access to life-long treatment 
with medicines. Adherence to these medicines is important for effective drug therapy, 
making it an important quality of care measure related to access to medicines.  Only a small 
number of studies related to adherence to chronic disease medicines were identified within 
developing countries and no studies specifically examined the effect of government policies 
on adherence in these settings. This study found that in 2017, just over half of NHF claimants 
with diabetes and/or hypertension were adherent with their medication.  The overall 
percentage who were adherent declined from 54% in 2008 to 50% in 2017 in this population 
(chi-square=159.04, Cramer’s V=0.04, p <0.001), although the degree of decline was small.   
The percent who were adherent to Statin therapy was relatively low compared to antidiabetic 
and antihypertensive therapies in the study population. This is concerning as Statin therapy 
is an effective treatment for high cholesterol in diabetics and hypertensives and is known to 
reduce cardiovascular risk in these populations (Parris et al, 2005; ADA, 2020).  The overall 
low percentage of individuals with diabetes or hypertension who were found to be adherent 
with chronic disease therapy, supports previous studies showing low prevalence of good 
glycemic and blood pressure control among adult diabetics or hypertensives in Jamaica 
(Wilks et al ,2000; Duff et al, 2006; Harris et al, 2014; Cunningham-Myrie et al, 2013; 
Ferguson et al, 2013).  Using the Andersen-Newman Behavioural Model of Health Service 
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Utilization, the study found that a combination of predisposing, need, enabling and 
contextual factors were associated with adherence behaviour among NHF users with 
diabetes or hypertension in 2008 and 2017.   In the most recent year examined (2017), eight 
variables were significantly associated with adherence. The strongest predictor of 
adherence in 2008 and 2017, was monthly out-of-pocket expense.  This was the portion of 
the medicine cost that was not subsidized by the NHF. Lower adherence was observed 
among individuals with the lowest out-of-pocket expense. Out-of-pocket expense has been 
linked to family income and therefore represents resources at the family or individual level 
(Monteiro et al, 2016; Bertoldi et al, 2011).  Studies have found that lower income families 
spend less on medicines compared to upper income families (Monteiro et al, 2016; Bertoldi 
et al, 2011).  Monthly out-of-pocket expenses may also reflect variation in cost of medicines 
to treat the same condition.  In the private sector in Jamaica, the cost of originator brands 
for treating hypertension was estimated at 5.2 days' worth of wages for low-income 
individuals compared to 80% of a day’s wage for a 30-day supply of the generic equivalent 
(PAHO, 2012). Similarly, the cost of originator brands for treating diabetes was 2.1 days’ 
worth of wages compared 10% of a day’s wage for a 30-day supply of generic equivalent 
(PAHO, 2012).  Considering, that the amount of the NHF subsidy is not dependent on 
income and the Jamaican government has no policy to regulate the price of medicines (NHF 
Act, 2003; PAHO, 2012), low-income individuals may forego treatment in the absence of a 
low-cost generic equivalent. One possible explanation for the decreased adherence seen in 
this population from 2008 to 2017 could be due to decreases in NHF subsidy rates over time 
(NHF 2016, 2018).  This view is supported by numerous studies in other settings, which 
showed that cost of medicines is an important predictor of adherence to chronic disease 
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medicines, even among those in receipt of subsidies (Macquart de Terline, 2019; Aziz et al, 
2016; Zheng et al, 2012; Jensen et al, 2012). It is also consistent with a household survey 
conducted in Jamaica, where one-quarter of respondents identified cost as the most 
significant barrier to adherence (PAHO, 2012).   
 
Other significant predictors of medication adherence in this population were, number of 
therapies, number of years enrolled, administrative health region, comorbidity, sex, age and 
rurality.  These predictors although described in the analysis as having small effects on 
adherence, were considered to be significant from a public health perspective, because a 
small increase in adherence levels within this population can have a significant impact at 
the individual and societal level. Also, the relatively small effect of some these variables was 
expected, given that adherence is a complex behaviour determined by many inter-related 
factors. The predictors of adherence in 2008 cohort were largely consistent with the findings 
from the 2017 cohort.  
 
The findings from this study supports previous findings that medication adherence is a 
complex behavior predicted by multiple factors. The consistent finding from both study years 
that enabling and contextual factors were among the predictors of medication adherence, 
indicates the likelihood that socio-economic and geographic differences were impacting 
continued access to medicines through the NHF.  This is also consistent with previous 
studies in Jamaica that identified poor socio-economic conditions, gender, cultural beliefs, 
low education levels, comorbidity and not having private health insurance as significant 
predictors of adherence to chronic disease medicines (Bridgelal-Nagassar et al, 2016; Wilks 
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et al, 2008; Swaby et al, 2001). Other factors that were found to be significant from previous 
Jamaican studies were, medication side effects, affordability, poor availability, use of 
alternate therapy, symptom experience, disease perception, duration of illness, treatment 
modality, health literacy and health status (Wilks et al, 2008; Chambers et al, 2008, Mowatt 
et al, 2011). These findings are also consistent with studies on adherence in other 
developing countries that identified a range of factors associated with adherence (Macquart 
de Terline et al, 2019; Marfo et al, 2017; Jande et al, 2015; Shams et al, 2016; Sarayani et 
al, 2013).   
 
2.3 Effect of the removal of user fees from primary care on use of the 
NHF 
 
The removal of user fees from public health facilities in Jamaica in 2008 marked an important 
policy to mitigate the economic burden of accessing primary care and by extension 
medicines. This study examined whether the introduction of that policy had the desired effect 
of improving access to the NHF among adults with diabetes or hypertension. Based on 
Interrupted Time Series (ITS) models, this study found that there was an increase in the rate 
of new NHF enrollment in the post-policy period, although this effect was not deemed to be 
significant in the ITS Model. The time series trend also suggests that there was an increase 
in new enrollments several months following the policy implementation date (February 
2009). This increase may have been due to periodic public advertising campaigns or 
community outreach events to promote NHF enrollment. However,  the exact timing and 
nature of these events in 2009 are unknown. In terms of the policy’s impact on the number 
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of NHFCard users, there was an overall increasing trend during the post-policy period.   
However, the rate of increase was significantly lower when compared to the pre-policy 
period. The reduced rate in NHFCard use versus the increased rate of new NHF enrollments 
seems counterintuitive, since one would expect increased rate of enrollment would lead to 
increased rate of NHFCard use. As these trends could be influenced by multiple system 
related factors, the exact reasons would need further exploration. For example, the Auditor 
General (2011) reported that between 2006 and 2010, pharmacies were unable to satisfy 
the demand for medicines in primary care, due to low medicine stock levels at the 
government’s central pharmaceutical warehousing and distribution centre. NHFCard use is 
based on the dispensation of available chronic medicines among individuals who are 
enrolled in the NHF.  The increased demand for chronic disease medicines in the post-policy 
period, may have exacerbated the lack of availability of medicines, resulting in reduced drug 
dispensation among holders of the NHFCard.  A more recent Auditor General report (2017) 
also noted continued deficiencies in the management of inventory as it relates to medicine 
stocks between 2011 and 2017 in public pharmacies. Furthermore, the literature review 
highlighted that some countries experienced unintended consequences of government 
policies aimed at improving access to medicines.  Drug supply as well as other access 
issues may have impacted access to the NHF in the post-policy period. 
 
In addition to the unstratified ITS Models used to evaluate the effect on the policy to remove 
user fees from public health facilities on NHF enrollment and NHFCard use, several 
independent ITS models were also used to examine if the policy had an effect on specific 
sub-groups. Sub-group analysis was used to determine if the effect of the policy on specific 
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sub-groups was obscured in the unstratified ITS Models. These independent ITS studies 
found that the policy significantly increased new NHF enrollments among females; people 
living in urban areas; people in the 18 to 24 years, 45 to 49 years and 50 to 54 years age 
groups. However, there was no indication that the policy impacted NHFCard use differently 
in these same sub-groups examined. A previous study by Campbell (2013), reported an 
increase in access to medicines at public health facilities immediately following the 
implementation of the policy to remove user fees. The findings from this study suggests that 
the policy, which removed a cost barrier from primary care in public health facilities, enabled 
access to the NHF among some individuals who were previously not enrolled. However, the 
study found no evidence that the policy increased continued access to medicines through 
the NHF. Since there were no direct comparisons made during the stratified ITS analysis,  
the sub-group differences highlighted in the independent ITS Models need further analysis 
to determine if these differences were significant. Additionally, observed statistical 
significance within the sub-group analysis were likely influenced by sub-group sample sizes, 
for example, the study showed that the rate of new NHF enrollment within the 55 to 59 age-
group did not reach statistical significance (p=0.09), compared to the 18 to 39 age-group 
(p=0.04), although the change during the post-poicy period in the 55 to 59 age-group (Trend 
change in the post-policy period = 6.45) was observed to be greater than in the 18 to 39 









This was a novel study intended to build a body of evidence to inform the design of effective 
policies around interventions aimed at improving access and adherence to diabetes and 
hypertension medicines in Jamaica. The information gained from this research will be able 
to support policy decisions around efficient allocation of public health resources, and to 
reduce health inequities in the country. It will also be useful to support the development of a 
National Pharmaceutical Policy to ensure equitable access and quality use of medicines for 
treating NCDs in Jamaica.  
 
The use of multiple quantitative methodological approaches in the study allowed for the 
interrogation of existing secondary data sources to address multiple policy questions 
relevant to access and use of the NHF at a national level.   To ensure the findings were 
relevant to policy makers, different conceptual frameworks were used to characterize the 
relationship between the explanatory and outcome variables. The frameworks used had 
theoretical as well as practical applicability for future health services research in the country.  
Because of this approach, multiple insights were gained from this study as it relates to 
access to chronic disease medicines that would have otherwise been impractical and 
expensive to operationalize as a primary study. It also provides a roadmap for researchers 
interested in drug utilization research, which to date is limited in Jamaica. Furthermore it 
was the first study to examine the factors associated with medication adherence on two 
large cohorts at a national level. It is firmly established that improving adherence to 
medicines to treat chronic disease such as hypertension and diabetes would lead to public 
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health and economic gains in many countries.  Understanding the factors that contribute to 
decreased adherence for these conditions is needed to support policies and programmes 
to improve quality drug therapy.   
 
A secondary goal of the research was to demonstrate the importance and utility of real-world 
data in advancing healthcare utilization research in Jamaica. It is the first of its kind in 
Jamaica to mine and use real world data to examine access and adherence to medicines 
and fills an important gap in research related to the quality of drug therapy in the country. 
The main advantages of using real world data, is they are inexpensive, objective and non-
invasive sources for studying drug use patterns within the population (Hess et al, 2006). As 
was demonstrated in this study, they have been shown to provide valuable information 
related to prescribing and dispensing patterns and adherence to drug therapy (Cadarette & 




There were several limitations related to the use secondary data sources in this research 
project. Firstly, the JHLS (II) which was conducted in 2008 may not reflect NHF enrollement 
patterns of today. However, since there has been no formal evaluation of the characteristics 
influencing access and use of this important drug subsidy programme since its 
implementation in 2003, this survey provided a unique opportunity to examine these factors.  
Secondly, as is the case with most face-to-face interviewer-administered survey, there was 
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a potential for ‘yes-saying’ and interviewer bias in the JHLS (II). These biases could have 
ultimately affected the validity of the results related to NHF enrollment. Thirdly, the use of 
the NHF Pharmacy Claims database, meant that potential confounders such as income, 
education, medication side effects, health insurance coverage and duration of disease were 
missing from the analyses (Macquart de Terline et al, 2019; Shams et al, 2016; Wilks et al, 
2008; Chambers et al, 2008, Mowatt et al, 2011; Bridgelal-Nagassar et al, 2016; Swaby et 
al, 2001). The availability of those variables would have strengthened the findings of the 
research. The possibility of supplementing the pharmacy claims with primary care data 
collection, though contemplated, was not feasible due to the extra cost related to 
operationalizing such a data collection strategy, and thus beyond the scope of this PhD 
Thesis.  Finally, in terms of its inclusivity, the NHF pharmacy claims database captures the 
dispensation of medicines to Jamaicans enrolled in the NHF, it is important to note that it 
does not include prescriptions that were written but not dispensed, prescriptions not eligible 
for NHF subsidy nor does it include information on prescriptions that were dispensed and 
not taken.  Individuals may also take their prescriptions to be filled outside of these private 
pharmacies and so no record of the medication being dispensed from these sources is 
captured.  It also does not capture prescriptions among diabetics and hypertensives who 
are not enrolled in the NHF.   
 
The use of a cut-off of 80% medication possession ratio (MPR) is often used in similar 
research to classify individuals as adherent versus non-adherent (Karve et al, 2009), but 
this may oversimplify the complex relationship between medication adherence and the 
multiple factors influencing this behaviour.  Additionally, due to methodological differences, 
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it was difficult to compare the medication adherence measure used in this study to those 
used in previous Jamaican studies (Swaby et al, 2001; Duff et al, 2006; Wilks et al, 2008; 
Mowatt et al, 2011; Bridgelal-Nagassar et al, 2016).  Previous studies were all done in clinic 
settings, on selective populations with relatively small sample sizes and measurement of 
adherence varied between the studies (Swaby et al, 2001; Duff et al, 2006; Bridgelal-
Nagassar et al, 2016). In addition, most studies relied on patient self-reported measures of 
adherence, which has been shown to overestimate adherence behaviour compared to other 
assessment methods (Stirrat et al, 2015; Fujita et al, 2015).  
 
There were also some key limitations with the ITS Models used to determine the effect of 
the removal of user fees in public health facilities on NHF access. Firstly, the assumption 
that a change will occur at the time of the intervention does not account for delays in 
intervention effects, which is characteristic of complex healthcare interventions (Cruz et al, 
2017). It also does not account for the sometimes-varied effects of these of complex 
interventions in real-world settings due to undetected exogenous factors (Cruz et al, 2017).  
Secondly, even though first order autocorrelation was not detected by the Durbin-Watson 
test, the ITS approach used in this study did not specifically address the effect of 
autocorrelation on the model estimates. However, it is noteworthy that 50% of drug utilization 
studies reportedly used a similar approach to ITS modelling as the one used in this study 
i.e. Segmented Regression (Hawley et al, 2019).  
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CHAPTER 7 - CONCLUSION 
1 Chapter introduction 
 
Diabetes and hypertension are significant public health problems in Jamaica. At the same 
time, the healthcare system with its mix of public and private health sectors is complex 
and poses additional challenges with equitable access to health services. This study 
utilized real world data from two sources to identify key factors that may be facilitating or 
impeding access to chronic disease medicines for adult Jamaicans with diabetes or 
hypertension. The study was specifically concerned with examining access and use of 
the National Health Fund (NHF) Individual Benefit programme. A programme designed 
and implemented in 2003 to improve access to medicines for Jamaicans with chronic 
diseases.  
 
This study found multiple barriers to accessing medicines through the NHF and highlights 
the need for government policies and interventions to take a multidimensional approach 
to policy and programme development.  Some policy implications derived from this 
research are discussed in this chapter. The chapter closes by proposing further research 
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2 Policy Implications 
 
The literature review highlighted that the factors associated with access to chronic 
disease medicines varied by region and country (Ewen et al, 2019; Barbar et al, 2019; 
Macquart de Terline et al, 2019; Chow et al, 2018; Attaei et al, 2017; Ewen et al 2017; 
Emmerick et al, 2015; Srivastava et al, 2015; Vialle-Vallentin et al, 2015; Wagner et al, 
2011), largely because of differences in the healthcare system and other contextual 
factors that drive the consumption of medicines. However, a key takeaway from the 
systematic review of experiences in other developing countries, was that policies primarily 
aimed at addressing affordability of medicines were either ineffective or created 
unintended consequences around the use of chronic disease medicines (Ding et al, 2017; 
Guo et al, 2017; He at al, 2018; Maiga et al, 2003; Huang et al, 2018; Xi et al, 2018; Yao 
et al, 2015).   This  was largely because, they ignored other important dimensions of 
access to chronic disease medicines and as a result, disparities in access to chronic 
disease medicines was still a problem in many developing countries (Rockers et al, 2019; 
Shannon et al, 2019; Ewen et al, 2019; Barbar et al, 2019; Macquart de Terline et al, 
2019; Chow et al, 2018; Rahmawati et al, 2018; Rockers et al, 2018; Attaei et al, 2017; 
Ewen et al 2017; Marfo et al, 2017; Jande et al, 2017; Flood et al, 2017; Elias et al, 2017; 
Shams et al, 2016; Christiani et al, 2016; Murphy et al, 2016; Srivastava et al, 2015; 
Emmerick et al, 2015; Vialle-Vallentin et al, 2015; Sarayani et al, 2014; Sarayani et al, 
2013; Gama et al, 2013; Wagner et al, 2011).  Similarly, the NHF Individual Benefits 
provides a subsidy which addresses the affordability of chronic disease medicines.  
However, the amount and type of benefit received is the same regardless of age, gender 
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and socio-economic status. Additionally, those with private health insurance are at an 
advantage because they may get an additional reduction on the cost of their medicines. 
However, previous Jamaican studies have highlighted significant disparities in chronic 
disease burden among specific groups such as females, rural populations, and people in 
lower socio-economic groups (Tulloch-Reid, 2013; Scott & Theodore, 2013).  This study 
found that enrollement was largely equitable with need and predisposing factors (chronic 
disease burden and age) being the strongest predictors of NHF enrollement. However, 
adherence to medicines among NHF enrolless,  may not have been equitable as other 
non-need factors were found to be significant predictors, with out-of-pocket expense 
being the strongest predictor of adherence. It could therefore be argued that the NHF 
does not adequately reduce disparities in access to medicines for the groups with the 
highest chronic disease burden in Jamaica.  As such, policymakers in Jamaica should 
consider whether more targeted strategies are needed in order to ensure equitable 
access to chronic disease medicines. Also, I would argue that the removal of user fees 
from public health facilities to increase access to primary care and by extension access 
to the NHF, had only limited impact, because of the private sector dominance in primary 
healthcare. This highlighted the importance for policies targeting primary care providers, 
especially in a healthcare system like Jamaica where the government is not the 
predominant provider of primary care services.   
 
Furthermore, to ensure all Jamaicans with diabetes or hypertension gain access to low-
cost essential medicines, government interventions may be needed to improve 
awareness about the NHF individual benefits and the role of primary care in accessing 
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chronic disease medicines.  The study identified that younger adults were less likely to 
enroll in the NHF.  Younger people reportedly have a lower risk perception of themselves 
and are less likely to have a usual place of primary care (Victor et al, 2008; Appleton et 
al, 2012; Heidemann et al, 2019).   Considering NHF enrollment is predicated on primary 
care access, and the onset of diabetes and hypertension occur at a younger age in 
developing countries, these interventions would be an important step towards quality 
chronic disease management for younger people.  Given that both age and comorbidity 
status had a strong effect on NHF enrollment, awareness interventions could also target 
physicians to ensure that younger at-risk populations are screened and individuals with a 
single condition are referred for NHF enrollment. 
 
Once individuals are enrolled in the NHF, interventions to improve medication adherence 
in persons with diabetes or hypertension are also needed in Jamaica. The NHF 
programme, by subsidizing the cost of chronic disease medicines, accounts for the 
affordability dimension of access to medicines. But as was seen from the experience in 
other developing countries that adopted national policies or programmes to address 
access to medicines, patients face many other barriers to medication adherence.  
Although the reasons for low medication adherence was not specifically explored in this 
study, one could argue that this is  also one of the main reasons why  adherence to 
essential medicines was low among this NHF subsidized population and showed signs of 
a decline over time. The finding that enabling and contextual factors were significant 
predictors of adherence, suggests that there are health-system, drug-related and socio-
economic factors acting as barriers to continued access to chronic disease medicines.   




Differences in adherence by contextual factors i.e., geographic factors (rurality) and 
administrative health region, indicate that there are disparities in accessibility and 
accommodations within the health system. The barriers may include, geographic location 
of primary care services, where patients can be diagnosed, receive ongoing monitoring 
and access pharmacies to fill their prescriptions.  Primary care is the gateway to 
accessing medicines through the NHF in Jamaica.  As the literature review highlighted, 
organization of primary care can have a significant impact on access to chronic disease 
medicines (Elias et al, 2016; Christiani et al, 2016; Sarayani et al, 2014).  The volume of 
patients receiving primary care services in the private sector where fees are unregulated, 
is likely contributing to disparities in access to chronic disease medicines in Jamaica. This 
is one possible explanation for why the policy to remove user fees from public health 
facilities did not increase use of the NHF.  The policy only addressed user fees in the 
public sector and did not alleviate the financial cost for the majority of Jamaicans who 
utilize primary care in the private sector in order to access NHF benefits.   Due to the 
perception of better-quality care, there is a tendency towards higher utilization of more 
expensive private healthcare in developing countries (Wagner et al, 2011).  
Accommodation issues, such as longer wait times and less comfortable settings in public 
health facilities versus private clinics contribute to these negative perceptions of public 
health facilities.   In the case of Jamaica, declining use of the public health sector was 
reportedly due to lack of financing and inefficient organization and delivery of primary 
healthcare services in the public sector (MOHW, 2019).   Studies in other countries have 
shown that positive perception of the public health sector leads to better access to care 
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and medicines in developing countries (Wagner et al, 2011).  Expansion and 
improvement of government facilities and services may be needed in the long-term to 
increase use of public health facilities and reduce these disparities.  Efforts should focus 
on rural areas, where poverty was highlighted as a significant barrier to accessing health 
services (Bourne et al, 2010; Theodore et al, 2013).  Secondly, eighty (80%) of medicines 
are purchased in private pharmacies and the government has no medicine monitoring 
system to track these prices and no policies to regulate them.  Therefore, even with the 
NHF subsidizing the cost of medicines, the out-of-pocket costs are still financially 
burdensome for some Jamaicans, particularly in light of the declining subsidy rates over 
time (NHF, 2018). People in rural areas who are less likely to have health insurance, will 
face more financial barriers (Chambers et al, 2008; Mowatt et al, 2011).  Studies in other 
settings have shown that when medicine prices are unregulated, markups can be as high 
as 150%, thus contributing to a larger share of the medicine’s price (Srivastava et al, 
2015).  On the other hand, government price regulations have been shown to improve 
affordability of medicines in some settings (Sarayani et al, 2014).   Considering that out-
of-pocket expense had a strong effect on medication adherence, policies and 
mechanisms for government to track and regulate the retail price of medicines should be 
prioritized in order to ensure affordability.  The government should also make every effort 
to seek out cost savings in their NCD drug purchases and pass those savings on the 
consumers.  
 
Other important dimensions of access should also be addressed within the health system.  
For example, this study found that the number of drug therapies (polypharmacy) 
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significantly increased risk of non-adherence among NHF enrollees. Although 
polypharmacy had a small effect on medication adherence in this study, the findings 
suggests that to some degree, treatment acceptability was a barrier to continued access 
to chronic disease medicines. Evidence-based policies or guidelines are needed to 
address combination therapies in order to reduce polypharmacy and drug side effects. 
Interventions to improve medication adherence also need to target patients at enrollment 
and address the disparities in women and younger adults with these conditions.  
 
The literature review also highlighted the  key role of health system infrastructure in 
supporting efforts to improve access to medicines. Thus, the health system infrastructure 
while complex should be a key consideration for policymakers when developing or 
evaluating pharmaceutical policies or programmes aimed at increasing access to chronic 
diseases medicines.  Emmerick et al (2015), whose study focused on access to 
medicines in three Latin American countries, found that the main factor associated with 
access to medicines for treating chronic diseases was seeking care in the formal 
healthcare system. The strong private sector presence in the management of chronic 
diseases in Jamaica might be challenging for policymakers when it comes to 
strengthening the healthcare system, none-the-less, Emmerick et al (2015) reinforced the 
need for policymakers to focus in this area. This study supports the argument by 
Emmerick et al (2012) and also highlights the need for programmes and policies to take 
a multi-dimensional approach to improving access to medicines. This recommendation 
aligns with a multi-dimensional framework proposed by Jacobs et al (2012) to tackle 
interventions aimed at improving access to health services in developing countries.  




Due to the complex nature of access to medicines and adherence behaviour, many of the 
predictor variables explored in this study were observed to have a small effect. However, 
it should be noted that weak associations were not regarded in this study as an indication 
of public health insignificance, as there is an expectation that weak associations will be 
observed in real world settings, where each predictor variable is only partially explaining 
the complex outcomes being investigated in this study (McHugh M.L., 2013). 
 
3 Further research 
 
This study is the first to examine access and adherence to medicines on such a large 
population in Jamaica and it offers some important insights for policy makers and 
researchers alike. It fills an important gap in research on access to chronic disease 
medicines, specifically in the Caribbean region. It also underscores numerous challenges 
developing countries face when implementing chronic disease medicine policies to 
address the wide range of factors influencing access to medicines. In order for the 
government to design a comprehensive multidimensional policy to address access to 
chronic disease medicines, research is also needed to understand factors associated with 
access and adherence to medicines in the older population (60+ years). Due to data 
limitations, this population was not included in this study. The prevalence of diabetes and 
hypertension in Jamaicans over 60 years has increased significantly over the past three 
decades (Mitchell-Fearon et al, 2014). They are also at greater risks of having poor 
medical outcomes because of these conditions.  The finding from this study that females 
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are less likely to be adherent to chronic disease medicines requires further investigation. 
Although, gender had a small effect on adherence in this study, it warrants further 
exploration since a previous Jamaican study showed  excess cardiovascular risk burden 
in females (Tulloch-Reid et al, 2013). Therefore, females are at a higher risk of poor 
medical outcomes without quality drug therapy. Research is also needed to understand 
access barriers encountered by young adults with diabetes or hypertension. As the 
majority of primary care is provided by the private sector, research is also needed to 
understand barriers to accessing primary care in the private sector and their impact on 
access and adherence to medicines in Jamaica. The drug utilization profile described in 
this study provides useful information on physician prescribing behavior within this 
population. However, more research is needed to understand if irrational prescribing 
exists as have been found in other settings (Jia et al, 2014; Luiza et al, 2015; Kolasa & 
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CHAPTER 2 -APPENDICES 
Appendix 2.1 – Scoping review search terms 
( adherence )  AND  TITLE-ABS ( medicine* ) )  AND  ( TITLE-ABS-KEY-AUTH ( "chronic 
diseases" )  OR  TITLE-ABS-KEY-AUTH ( "chronic disease" )  OR  TITLE-ABS-KEY-
AUTH ( "chronic illness" )  OR  TITLE-ABS-KEY-AUTH ( "chronic illnesses" )  OR  TITLE-
ABS-KEY-AUTH ( "chronic conditions" )  OR  TITLE-ABS-KEY-AUTH ( "chronic 
condition" )  OR  TITLE-ABS-KEY-AUTH ( diabetes )  OR  TITLE-ABS-KEY-AUTH ( 
hypertension )  OR  TITLE-ABS-KEY-AUTH ( "high blood pressure" ) )  AND  ( TITLE-
ABS ( "developing country" )  OR  TITLE-ABS ( "developing countries" )  OR  TITLE-ABS 
( "low-income countries" )  OR  TITLE-ABS ( "low-income country" )  OR  TITLE-ABS ( 
"low income country" )  OR  TITLE-ABS ( "low income countries" )  OR  TITLE-ABS ( 
"resource poor" )  OR  TITLE-ABS ( "middle income country" )  OR  TITLE-ABS ( "middle 
income countries" )  OR  TITLE-ABS ( "middle-income country" )  OR  TITLE-ABS ( 
"middle-income countries" ) )  AND NOT  ( ( TITLE-ABS-KEY-AUTH ( children )  OR  
TITLE-ABS-KEY-AUTH ( paediatric )  OR  TITLE-ABS-KEY-AUTH ( pediatric ) )  AND  ( 
TITLE-ABS ( "developing country" )  OR  TITLE-ABS ( "developing countries" )  OR  
TITLE-ABS ( "low-income countries" )  OR  TITLE-ABS ( "low-income country" )  OR  
TITLE-ABS ( "low income country" )  OR  TITLE-ABS ( "low income countries" )  OR  
TITLE-ABS ( "resource poor" )  OR  TITLE-ABS ( "middle income country" )  OR  TITLE-
ABS ( "middle income countries" )  OR  TITLE-ABS ( "middle-income country" )  OR  
TITLE-ABS ( "middle-income countries" ) ) )  AND  ( LIMIT-TO ( LANGUAGE ,  "English" 
) )  AND  ( LIMIT-TO ( DOCTYPE ,  "ar" )  OR  LIMIT-TO ( DOCTYPE ,  "re" ) )  AND  ( 
LIMIT-TO ( SUBJAREA ,  "MEDI" )  OR  LIMIT-TO ( SUBJAREA ,  "SOCI" )  OR  LIMIT-
TO ( SUBJAREA ,  "ECON" )  OR  LIMIT-TO ( SUBJAREA ,  "NURS" )  OR  LIMIT-TO ( 
SUBJAREA ,  "PHAR" )  OR  LIMIT-TO ( SUBJAREA ,  "MULT" )  OR  LIMIT-TO ( 
SUBJAREA ,  "HEAL" )  OR  LIMIT-TO ( SUBJAREA ,  "Undefined" ) )  AND  ( LIMIT-TO 
( PUBYEAR ,  2019 )  OR  LIMIT-TO ( PUBYEAR ,  2018 )  OR  LIMIT-TO ( PUBYEAR ,  
2017 )  OR  LIMIT-TO ( PUBYEAR ,  2016 )  OR  LIMIT-TO ( PUBYEAR ,  2015 )  OR  
LIMIT-TO ( PUBYEAR ,  2014 )  OR  LIMIT-TO ( PUBYEAR ,  2013 )  OR  LIMIT-TO ( 
PUBYEAR ,  2012 )  OR  LIMIT-TO ( PUBYEAR ,  2011 )  OR  LIMIT-TO ( PUBYEAR ,  
2010 )  OR  LIMIT-TO ( PUBYEAR ,  2009 )  OR  LIMIT-TO ( PUBYEAR ,  english ) )  
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Appendix 2.2 - Systematic review search terms 
 
Filters: English Language  
 
1) MH [developing countries] 
 
2) TIAB [“developing countr*” OR “under-developed countr*” OR “under developed 
countr* “OR “third-world countr*” OR “third world countr*” OR “developing 
nation*” OR “under-developed nation*” OR “under developed nation*” OR “third-
world nation*” OR “third world nation*” OR  l”ess-developed countr* “OR “less 
developed countr*” OR “less-developed nation*” OR l”ess developed nation*” OR 
“low income countr*” OR  “low and middle income countr*” OR “low-income 
countr*” OR “low-and-middle income countr*” OR “middle income countr*” OR 
“middle-income countr*” OR “LMIC*”; “deprived countr*” OR “low income 
econom*” OR “low-income econom*” OR “low gross domestic” OR “low gross 
national” OR “low GDP “OR “low GNP” OR “poor* countr*” ] 
 
3) MH [Africa OR Latin America OR Central America OR Caribbean Region OR 
South America OR Asia] 
 
4) [Afghanistan OR Albania OR Algeria OR “American Samoa” OR Angola OR 
Armenia OR Azerbaijan OR Bangladesh OR Belarus OR Byelarus OR Belorussia 
OR Belize OR Benin OR Bhutan OR Bolivia OR Bosnia OR Botswana OR Brazil 
OR Bulgaria OR Burma OR “Burkina Faso” OR Burundi OR “Cabo Verde” OR 
“Cape verde” OR Cambodia OR Cameroon OR “Central African Republic” OR 
Chad OR China OR Colombia OR Comoros OR Comores OR Comoro OR 
Congo OR “Costa Rica” OR “Côte d'Ivoire” OR Cuba OR Djibouti OR Dominica 
OR “Dominican Republic” OR Ecuador OR Egypt OR “El Salvador” OR Eritrea 
OR Ethiopia OR Fiji OR Gabon OR Gambia OR Gaza OR “Georgia Republic” 
OR Georgian OR Ghana OR Grenada OR Grenadines OR Guatemala OR 
Guinea OR “Guinea Bisau” OR Guyana OR Haiti OR Herzegovina OR 
Hercegovina OR Honduras OR India OR Indonesia OR Iran OR Iraq OR Jamaica 
OR Jordan OR Kazakhstan OR Kenya OR Kiribati OR Korea OR Kosovo OR 
Kyrgyz OR Kirghizia OR Kirghiz OR Kirgizstan OR Kyrgyzstan OR “Lao PDR” 
OR Laos OR Lebanon OR Lesotho OR Liberia OR Libya OR Macedonia OR 
Madagascar OR Malawi OR Malay OR Malaya OR Malaysia OR Maldives OR 
Mali OR “Marshall Islands” OR Mauritania OR Mauritius OR Mexico OR 
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Micronesia OR Moldova OR Mongolia OR Montenegro OR Morocco OR 
Mozambique OR Myanmar OR Namibia OR Nepal OR Nicaragua OR Niger OR 
Nigeria OR Pakistan OR Palau OR Panama OR “Papua New Guinea” OR 
Paraguay OR Peru OR Philippines OR Phillippines OR Philipines OR Phillipines 
OR Principe OR Romania OR Rwanda OR Ruanda OR Samoa OR “Sao Tome” 
OR Senegal OR Serbia OR “Sierra Leone” OR “Solomon Islands” OR Somalia 
OR “South Africa” OR “South Sudan” OR “Sri Lanka” OR “St Lucia” OR “St 
Vincent” OR Sudan OR Surinham OR Suriname OR Swaziland OR Syria OR 
“Syrian Arab Republic” OR Tajikistan OR Tadzhikistan OR Tadjikistan OR 
Tadzhik OR Tanzania OR Thailand OR Timor OR Togo OR Tonga OR Tunisia 
OR Turkey OR Turkmen OR Turkmenistan OR Tuvalu OR Uganda OR Ukraine 
OR Uzbek OR Uzbekistan OR Vanuatu OR Vietnam OR “West Bank” OR Yemen 
OR Zambia OR Zimbabwe] 
 
5) 1 OR 2 OR 3 OR 4 
 
6) MH [public policy OR health policy OR healthcare financing OR government 
financing OR public sector or healthcare sector] OR Keyword [pharmaceutical 
policy OR healthcare financing OR national drug policy] 
 
7) TIAB [“public polic*” OR “health polic*” OR “healthcare financing” OR 
“government financ*” OR “public sector” OR “healthcare sector” OR “national 
drug polic*” OR “pharmaceutical polic*”] 
 
8) 6 OR 7 
 
9) MH [“pharmaceutical fees” OR “pharmaceutical services” OR “pharmaceutical 
economics” OR “pharmaceutical insurance services” OR “prescription fees” OR 
“prescription drugs” OR “insurance benefits” OR “health insurance” OR 
“deductibles” OR “Coinsurance” OR “cost sharing”] OR Keyword [drug insurance 
OR coinsurance] 
 
10) TIAB “pharmaceutical service*” OR “prescription fee*” OR “prescription drugs” 
OR “pharmaceutical insurance” OR “cost-sharing” OR “cost sharing” OR “drug 
insurance” OR “drug benefits” OR “deductible*” OR “copay*” OR “co-pay*” OR 
“drug user fee*” OR “drug user-fee*” OR “drug subsidy” OR “medication subsidy” 
OR “co-insurance” OR “coinsurance” OR “insurance coverage” OR “insurance 
benefits” OR “health insurance” 
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11) 9 OR 10 
 
12) MH [health service accessibility OR drugs, essential OR drug substitution OR 
treatment adherence and compliance OR medication adherence OR drug 
utilization OR drug utilization review OR prescription drug misuse OR 
prescription drug overuse OR drug prescription OR inappropriate prescribing OR 
hospitalization OR drug costs OR healthcare cost OR cost-benefit analysis OR 
cost savings OR treatment outcomes OR medication therapy management OR 
disease management] 
  
13) TIAB “access to medicine*” OR “access to prescription” OR “essential medicine*” 
OR “essential drugs” OR “adherence” medication management” OR “medication 
therapy” OR “prescription” OR “prescribing patterns” OR “dispensing patterns” 
OR “generic drugs” OR “generic medicine*” OR “drug utilization” OR “drug 
utilisation” OR “drug use” OR “hospitalization” OR “hospitalisation OR “hospital 
use *”  OR “out of pocket” OR “out-of-pocket” OR “cost-saving” OR “cost saving” 
OR “treatment outcome*”  
 
14) 12 OR 13 
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Appendix 2.3 - Data Extraction Elements 
● First author, year of publication, title 
● Study setting 
● Characteristics of policies and interventions 
● Study objective 
● Study design 
● Outcome measures  
● Results from main outcome measures 
● Sources of data (e.g. surveys, administrative etc.) 
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Appendix 2.4 – Methodological Quality Assessment Tool 
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Zhang et al, 
2017 
Moderate Moderate Strong Strong Strong Strong Strong 
Mengue et al, 
2016 
Moderate Weak Strong Strong Strong NA Moderate 
Holloway et 
al, 2001 
Strong Moderate Strong Weak Moderate NA Moderate 
Huang et al, 
2018 
Strong Weak Weak Weak Weak Weak Weak 
Bertoldi et al, 
2012 
Weak Weak Weak Weak Weak NA Weak 
Bertoldi et al, 
2009 
Strong Weak Strong Weak Weak NA Weak 
Bertoldi et al, 
2011 
Moderate Weak Strong Weak Weak NA Weak 
Monteiro et 
al, 2016 
Moderate Weak Strong Weak Weak NA Weak 
Araujo et al, 
2014 
Moderate Weak Weak Weak Weak NA Weak 
Paniz et al, 
2010 
Moderate Weak Weak Weak Weak NA Weak 
Ding et al, 
2017 
Moderate Moderate Strong Weak Weak NA Weak 
Song et al, 
2014 
Moderate Moderate Strong Weak Weak NA Weak 
Zhang et al, 
2014 
Moderate Moderate Strong Weak Weak NA Weak 
Chen et al, 
2014 
Moderate Moderate Weak Weak Weak NA Weak 
Song et al, 
2014 
Moderate Moderate Strong Weak Weak NA Weak 
Yao et al, 
2015 
Moderate Moderate Weak Weak Weak NA Weak 
Zhou et al, 
2015 
Moderate Moderate Moderate Weak Weak NA Weak 
Guo et al, 
2017 
Strong Weak Weak Weak Weak Strong Weak 
He et al, 2018 Weak Moderate Weak Weak Weak NA Weak 
Yi et al, 2015 Weak Weak Strong Weak Strong Weak Weak 
Sun et al, 
2009 
Moderate Moderate Strong Weak Weak NA Weak 
Yang et al, 
2013 
Moderate Moderate Weak Weak Weak NA Weak 
Xi et al, 2018 Weak Weak Weak Weak Strong NA Weak 
Maiga et al, 
2003 
Weak Weak Moderate Weak Weak NA Weak 
Moye-Holz et 
al, 2018 
Moderate Moderate Weak Weak Weak NA Weak 






Weak Weak Weak Weak Moderate NA Weak 
Holloway et 
al, 2001 
Moderate Moderate Strong Weak Weak NA Weak 
Uzochukwu 
et al, 2001 
Weak Moderate Weak Weak Weak NA Weak 
Gray et al, 
2016 
Moderate Moderate Weak Weak Weak NA Weak 
Liu et al, 
2003 
Moderate Moderate Weak Weak Weak NA Weak 
Chu et al, 
2011 
Moderate Moderate Weak Weak Weak NA Weak 
Chu et al, 
2008 
Moderate Moderate Weak Weak Weak NA Weak 
Garabedian, 
2012 
moderate Moderate Weak Weak Weak NA Weak 
Gur Ali et al, 
2011 












CHAPTER 4 - APPENDICES 
Appendix 4.1 – NHF Technical Specification cohort selection 
Cohort 
Year (NHF card was used 
to purchase medicine) 
Inclusion criteria 
(Records to include) 
Exclusion criteria 




Jan 1, 2017 - Dec 31, 2017 
AND 
Jan 1, 2008 - Dec 31, 2008 
1. All parishes 
 
2. All eligible and 
enrolled male and 
female 
 
3. Disease condition 
on the NHF 
enrollment form = 
'Diabetes' (type 2) 
and/or 'hypertension' 
 
4. Used NHF card to 
purchase medicines 
at least once between 
Jan 1, 2017-Dec 31, 
2017 
 
5. Age at the time of 
enrollment was 
between 18 and 59 
1. Diabetes (type 2) 
OR Hypertension 
NOT among 
conditions on NHF 
enrollment Form 
 
2. Patient < 18 or >= 
60 years at the time of 
NHF enrollment 
Three (3) Record 
level MS Excel File 
linkable by an 
anonymous unique 
identifier: 
1) Patient table1 
 
2) Patient Disease 
Table2 
 




three Jan 1, 2004 - Dec 31, 2012 
1. All parishes 
 
2. All eligible and 
enrolled male and 
female 
 
3. Disease condition 
on the NHF 
enrollment form = 
'Diabetes' (type 2) 
and/or 'hypertension' 
 
4. Used NHF card to 
purchase medicines 
at least once between 
Jan 1, 2004-Dec 31, 
2012 
 
5. Age at the time of 
enrollment was 
between 18 and 59 
1. Diabetes (type 2) 
OR Hypertension 
NOT among 
conditions on NHF 
enrollment Form 
 
2. Patient < 18 or >= 
60 years at the time of 
NHF enrollment 
Three (3) Record 
level MS Excel File 
linkable by an 
anonymous unique 
identifier: 
1) Patient table1 
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Appendix 4.2: NHF Technical Specifications (Patient Table) 
Data element Description Data values Data type 
Patient ID 
Anonymous unique 
patient identifier   varchar 
Age 
Age at the time patient 
enrolled for NHF card   Numeric 
Parish of residence 
Parish patient was 
residing at the time of 
enrollment 
Kingston; St. Andrew; St. 
Catherine; St. Ann; 
Trelawny; St. James; 
Hanover; Westmoreland; 
St. Elizabeth; 
Manchester; St. Mary; St. 
Thomas; Portland; 
Clarendon varchar 
Gender Male/Female/Unknown M; F varchar 
Occupation 
Occupation on the NHF 
enrollment form   varchar 
Date of NHF enrollment 
Date the patient first 
enrolled in the NHF 
program yyyy-mm-dd Date 
 
Appendix 4.3: NHF Technical Specifications (Patient Disease Table) 
Data elements Description Data values Data type 
Patient ID 
Anonymous unique patient 
identifier from patient table Unique number  Numeric 
Disease ID 
Unique identifier for each of 
the 16 chronic disease 
condition eligible for NHF 
subsidy Unique number  Numeric 
Diseases condition 
Disease condition on NHF 
enrollment form 
1 of the 16 eligible 
chronic diseases 
covered by the NHF varchar 
Date certified by physician 
Date the disease was 
certified by a physician as 
indicated on the NHF 
enrollment form yyyy-mm-dd Date 
Disease Severity 
Disease severity as 
indicated on the NHF 
enrollment form Mild; Severe varchar 
 
Appendix 4.5: NHF Technical Specifications (Patient Claims Table) 
Data elements Description Data values Data type 
Patient ID 
Anonymous unique patient 
identifier from patient table unique numbers numeric 
Pharmacy ID 
Anonymous unique ID for 
pharmacies unique numbers numeric 
Pharmacy is 
private/public 
Determine if pharmacy is 
privately/publicly owned Private; public varchar 





Parishes where pharmacy is 
located 
Kingston; St. Andrew; St. 
Catherine; St. Ann; 
Trelawny; St. James; 
Hanover; Westmoreland; 
St. Elizabeth; Manchester; 
St. Mary; St. Thomas; 
Portland; Clarendon varchar 
Prescription fill date 
Date the patient used the 
NHF Card to fill prescription 
at the pharmacy   Date 
Generic Product 
Identifier 
Unique identifier of the 
medication   numeric 
Medication name 
Name as is listed on the 
NHF list of 'Individuals 
benefit for prescription 
drugs' e.g. Metformin   varchar 
Total cost of medicine 
(j$) 
This is the absolute retail 
cost of the medicine 
including applicable taxes Dollar amount (j$) numeric 
Cost in J$ paid by NHF  
This is the portion of the 
absolute retail cost covered 
by the NHF Dollar amount (j$) numeric 
Cost in J$ paid by 
patient/claimant 
This is the amount the 
patient/claimant paid out of 
pocket for the medicine Dollar amount (j$) numeric 
Quantity purchased 
This quantity of medication 
purchased e.g. 112 pills   numeric 
Days supplied 
The is number of days of 
medication supplied to the 
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Appendix 4.6: SQL Code used to mine NHF data 
1) Research Objective two 
 
CREATE TABLE PATIENT_CLAIM_TABLE AS 
 
select distinct b.Age 
,b.Age + (cast (julianday(d.ABS_min_date)- julianday (b.date_enrolled) as integer)/ 365) 
as Age_at 
,b.parish as Parish_Residence 
,b.Gender 
,b.Occupation 
,b.Date_enrolled as Date_enrolled 
,a.* 
,c.MajorClass_recode as MC 
,c.total_cost 
,c.Subsidy_amount 
,(c.total_cost - Subsidy_amount) as OOP 
,c.Min_date 
,c.Max_date 
,cast (julianday(d.ABS_min_date)- julianday (b.date_enrolled) as integer)/ 30 as 
Since_enrollment 
,cast (julianday(c.max_date)- julianday (c.min_date) as integer)as Days_period 
,cast (julianday(d.max_date)- julianday (d.ABS_min_date) as integer)/ 30 as 
months_period 
from Revised_SUM_Supplies a 
join Revised_Days_Period c on c.MemberID=a.MemberID and 
a.MajorClass_recode=c.MajorClass_recode 
join Revised_Patient b on a.MemberID=b.MemberID 
join MIN_MAX_DATE d on d.MemberID=a.memberID 
 




,case when age_at between 18 and 39 then 0 
when age_at between 40 and 44 then 1 
when age_at between 45 and 49 then 2 
when age_at between 50 and 54 then 3 
when age_at >= 55 then 4 end as 'Age_Range' 
,case when Parish_Residence in ('KINGSTON','ST. ANDREW') then 'KSA' else 
Parish_Residence end as 'Paris_Residence' 
,case when Parish_Residence in ('KINGSTON', 'ST. ANDREW', 'ST. CATHERINE', 'ST. 
JAMES') then 0 else 1 END AS 'RURAL'  
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,case when Parish_residence in ('KINGSTON','ST. ANDREW', 'ST. CATHERINE', 'ST. 
THOMAS') THEN 1 
when Parish_residence in ('PORTLAND','ST. ANN','ST. MARY') THEN 2 
WHEN PARISH_RESIDENCE IN ('MANCHESTER', 'CLARENDON', 'ST.ELIZABETH') 
THEN 3 
WHEN PARISH_RESIDENCE IN ('TRELAWNY', 'HANOVER', 'ST. JAMES', 
'WESTMORELAND') THEN 4 







,Max_date as date 
,MajorClass_Recode 
,sum_supplies 
,case when sum_Supplies > (Days_period + Last_day_supplies) then (Days_period + 
Last_day_supplies) 
else sum_supplies end as RECAL_SUM_Supplies 
,Last_day_supplies 
,Days_Period 





,case when since_enrollment < 12 then 1 
when since_enrollment between 12 and 24 then 2 
when since_enrollment between 25 and 36 then 3 
when since_enrollment between 37 and 48 then 4 
when since_enrollment between 49 and 60 then 5 
else 6 end as 'enrollment_period' 
,Case when c.AVG_monthly_OOP < 5000 then 1 
when c.AVG_monthly_OOP between 5000 and 10000 then 2 
when c.AVG_monthly_OOP > 10000 then 3 end as Mthly_OOP 
from PATIENT_CLAIM_TABLE a 
join Revised_Patient_Disease b on a.memberid=b.memberid 
join Monthly_OOP c on c.memberid=a.memberid 
where a.MajorClass_recode in ('ANTIDIABETICS', 'ANTIHYPERTENSIVES', 
'ANTIHYPERLIPIDEMICS') 
and a.memberid not in (select memberID from INSULIN_TABLE) 
and (diabetes = 1 OR hypertension = 1) 
and Days_Period >= 180 
 
 




CREATE TABLE FINAL_DIAB_HYP_COHORT AS 
select distinct a.MemberID 
,Age_range 
,CASE WHEN gender = 'F' THEN 0 ELSE 1 END AS GENDER 
,CASE WHEN PARIS_RESIDENCE = 'KSA' THEN 1 
WHEN PARIS_RESIDENCE = 'ST. THOMAS' THEN 2 
WHEN PARIS_RESIDENCE = 'ST. CATHERINE' THEN 3 
WHEN PARIS_RESIDENCE = 'ST. ANN' THEN 4 
WHEN PARIS_RESIDENCE = 'ST. MARY' THEN 5 
WHEN PARIS_RESIDENCE = 'PORTLAND' THEN 6 
WHEN PARIS_RESIDENCE = 'MANCHESTER' THEN 7 
WHEN PARIS_RESIDENCE = 'CLARENDON' THEN 8 
WHEN PARIS_RESIDENCE = 'ST.ELIZABETH' THEN 9 
WHEN PARIS_RESIDENCE = 'ST. JAMES' THEN 10 
WHEN PARIS_RESIDENCE = 'HANOVER' THEN 11 
WHEN PARIS_RESIDENCE = 'TRELAWNY' THEN 12 









,case when c.MemberId is not null then 1 else 0 end as Hypertension 
,case when d.MemberId is not null then 1 else 0 end as high_cholesterol 
,case when e.MemberId is not null then 1 else 0 end as diabetes 
--,case when c.memberid is not null AND d.memberID is not null then 1 else 0 end as 
hyp_chol 
,Round(RECAL_SUM_Supplies,2)/round(RECAL_last_days_supplies, 2) as MPR 
from INTERIM_DIAB_HYP_COHORT a 
join Number_Therapeutic_Class b on a.MemberID=b.MemberID 
left outer Join (Select distinct memberID from Revised_Patient_Disease where 
hypertension = 1 )c on c.MemberID=a.MemberID 
left outer join (Select distinct memberId from Revised_Patient_Disease where 
High_cholesterol =1) d on d.MemberID=a.MemberID 
left outer join (Select distinct memberId from Revised_Patient_Disease where Diabetes 




CREATE TABLE INSULIN_TABLE AS  
Select distinct memberid from Revised_Drug_Claim_Class 
where subClass = 'INSULIN' 


















,Case when (diabetes = 1 AND hypertension = 1) then 1 
when (hypertension = 1 AND diabetes = 0) then 2 else 3 end as comorbidity  
--,hyp_chol 
,case when (hypertension = 1 AND high_cholesterol = 0 and diabetes = 0)then 1 
when (hypertension = 0 AND high_cholesterol = 0 and diabetes = 1)then 1 
when (hypertension = 1 AND high_cholesterol = 0 and diabetes = 1)then 2 
when (hypertension = 1 AND high_cholesterol = 1 and diabetes = 0)then 2 
when (hypertension = 0 AND high_cholesterol = 1 and diabetes = 1)then 2 
when (hypertension = 1 AND high_cholesterol = 1 and diabetes = 1)then 3 end as 
Number_CD 
,AVG (MPR) as Avg_MPR 
from FINAL_DIAB_HYP_COHORT  













,Case when (diabetes = 1 AND hypertension = 1) then 1 
when (hypertension = 1 AND diabetes = 0) then 2 else 3 end 
,case when (hypertension = 1 AND high_cholesterol = 0 and diabetes = 0)then 1 
when (hypertension = 0 AND high_cholesterol = 0 and diabetes = 1)then 1 
when (hypertension = 1 AND high_cholesterol = 0 and diabetes = 1)then 2 
when (hypertension = 1 AND high_cholesterol = 1 and diabetes = 0)then 2 
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when (hypertension = 0 AND high_cholesterol = 1 and diabetes = 1)then 2 




select count (distinct a.memberid), a.MajorClass_Recode, subclass  
from Revised_Drug_Claim_Class a 
join Revised_Patient_Disease b on a.memberid=b.memberid 
join PATIENT_CLAIM_TABLE c on c.MemberID=a.MemberID 
where (diabetes=1 OR hypertension=1) 
AND 
a.MajorClass_Recode in ('ANTIDIABETICS', 
'ANTIHYPERTENSIVES','ANTIHYPERLIPIDEMICS') 
AND 
Days_Period >= 180 
group by a.MajorClass_Recode, subclass 
 
 
2) Research Objective three  
 
a. Unstratified code for Segmented Regression – New enrollment 
select count (distinct a.MemberID) as count , substr(date_enrolled, 1,4) as 
year , case when substr(Date_enrolled, 6,2) in ('01') then 1 when 
substr(Date_enrolled, 6,2) in ('02') then 2 when substr(Date_enrolled, 6,2) in 
('03') then 3 when substr(Date_enrolled, 6,2) in ('04') then 4 when 
substr(Date_enrolled, 6,2) in ('05') then 5 when substr(Date_enrolled, 6,2) in 
('06') then 6 when substr(Date_enrolled, 6,2) in ('07') then 7 when 
substr(Date_enrolled, 6,2) in ('08') then 8 when substr(Date_enrolled, 6,2) in 
('09') then 9 when substr(Date_enrolled, 6,2) in ('10') then 10 when 
substr(Date_enrolled, 6,2) in ('11') then 11 when substr(Date_enrolled, 6,2) 
in ('12') then 12 end as month  
from Revised_Patient a  
join Revised_Patient_Disease b on a.MemberID=b.MemberID  
where (diabetes = 1 or hypertension =1)  
and date_enrolled between '2006-04-01' and '2009-04-30' 
and age between 18 and 59 
          group by substr(date_enrolled, 1,4) 
, case when substr(Date_enrolled, 6,2) in ('01') then 1 when 
substr(Date_enrolled, 6,2) in ('02') then 2 when substr(Date_enrolled, 6,2) in 
('03') then 3 when substr(Date_enrolled, 6,2) in ('04') then 4 when 
substr(Date_enrolled, 6,2) in ('05') then 5 when substr(Date_enrolled, 6,2) in 
('06') then 6 when substr(Date_enrolled, 6,2) in ('07') then 7 when 
substr(Date_enrolled, 6,2) in ('08') then 8 when substr(Date_enrolled, 6,2) in 
('09') then 9 when substr(Date_enrolled, 6,2) in ('10') then 10 when 
substr(Date_enrolled, 6,2) in ('11') then 11 when substr(Date_enrolled, 6,2) in 
('12') then 12 end 




b. Unstratified code for Segmented Regression – NHF Card Use 
 
select count (distinct a.MemberID) as count , substr(datepurchase, 1,4) as year , 
case when substr(Datepurchase, 6,2) in ('01') then 1 when substr(datepurchase, 
6,2) in ('02') then 2 when substr(datepurchase, 6,2) in ('03') then 3 when 
substr(datepurchase, 6,2) in ('04') then 4 when substr(datepurchase, 6,2) in ('05') 
then 5 when substr(datepurchase, 6,2) in ('06') then 6 when substr(datepurchase, 
6,2) in ('07') then 7 when substr(datepurchase, 6,2) in ('08') then 8 when 
substr(datepurchase, 6,2) in ('09') then 9 when substr(datepurchase, 6,2) in ('10') 
then 10 when substr(datepurchase, 6,2) in ('11') then 11 when 
substr(datepurchase, 6,2) in ('12') then 12 end as month  
from Revised_Patient a  
join Revised_Patient_Disease b on a.MemberID=b.MemberID  
Join Revised_Claims1_Finale c on c.MemberID=b.MemberID  
where (diabetes = 1 or hypertension =1) and datepurchase between '2006-01-01' 
and '2010-12-31' and age between 18 and 59 
group by substr(datepurchase, 1,4) 
, case when substr(Date_enrolled, 6,2) in ('01') then 1 when substr(datepurchase, 
6,2) in ('02') then 2 when substr(datepurchase, 6,2) in ('03') then 3 when 
substr(datepurchase, 6,2) in ('04') then 4 when substr(datepurchase, 6,2) in ('05') 
then 5 when substr(datepurchase, 6,2) in ('06') then 6 when substr(datepurchase, 
6,2) in ('07') then 7 when substr(datepurchase, 6,2) in ('08') then 8 when 
substr(datepurchase, 6,2) in ('09') then 9 when substr(datepurchase, 6,2) in ('10') 
then 10 when substr(datepurchase, 6,2) in ('11') then 11 when 
substr(datepurchase, 6,2) in ('12') then 12 end 
 
c. Stratified code for Segmented Regression – New enrollment 









select count (distinct a.MemberID) as Female 
, substr(date_enrolled, 1,4) as year 
, case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
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when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient a 
join Revised_Patient_Disease b on a.MemberID=b.MemberID 
where (diabetes = 1 or hypertension =1) 
and date_enrolled between '2007-01-01' and '2009-12-31' 
and age between 18 and 59 
and gender = 'F' 
group by substr(date_enrolled, 1,4)  
, case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 





select count (distinct e.MemberID) as male 
, substr(date_enrolled, 1,4) as year 
, case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient e 
join Revised_Patient_Disease f on e.MemberID=f.MemberID 
where (diabetes = 1 or hypertension =1) 
and date_enrolled between '2007-01-01' and '2009-12-31' 
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and age between 18 and 59 
and gender = 'M' 
group by substr(date_enrolled, 1,4)  
, case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end 
 
 




select count (distinct g.MemberID) as urban 
, substr(date_enrolled, 1,4) as year 
, case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient g 
join Revised_Patient_Disease h on g.MemberID=h.MemberID 
where (diabetes = 1 or hypertension =1) 
and date_enrolled between '2007-01-01' and '2009-12-31' 
and age between 18 and 59 
and Parish in ('KINGSTON', 'ST. ANDREW', 'ST. CATHERINE', 'ST. JAMES') 
group by substr(date_enrolled, 1,4)  
, case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
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when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end 




select count (distinct i.MemberID) as Rural 
, substr(date_enrolled, 1,4) as year 
, case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient i 
join Revised_Patient_Disease j on i.MemberID=j.MemberID 
where (diabetes = 1 or hypertension =1) 
and date_enrolled between '2007-01-01' and '2009-12-31' 
and age between 18 and 59 
and Parish not in ('KINGSTON', 'ST. ANDREW', 'ST. CATHERINE', 'ST. JAMES') 
group by substr(date_enrolled, 1,4)  
, case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end 
)z on w.year=z.year and w.quarter=z.quarter 






select count (distinct i1.MemberID) as SERHA 
, substr(date_enrolled, 1,4) as year 
,case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient i1 
join Revised_Patient_Disease j1 on i1.MemberID=j1.MemberID 
where (diabetes = 1 or hypertension =1) 
and date_enrolled between '2007-01-01' and '2009-12-31' 
and age between 18 and 59 
and Parish in ('KINGSTON', 'ST. ANDREW', 'ST. CATHERINE', 'ST. THOMAS') 
group by substr(date_enrolled, 1,4)  
, case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end 




select count (distinct i2.MemberID) as NERHA 
, substr(date_enrolled, 1,4) as year 
, case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
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when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient i2 
join Revised_Patient_Disease j2 on i2.MemberID=j2.MemberID 
where (diabetes = 1 or hypertension =1) 
and date_enrolled between '2007-01-01' and '2009-12-31' 
and age between 18 and 59 
and Parish in ('ST. ANN', 'ST. MARY', 'PORTLAND') 
group by substr(date_enrolled, 1,4)  
, case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end 




select count (distinct i3.MemberID) as SRHA 
, substr(date_enrolled, 1,4) as year 
,case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient i3 
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join Revised_Patient_Disease j3 on i3.MemberID=j3.MemberID 
where (diabetes = 1 or hypertension =1) 
and date_enrolled between '2007-01-01' and '2009-12-31' 
and age between 18 and 59 
and Parish in ('ST.ELIZABETH', 'CLARENDON', 'MANCHESTER') 
group by substr(date_enrolled, 1,4)  
, case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end 




select count (distinct i4.MemberID) as WRHA 
, substr(date_enrolled, 1,4) as year 
, case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient i4 
join Revised_Patient_Disease j4 on i4.MemberID=j4.MemberID 
where (diabetes = 1 or hypertension =1) 
and date_enrolled between '2007-01-01' and '2009-12-31' 
and age between 18 and 59 
and Parish in ('ST. JAMES', 'HANOVER', 'WESTMORELAND', 'TRELAWNY') 
group by substr(date_enrolled, 1,4)  
, case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
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when substr(Date_enrolled, 6,2) in ('04') then 4 
when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end 
)z4 on w.year=z4.year and w.quarter=z4.quarter 
join 
( 
select count (distinct m1.MemberID) as Age_Cat1 
, substr(date_enrolled, 1,4) as year 
, case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient m1 
join Revised_Patient_Disease o1 on m1.MemberID=o1.MemberID 
where (diabetes = 1 or hypertension =1) 
and date_enrolled between '2007-01-01' and '2009-12-31' 
and age between 18 and 39 
group by substr(date_enrolled, 1,4)  
, case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end 
)n1 on w.year=n1.year and w.quarter=n1.quarter 
 





select count (distinct m2.MemberID) as Age_Cat2 
, substr(date_enrolled, 1,4) as year 
, case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient m2 
join Revised_Patient_Disease o2 on m2.MemberID=o2.MemberID 
where (diabetes = 1 or hypertension =1) 
and date_enrolled between '2007-01-01' and '2009-12-31' 
and age between 40 and 44 
group by substr(date_enrolled, 1,4)  
, case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end 




select count (distinct m3.MemberID) as Age_Cat3 
, substr(date_enrolled, 1,4) as year 
, case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
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when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient m3 
join Revised_Patient_Disease o3 on m3.MemberID=o3.MemberID 
where (diabetes = 1 or hypertension =1) 
and date_enrolled between '2007-01-01' and '2009-12-31' 
and age between 45 and 49 
group by substr(date_enrolled, 1,4)  
, case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end 




select count (distinct m4.MemberID) as Age_Cat4 
, substr(date_enrolled, 1,4) as year 
, case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient m4 
join Revised_Patient_Disease o4 on m4.MemberID=o4.MemberID 
where (diabetes = 1 or hypertension =1) 
and date_enrolled between '2007-01-01' and '2009-12-31' 
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and age between 50 and 54 
group by substr(date_enrolled, 1,4)  
, case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end 




select count (distinct m5.MemberID) as Age_Cat5 
, substr(date_enrolled, 1,4) as year 
, case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient m5 
join Revised_Patient_Disease o5 on m5.MemberID=o5.MemberID 
where (diabetes = 1 or hypertension =1) 
and date_enrolled between '2007-01-01' and '2009-12-31' 
and age between 55 and 59 
group by substr(date_enrolled, 1,4)  
,case when substr(Date_enrolled, 6,2) in ('01') then 1 
when substr(Date_enrolled, 6,2) in ('02') then 2 
when substr(Date_enrolled, 6,2) in ('03') then 3 
when substr(Date_enrolled, 6,2) in ('04') then 4 
when substr(Date_enrolled, 6,2) in ('05') then 5 
when substr(Date_enrolled, 6,2) in ('06') then 6 
when substr(Date_enrolled, 6,2) in ('07') then 7 
when substr(Date_enrolled, 6,2) in ('08') then 8 
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when substr(Date_enrolled, 6,2) in ('09') then 9 
when substr(Date_enrolled, 6,2) in ('10') then 10 
when substr(Date_enrolled, 6,2) in ('11') then 11 
when substr(Date_enrolled, 6,2) in ('12') then 12 end 




d. Stratified code for Segmented Regression – NHF Card Use 









select count (distinct a.MemberID) as Female 
, substr(datepurchase, 1,4) as year 
, case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
when substr(datepurchase, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient a 
join Revised_Patient_Disease b on a.MemberID=b.MemberID 
Join Revised_Claims1_Finale c on c.MemberID=b.MemberID 
where (diabetes = 1 or hypertension =1) 
and datepurchase between '2007-01-01' and '2009-12-31' 
and age between 18 and 59 
and gender = 'F' 
group by substr(datepurchase, 1,4)  
, case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
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when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 




select count (distinct e.MemberID) as male 
, substr(Datepurchase, 1,4) as year 
, case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
when substr(datepurchase, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient e 
join Revised_Patient_Disease f on e.MemberID=f.MemberID 
Join Revised_Claims1_Finale cc1 on cc1.MemberID=e.MemberID 
where (diabetes = 1 or hypertension =1) 
and datepurchase between '2007-01-01' and '2009-12-31' 
and age between 18 and 59 
and gender = 'M' 
group by substr(datepurchase, 1,4)  
,case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
when substr(datepurchase, 6,2) in ('12') then 12 end 
)x on w.year=x.year and w.quarter=x.quarter 
 





select count (distinct g.MemberID) as urban 
, substr(datepurchase, 1,4) as year 
, case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
when substr(datepurchase, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient g 
join Revised_Patient_Disease h on g.MemberID=h.MemberID 
Join Revised_Claims1_Finale cc2 on cc2.MemberID=g.MemberID 
where (diabetes = 1 or hypertension =1) 
and datepurchase between '2007-01-01' and '2009-12-31' 
and age between 18 and 59 
and Parish in ('KINGSTON', 'ST. ANDREW', 'ST. CATHERINE', 'ST. JAMES') 
group by substr(datepurchase, 1,4)  
, case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
when substr(datepurchase, 6,2) in ('12') then 12 end 
 




select count (distinct i.MemberID) as Rural 
, substr(datepurchase, 1,4) as year 
, case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
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when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
when substr(datepurchase, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient i 
join Revised_Patient_Disease j on i.MemberID=j.MemberID 
Join Revised_Claims1_Finale cc3 on cc3.MemberID=i.MemberID 
where (diabetes = 1 or hypertension =1) 
and datepurchase between '2007-01-01' and '2009-12-31' 
and age between 18 and 59 
and Parish not in ('KINGSTON', 'ST. ANDREW', 'ST. CATHERINE', 'ST. JAMES') 
group by substr(datepurchase, 1,4)  
, case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
when substr(datepurchase, 6,2) in ('12') then 12 end 




select count (distinct i1.MemberID) as SERHA 
, substr(datepurchase, 1,4) as year 
, case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
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when substr(datepurchase, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient i1 
join Revised_Patient_Disease j1 on i1.MemberID=j1.MemberID 
Join Revised_Claims1_Finale cc4 on cc4.MemberID=i1.MemberID 
where (diabetes = 1 or hypertension =1) 
and datepurchase between '2007-01-01' and '2009-12-31' 
and age between 18 and 59 
and Parish in ('KINGSTON', 'ST. ANDREW', 'ST. CATHERINE', 'ST. THOMAS') 
group by substr(datepurchase, 1,4)  
, case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
when substr(datepurchase, 6,2) in ('12') then 12 end 




select count (distinct i2.MemberID) as NERHA 
, substr(datepurchase, 1,4) as year 
, case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
when substr(datepurchase, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient i2 
join Revised_Patient_Disease j2 on i2.MemberID=j2.MemberID 
Join Revised_Claims1_Finale cc5 on cc5.MemberID=i2.MemberID 
where (diabetes = 1 or hypertension =1) 
and datepurchase between '2007-01-01' and '2009-12-31' 
and age between 18 and 59 
and Parish in ('ST. ANN', 'ST. MARY', 'PORTLAND') 
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group by substr(datepurchase, 1,4)  
, case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
when substr(datepurchase, 6,2) in ('12') then 12 end 




select count (distinct i3.MemberID) as SRHA 
, substr(datepurchase, 1,4) as year 
, case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
when substr(datepurchase, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient i3 
join Revised_Patient_Disease j3 on i3.MemberID=j3.MemberID 
Join Revised_Claims1_Finale cc6 on cc6.MemberID=i3.MemberID 
where (diabetes = 1 or hypertension =1) 
and datepurchase between '2007-01-01' and '2009-12-31' 
and age between 18 and 59 
and Parish in ('ST.ELIZABETH', 'CLARENDON', 'MANCHESTER') 
group by substr(datepurchase, 1,4)  
, case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
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when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
when substr(datepurchase, 6,2) in ('12') then 12 end 




select count (distinct i4.MemberID) as WRHA 
, substr(datepurchase, 1,4) as year 
, case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
when substr(datepurchase, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient i4 
join Revised_Patient_Disease j4 on i4.MemberID=j4.MemberID 
Join Revised_Claims1_Finale cc7 on cc7.MemberID=i4.MemberID 
where (diabetes = 1 or hypertension =1) 
and datepurchase between '2007-01-01' and '2009-12-31' 
and age between 18 and 59 
and Parish in ('ST. JAMES', 'HANOVER', 'WESTMORELAND', 'TRELAWNY') 
group by substr(datepurchase, 1,4)  
, case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
when substr(datepurchase, 6,2) in ('12') then 12 end 
)z4 on w.year=z4.year and w.quarter=z4.quarter 
join 
( 
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select count (distinct m1.MemberID) as Age_Cat1 
, substr(datepurchase, 1,4) as year 
, case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
when substr(datepurchase, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient m1 
join Revised_Patient_Disease o1 on m1.MemberID=o1.MemberID 
Join Revised_Claims1_Finale cc8 on cc8.MemberID=m1.MemberID 
where (diabetes = 1 or hypertension =1) 
and datepurchase between '2007-01-01' and '2009-12-31' 
and age between 18 and 39 
group by substr(datepurchase, 1,4)  
, case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
when substr(datepurchase, 6,2) in ('12') then 12 end 




select count (distinct m2.MemberID) as Age_Cat2 
, substr(datepurchase, 1,4) as year 
,case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
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when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
when substr(datepurchase, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient m2 
join Revised_Patient_Disease o2 on m2.MemberID=o2.MemberID 
Join Revised_Claims1_Finale cc9 on cc9.MemberID=m2.MemberID 
where (diabetes = 1 or hypertension =1) 
and datepurchase between '2007-01-01' and '2009-12-31' 
and age between 40 and 44 
group by substr(datepurchase, 1,4)  
, case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
when substr(datepurchase, 6,2) in ('12') then 12 end 




select count (distinct m3.MemberID) as Age_Cat3 
, substr(datepurchase, 1,4) as year 
, case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
when substr(datepurchase, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient m3 
join Revised_Patient_Disease o3 on m3.MemberID=o3.MemberID 
Join Revised_Claims1_Finale cc10 on cc10.MemberID=m3.MemberID 
where (diabetes = 1 or hypertension =1) 
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and datepurchase between '2007-01-01' and '2009-12-31' 
and age between 45 and 49 
group by substr(datepurchase, 1,4)  
, case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
when substr(datepurchase, 6,2) in ('12') then 12 end 




select count (distinct m4.MemberID) as Age_Cat4 
, substr(datepurchase, 1,4) as year 
, case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
when substr(datepurchase, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient m4 
join Revised_Patient_Disease o4 on m4.MemberID=o4.MemberID 
Join Revised_Claims1_Finale cc11 on cc11.MemberID=m4.MemberID 
where (diabetes = 1 or hypertension =1) 
and datepurchase between '2007-01-01' and '2009-12-31' 
and age between 50 and 54 
group by substr(datepurchase, 1,4)  
, case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
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when substr(datepurchase, 6,2) in ('07') then 7 
when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
when substr(datepurchase, 6,2) in ('12') then 12 end 




select count (distinct m5.MemberID) as Age_Cat5 
, substr(datepurchase, 1,4) as year 
, case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
when substr(datepurchase, 6,2) in ('12') then 12 end as quarter 
from Revised_Patient m5 
join Revised_Patient_Disease o5 on m5.MemberID=o5.MemberID 
Join Revised_Claims1_Finale cc12 on cc12.MemberID=m5.MemberID 
where (diabetes = 1 or hypertension =1) 
and datepurchase between '2007-01-01' and '2009-12-31' 
and age between 55 and 59 
group by substr(datepurchase, 1,4)  
, case when substr(Datepurchase, 6,2) in ('01') then 1 
when substr(datepurchase, 6,2) in ('02') then 2 
when substr(datepurchase, 6,2) in ('03') then 3 
when substr(datepurchase, 6,2) in ('04') then 4 
when substr(datepurchase, 6,2) in ('05') then 5 
when substr(datepurchase, 6,2) in ('06') then 6 
when substr(datepurchase, 6,2) in ('07') then 7 
when substr(datepurchase, 6,2) in ('08') then 8 
when substr(datepurchase, 6,2) in ('09') then 9 
when substr(datepurchase, 6,2) in ('10') then 10 
when substr(datepurchase, 6,2) in ('11') then 11 
when substr(datepurchase, 6,2) in ('12') then 12 end 
)n5 on w.year=n5.year and w.quarter=n5.quarter 
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